Role of Nox2 oxidase during the cardiac infiltration of T-cells in a model of hypertension by Emmerson, Amber Chi
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 













Download date: 06. Nov. 2017
1 
 
Role of Nox2 oxidase during the 
cardiac infiltration of T-cells in a 
model of hypertension 
 
 




BHF Centre of Research Excellence 
School of Medicine 
King’s College London 
 
 
Submitted for the Degree of Doctor of Philosophy from 




Supervised by  
Professor Ajay M. Shah  
Professor Giovanna Lombardi 
  2  
Abstract 
Chronic hypertension related to increased activation of the renin-angiotensin system causes 
cardiac remodelling, which can progress to heart failure. Previous studies indicate that NADPH 
oxidase-2 (Nox2) activation is involved in angiotensin II (AngII)-induced hypertension and 
cardiovascular remodelling in mice. Nox2 is expressed in multiple cell types including cardiac 
myocytes, endothelial cells and inflammatory cells.  The aim of this work was to investigate the 
role of T-cell Nox2 in the pathophysiology of AngII-induced cardiovascular remodelling. 
Studies were undertaken in mice subjected to chronic AngII infusion with analysis of cardiac 
function, blood pressure, histology, and myocardial inflammatory cell infiltration (flow 
cytometry of single cell suspensions). In wild-type (WT) mice, AngII-induced increase in blood 
pressure was associated with a time dependant infiltration of T-cells into the myocardium. 
There was an increase in infiltration of anti-inflammatory regulatory T-cells (Tregs) into the 
myocardium and an increase in mRNA expression of the Treg transcription factor, FoxP3, as 
well as Treg cytokines and functional surface makers. In global Nox2 knockout (KO) animals, 
there was a reduction in immune cell infiltration into the myocardium associated with a 
blunting of AngII-induced hypertension. A novel CD4-targeted Nox2KO model was generated, 
in which AngII-induced hypertension was also blunted. These mice exhibited an increase in 
Tregs in the myocardium at baseline as compared to WT littermates, and showed no AngII-
induced increase in Tregs. An adoptive transfer study was performed, in which Tregs from WT 
or global Nox2KO mice were injected via the tail vein into WT mice subsequently treated with 
AngII. AngII-induced hypertension was significantly blunted in WT-Treg treated mice and an 
even greater effect was observed in KO-Treg treated mice. Cardiomyocyte hypertrophy was 
also blunted in these animals. Flow cytometry revealed lower cardiovascular inflammation in 
both Treg treated groups, especially in the Nox2KO-Treg treated group. Furthermore, in vitro 
Treg suppression assays revealed that Nox2KO-Tregs were significantly more suppressive than 
WT-Tregs. 
These data reveal that myocardial T-cell, specifically CD4+ T-cell, infiltration is a feature of 
AngII-induced hypertension and is regulated by Nox2. Moreover, Nox2 modulates Treg 
suppressive function, with significant impact on the development of hypertension and cardiac 
remodelling. Taken together, these studies identify an important role for T-cell Nox2 in the 
pathophysiology of AngII-induced hypertension and cardiovascular remodelling. 
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GDI Guanosine diphosphate inhibitor 
GDP Guanosine diphosphate 
GITR Glucocorticoid-induced TNF receptor family related gene 
GM-CSF Granulocyte-monocyte colony stimulating factor 
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GMP Granulocyte-monocyte progenitor 
GPCR G-protein coupled receptor 
GTP Guanosine triphosphate 
GTPase Guanosine triphosphatase  
H&E Haematoxylin and eosin 
H2O2 Hydrogen peroxide 
HGF Hepatocyte growth factor 
HGFR Hepatocyte growth factor receptor 
HRP Horse radish peroxidase 
HSC Haematopoietic stem cell 
HW Heart weight 




IRF Interferon regulatory factor 
iTregs Inducible regulatory T-cells 
IVIS In vivo imaging system 
IVS Interventricular septum 
IκB-α  NFκ light polypeptide gene enhanced in B-cells inhibitor, alpha  
JG cells Juxtaglomerular cells 
KCl Potassium chloride 
KO Knockout 
LAG3 Lymphocyte-activation gene 3 
LN Lymph node 
LV Left ventricle 
LVED Left ventricle end diastolic 
LVEDV Left ventricular end-diastolic volume 
LVES Left ventricle end systolic 
LVESV Left ventricular end-systolic volume 
LVH Left ventricular hypertrophy 
M1 Macrophage type 1 cells 
M2 Macrophage type 2 cells 
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MAPK Mitogen activated protein kinases 
MCP-1 Monocyte chemotactic protein-1 
MEP Megakaryocyte, erythrocyte progenitor 
Mg2+ Magnesium 
MHC Major histocompatibility complex 
MI Myocardial infarction 
MMO Microsomal monooxygenase 
M-mode Motion-mode 
MMP Matrix metalloproteinases 
MPP Multipotent progenitor 
MPR Mean pump rate 
MRI Magnetic resonance imaging 
mRNA Messenger ribonucleic acid 
Na2+ Sodium 
NAC N-acetylcysteine 
NaCl Sodium chloride 
NADPH Nicotinamide adenine diphosphate 
NaOH Sodium hydroxide 
NCF-1 Neutrophil cytosolic factor-1 
ND-1000 Nanodrop-1000 
NF-κB Nuclear factor κB  
NK cells Natural killer cells 
NMRI Naval medical research institute 
NO Nitric oxide 
NOS Nitric oxide synthase 
Nox Nicotinamide adenine diphosphate oxide 
NoxA Nox Activator  e.g. NoxA1 or NoxA2 
NoxO Nox Organiser e.g. NoxO1 or NoxO2 
NTP Nucleoside trisphosphate 
nTregs Natural regulatory T-cells 
O2
•- Superoxide 
PAI1 Plasminogen activator inhibitor 1 
PAMP Pathogen-associated molecular patterns 
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PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PD-1 Programmed death-1 
PDGF Platelet derived growth factor  
PDI Protein disulphide isomerase 
PFA Paraformaldehyde 
PI3K Phosphatidylinositol 3-kinase  
PIZ Peri-infarct zone 
PKC Protein kinase C 
PKD Protein kinase D 
PKG Protein kinase G 
PLAX Parasternal long axis 
PMA Phorbol 12-myristate 13-acetate  
PPR Pattern recognition receptors 
PSAX Parasternal short axis 
PSC Pluripotent stem cell 
PSR Picrosirius red 
pTregs Peripheral-derived regulatory T-cells 
PX domain Phox homology domain 
qPCR  Quantitative polymerase chain reaction  
RAAS Renin-angiotensin-aldosterone system 
RAG Recombination-activating gene 
RAR Retinoic acid receptor 
Redox Reduction-oxidation 
RNA Ribonucleic acid 
RNase Ribonuclease 
RNS Reactive nitrogen species 
RORγt Retinoid-related orphan receptor gamma t 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute 
RSK Ribosomal S6 kinase 
RT Reverse transcription 
RyR Ryanodine receptor  
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SA Sinoatrial 
SEM Standard error of the mean 
SFO Subfornical organ 
SHR Spontaneous hypertensive rats 
siRNA Small interfering ribonucleic acid 
SLO Secondary lymphoid organs 
SOD Superoxide dismutase 
SOH Sulfenic acid  
Ssc Side scatter 
Ssc-A Side scatter area 
Ssc-H Side scatter height 
Ssc-W Side scatter width 
STAT Signal transducer and activator of transcription 
TAC Trans aortic constriction 
TBS Tris-buffered saline 
T-cell Thymus-derived cell 
TCR T-cell receptor 
Teff Effector T-cells 
TGFβ Transforming growth factor β  
Th T-helper 
TIM-3 T-cell immunoglobulin and mucin-domain containing-3 
TIMP Tissue inhibitors of matrix metalloproteinases 
TL Tibia length 
TLR Toll-like receptor 
TNF Tumour necrosis factor 
TNFR Tumour necrosis factor receptor 
Treg Regulatory T-cell 
tTregs Thymic-derived regulatory T-cells 
UV Ultraviolet 
VAT Visceral adipose tissue 
VCAM Vascular cell adhesion molecule 
VEGF Vascular endothelial growth factor 
VPR Volume-pressure recording 
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VSMC Vascular smooth muscle cell 
WGA Wheat germ agglutinin 
WT Wild-type 
XO Xanthine oxidase 
YFP Yellow fluorescent protein 
α-SMA α-smooth muscle actin 
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1.1 Reactive oxygen species 
1.1.1 Basics of oxidation and reduction 
Reduction-oxidation (redox) reactions include reactions involving molecules with an 
altered oxidation state due to the transfer or loss of electrons. Both oxidation and 
reduction occur simultaneously, where oxidation is the loss of electrons (an increase in 
oxidation state) and reduction is the gain of electrons (a decrease in oxidation state). 
Many biological processes involve redox reactions, such as respiration and 
photosynthesis, however there are also negative consequences. Free radicals can be 
generated as a by-product of these natural reactions; these are atoms or a group of 
atoms containing at least one unpaired election. They are highly reactive and can be 
involved in a number of different processes within the cell by beneficially or adversely 
altering lipids, proteins and deoxyribonucleic acid (DNA)1.  
 
1.1.2 ROS, sources and scavenging systems 
Most reactive oxygen species (ROS) and reactive nitrogen species (RNS) are free 
radicals derived from oxygen and nitrogen respectively1, an exception is hydrogen 
peroxide (H2O2), which is a ROS but does not contain unpaired electrons. ROS are 
involved in numerous signalling pathways in either physiological or pathological 
conditions, including the development of cardiac remodelling. ROS include molecules 
such as superoxide (O2
•-), H2O2, hydroxyl radical (
•OH), and singlet oxygen (1O2)
2,3. O2
•- 
is the most common ROS within the cell, and is the precursor to H2O2
4. There are a 
variety of sources of ROS including the mitochondrial electron transport chain (ETC), 
cytochrome P450 family proteins, uncoupled nitric oxide synthase (NOS), peroxisomes 
and nicotinamide adenine diphosphate (NADPH) oxidases (Nox)2,3,5-9.  
The mitochondrial ETC is an important source of ROS. During aerobic respiration, 
electrons are passed along the mitochondrial ETC to facilitate the movement of 
hydrogen. This generates an electrochemical gradient that allows the synthesis of 
adenosine triphosphate (ATP).  Electron leakage can occur before the electrons reach 
cytochrome C oxidase, where normally oxygen is reduced to water5. Electron leakage 
leads to a reaction with oxygen, forming O2
•- 5. Cytochrome P450 also contributes to 
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cellular ROS levels. Different isoforms of cytochrome P450 contribute to the 
membrane-bound microsomal monooxygenase (MMO) system within the endoplasmic 
reticulum (ER). Here, two electrons are transferred from endogenous and exogenous 
compounds to cytochrome P450, enabling oxidation. This in turn activates oxygen and 
allows the transfer of one oxygen atom to the substrate6. Electron leakage from this 
system increases generation and cellular levels of ROS. NOS catalyse the synthesis of 
nitric oxide (NO) by converting L-arginine to L-citrulline7. NOS can become ‘uncoupled’ 
due to certain cellular conditions, lack of substrates or cofactors. During this time NOS 
transfers electrons to oxygen, synthesising O2
•- instead of NO, thereby contributing to 
ROS production7. In addition, xanthine oxidase (XO) catalyses the oxidation of 
hypoxanthine, generating xanthine, that can then further be oxidised to form uric 
acid8. During this process, H2O2 and O2
•- are generated3. Although the main role of XO 
is to aid purine degradation it also contributes to the levels of ROS within the cell8.  
In contrast to the above enzymes, Nox are the only enzymes whose sole purpose is to 
produce O2
•- and H2O2, depending on their isoform
3, 9. The enzyme is membrane-
associated and is involved in catalysing the reduction of oxygen via NADPH9:   
NADPH + 2O2  NADP
+ + H+ + 2O2
•-
 
In addition to the numerous sources of ROS discussed above, there are also scavenging 
systems, which aim to maintain redox balance within the cell. These include 
superoxide dismutase (SOD)1, catalase10, glutathione peroxidases, peroxiredoxin and 
the thioredoxin system, and antioxidants such as ascorbate11. SOD catalyses the 
dismutation of O2
•- into H2O2, while catalase, glutathione peroxidase and peroxiredoxin 
reduce H2O2, generating water, thereby maintaining a safe level of ROS within the 
cell1,10,11. Thioredoxins are oxidoreductase enzymes that facilitate the reduction of 
other proteins such as peroxiredoxin and glutathione by cysteine thiol-disulfide 
exchange11. 
 
1.1.3 Concept of oxidative stress 
Maintaining redox homeostasis is essential due to its wide involvement in cellular 
responses and signalling. When ROS production increases or ROS scavenging 
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decreases, the delicate balance is shifted towards pro-oxidants. This imbalance leads 
to ‘oxidative stress’, which has been implicated in a range of different diseases1. 
Exposure to environmental, physiological and pathological agents can increase the 
levels of ROS within a cell. ROS are highly reactive, and can interact with vital 
components of the cell such as lipids, carbohydrates, DNA and proteins1. 
 
1.1.4 ROS as signalling molecules 
ROS are capable of reversibly altering protein structure and subsequent function, 
hence contributing to physiological and pathological signalling pathways. A selection of 
protein sensors can act as signal transducers, responding to local redox levels by a 
modification in protein conformation, stability, molecular interactions and hence 
activity4,12. Such proteins include ion transporters, receptors, kinases, phosphatases, 
transcription factors and even structural proteins4,12.  
Signalling initiated by ROS depends on specific redox-reactive residues such as cysteine 
thiols. When oxidised, cysteine forms reactive sulfenic acid (-SOH), which can in turn 
form disulphide bonds with other cysteine residues4. This oxidation can impair or 
enhance the structure of the protein involved, potentially also altering protein 
function. This level of oxidation remains reversible by scavenging systems, however 
further oxidation can also occur forming sulfinic acid (-SO2H) or sulfonic acid (-SO3H), 
which are relatively irreversible4.  
ROS can reversibly modify a number of signalling molecules involved in different 
pathways, which are essential in physiological and pathological cardiovascular 
processes4. Physiologically, ROS can direct cardiomyocyte differentiation and 
proliferation, for example by redox activation of the phosphatidylinositol 3-kinase 
(PI3K)-Akt pathway13. In addition ROS can alter proteins involved in excitation-
contraction coupling (ECC) such as ryanodine receptor 2- (RyR2) leading to changes in 
its conductance of calcium (Ca2+) ions14. Furthermore, ROS signalling can aid blood 
pressure regulation, for instance the oxidative activation of protein kinase G1α 
(PKG1α) is essential for effective vasodilation15. 
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During cardiac stress, ROS levels within the heart increase and their signalling here 
contributes to a variety of pathological processes, such as hypertrophy and fibrosis16,17. 
As an example, redox modulation of extracellular-signal regulated kinases 1/2 (ERK1/2) 
and nuclear factor-κB (NF-κB) is involved in the development of hypertrophy due to G-
protein-coupled receptor (GPCR) stimulation4. This can occur by oxidation of cysteine 
thiols in small guanosine triphosphatases (GTPases) such as Ras and Rac, which act as 
signal transducers in this setting18,19. ROS are also implicated in a number of other 
signalling cascades that lead to hypertrophy. In the setting of cardiac fibrosis, redox 
signalling within different cell types such as cardiomyocytes, fibroblasts or even 
immune cells may be involved4. ROS have been found to activate the main mediator of 
fibrosis, transforming growth factor β (TGFβ) and promote other pro-fibrotic 
transcription factors4,20,21.  
Further to this, the source of ROS within these settings has been linked to Nox, whose 
sole purpose is to generate ROS4.  
 
1.2 NADPH oxidases: structure and function 
1.2.1 Nox structure and biochemistry 
ROS produced by Nox may contribute to signalling pathways involved in cardiac 
remodelling4. There are seven different Nox enzymes: Nox1-5, dual oxidase (Duox) 1 
and Duox23,22. They each contain a different membrane-integrated catalytic subunit 
and a number of additional associated proteins; however these vary between the 
different Nox proteins (Table 1)22. All Nox catalytic subunits comprise a six 
transmembrane-spanning protein with an N- and C-termini within the cytosol22. Nox5 
also contains four N-terminal Ca2+ binding domains, which regulate activation of the 
enzyme22. Duox1 and 2 contain additional domains. Nox1-4 relies on p22phox for 
membrane targeting, activity and stabilization of the enzyme3. Nox1-3 also require 
p47phox (Nox organiser 2 (NoxO2)) or NoxO1, and p67phox (Nox activator 2 (NoxA2)) or 
NoxA1. In addition to this Nox2 also require p40phox 3. The catalytic activity of Nox1-3 is 
also dependent upon a small GTPase, Rac3. The structures of the Nox isoforms are 
illustrated in Figure 1-1.  
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The assembly and function of Nox enzymes is relatively similar amongst different 
isoforms, except for Nox4, which is constitutively active and does not require adaptor 
proteins. The main principle is that phosphorylation of adaptor proteins brings the 
specific components of the Nox complex together into an active complex, once NADPH 
is recruited this enables the transfer of electrons. Two electrons from NADPH transfer 
to the constitutively bound flavin adenine dinucleotide (FAD) molecule generating 
FADH2 and NADP
+ 3. One electron at a time is then transferred to one heme group and 
then to the other, gradually moving across the membrane complex3. The electron can 
then transfer to oxygen on the external membrane generating O2
•-
, which is produced 
by Nox1-3 and Nox53. Within Nox4, Duox1 and Duox2, O2
•- is thought to be quickly 




Table 1: Adaptor proteins that associate with different Nox isoforms. Adapted from 
Ghouleh et al, 2011), Altenhofer et al 2012 and El-Benna et al 20053,22,23. 
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Figure 1-1: Models of the active Nox isoforms. Adapted from Ghouleh et al, 20113. 
 
1.2.2 Nox isoform tissue-specificity and localisation 
The different tissue (Figure 1-2) and cellular organisation of Nox isoforms allow their 
specific roles3. Nox1 is predominantly expressed in the colon, but has also been 
identified in reproductive organs and vasculature24-26. Nox1 is expressed in epithelial 
cells, lymphocytes, vascular smooth muscle cells (VSMCs), endothelial cells and 
osteoclasts3,24,25,27. Nox2, also referred to as gp91phox, was first identified in neutrophils 
and is also found within the heart, vasculature, liver and immune system3,28. The 
enzyme has been identified within neutrophils, macrophages, VSMCs, fibroblasts, 
endothelial cells, skeletal muscle cells, cardiomyocytes and hepatocytes28-31. Nox3 is 
highly expressed within the inner ear, and at lower levels in the brain, skull and foetal 
tissues however its expression within specific cell types requires further 
clarification3,32. Nox4 is more universal, initially identified in the kidney but also 
discovered in many other organs such as the heart, reproductive organs and 
pancreas28,33. Expression of Nox4 involves VSMCs, fibroblasts, hematopoietic stem 
cells, osteoclasts, neurons and endothelial cells25,34-36. Nox5 is not expressed within the 
murine model but has been identified within human spleen, stomach, pancreas, 
reproductive tissues and foetal tissue3,28,37. Nox5 is expressed within VSMCs, 
endothelial cells, bone marrow, and lymph nodes (LNs)37,38. Duox1 and 2 are located 
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within the thyroid, airway and prostate; in addition, Duox2 has also been identified 
within the digestive system3,28,39. Moreover, Nox isoforms also exhibit distinct 
subcellular localisation, which potentially reflects the different responses of the 
enzymes to a stimulus25.  
 
 
Figure 1-2: Expression of different Nox isoforms within the human body. Adapted 
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1.2.3 The activation of Nox2  
The production of ROS by Nox2 occurs on the external side of the plasma membrane 
and releases ROS into the phagosome, endosomes or the extracellular space23. In 
comparison, other Nox enzymes release ROS into the intracellular space and tend to 
produce a smaller quantity.  
Assembly of the Nox2 complex (Figure 1-3) involves the phosphorylation of the SH3-
containing proteins p47phox and p67phox as well as p40phox that naturally accompanies 
p67phox within the cytoplasm40. This induces their translocation to the cell membrane 
where they all bind the membrane-integrated gp91phox/p22phox heterodimer. This 
translocation requires a stimulus-induced conformational change within p47phox 
allowing its two integral SH3-domains to interact with p22phox 40. Within a resting cell 
the phox homology (PX) domain of p47phox is bound to its internal SH3-domains and 
hence these domains are not accessible to bind to p22phox on the membrane41. Upon 
stimulus-dependent activation, p47phox is phosphorylated causing a conformational 
change that dissociates the PX domain from SH3-domains. This allows the PX domains 
to be free to bind phophoinositides and the SH3-domains open to bind to p22phox, 
therefore translocation to the membrane occurs41. Rac-guanosine diphosphate (GDP) 
exchanges its GDP with guanosine triphosphate (GTP) and loses its inhibitor, Rho-GDI, 
before binding between p67phox and Nox223. This induces activation of the complex via 
an activation domain within p67phox. This activation allows cytosolic NADPH to bind to 
the NADPH binding domain within the cytosolic C-terminus23. Two electrons transfer 
from NADPH to FAD enabling electrons to move across the membrane via heme 
groups, as described in section 1.2.1. Within Nox2 the electron is then transferred to 
oxygen, generating superoxide3.  
Many different physiological and pathological signals can trigger the activation and 
expression of Nox2, such as hypoxia, growth factors, cytokines, and components of the 
renin-angiotensin-aldosterone system (RAAS)42. 
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Figure 1-3: Activation of Nox2. Adapted from El Benna et al 200523. 
 
Nox2 is expressed in a variety of cell types, including immune cells. Endogenous Nox2-
derived ROS has the ability to signal in immune cells and potentially play a role in 
regulating their differentiation, activation, proliferation and overall phenotype. This 
modulatory function of immune cell Nox2 will be discussed in detail later.  
 
1.3 Immune cell function   
All cellular components of the blood, including immune cells, arise from pluripotent 
haematopoietic stem cells (HSCs) within the bone marrow (Figure 1-4). They then 
differentiate into two separate lineages; the lymphoid lineage (bone marrow-derived 
(B-), thymus-derived (T-) cells and natural killer (NK) cells) and the myeloid linage 
(neutrophils, eosinophils, basophils, monocytes and macrophages, dendritic cells (DCs) 
and mast cells as well as erythrocytes and platelets)43. The myeloid lineage of immune 
cells mainly comprises of cells involved in the innate immune response (section 1.3.1), 
whereas the lymphoid lineage mainly comprises cells of the adaptive immune 
response (section 1.3.2).  
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Figure 1-4: Process of haematopoiesis. Adapted from Ackermann et al 201543. 
 
1.3.1 The innate immune responses 
Innate immunity is a non-specific, initial response to invading pathogens44. There are a 
number of different factors that participate in the innate response, including 
anatomical barriers, complement and immune cell responses. Once an anatomical 
barrier, such as the skin or mucosal surfaces, is breached by an invading pathogen, an 
inflammatory response is initiated. Complement can be activated by three different 
biochemical pathways: the classical, alternative or lectin pathways45. The complement 
system consists of a range of complement regulators, recognition molecules, receptors 
and enzymes that enable opsonisation, cell lysis or chemotaxis. The cell-mediated 
response involves NK cells, eosinophils, basophils, macrophages, neutrophils and DCs. 
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Nox2 is expressed in all immune cells and may modulate specific signalling pathways 
involved in activation, antigen presentation, cytokine synthesis and cell function. These 
processes are discussed below; however the impact of Nox2 within these cell types is 
discussed in section 4.1.1.1. 
 
Eosinophils and basophils are less well understood; they appear to have a role against 
parasites as well as allergic inflammatory responses. Mast cells are also involved in 
allergic responses therefore these cells will not be discussed further.  
 
1.3.1.1 Natural killer cells 
NK cells are lymphocytes that do not respond to specific antigens, have the ability to 
recognize and kill abnormal cells44. Although recently thought to play a role in adaptive 
immunity, NK cells are traditionally associated with their cytotoxic mechanisms within 
the innate immune response. This is mainly due to their ability to directly instigate 
death of tumour cells and virus-infected cells, without having specific immunity44. In 
terms of cytokines, NK cells produce interferon-γ (IFN-γ), tumour necrosis factor-α 
(TNF-α), interleukins (IL-) for example IL-10 and IL-3, in addition to an array of C-C 
chemokine ligands (CCL2, CCL3, CCL4, CCL5, XCL-1 and CXCL8) and growth factors (for 
example, granulocyte-monocyte colony stimulating factor (GM-CSF) and granulocyte 
colony stimulating factor (G-CSF))44. These enable the modulation of the adaptive 
immune response in pathological and physiological conditions.  
 
1.3.1.2 Macrophages 
Macrophages, neutrophils and DCs are phagocytes, which are implicated in the first 
line of defence by engulfing, and killing invading pathogens46-48. 
Macrophages are long-lived tissue resident cells, which are thought to differentiate 
from circulating monocytes. They elicit the first phagocytic response but also have the 
capacity to orchestrate other immune responses, such as inflammation48. 
Macrophages play an important role in tissue surveillance in order to elicit an 
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immediate immune response upon discovery of tissue damage or invading 
organisms48. Tissue-resident macrophages also play an important homeostatic role, 
enabling removal of toxic materials, dead and dying cells48. Macrophages can be 
subdivided into two groups; M1 (classically activated) and M2 (alternatively activated) 
for which the distinct cytokine profile dictates their functions48. M1 is mainly involved 
in inflammation and therefore express pro-inflammatory cytokines such as TNF-α and 
IL-1249. In comparison M2 produces IL-10 as well as expressing CD163 and CD206, and 
has a role in regulating the immune response49. Hence M2 play a vital role in enabling 
tissue homeostasis following infection or injury.  
 
Both macrophages and DCs serve as antigen presenting cells (APCs), which process 
foreign material in order to present antigens to other immune cells within peripheral 
lymphoid organs. DCs act as mediators between the innate and adaptive responses 47.  
 
1.3.1.3 Dendritic cells 
Immature DCs reside within peripheral tissues where they continuously sample the 
antigenic environment47,50. Tissue damage or the presence of a foreign antigen 
encourages DCs to migrate into the LNs, initiating their maturation47,50. The antigen 
encountered is processed and presented on the major histocompatibility complex 
(MHC) and co-stimulatory molecules are up-regulated47. This allows DCs to effectively 
activate T-cells within the LN. By interacting with T-cells, DCs are able to modulate the 
T-cell response (Figure 1-5). In the absence of any danger signals, DCs infiltrate the LNs 
at a low-level maintaining T-cell tolerance to self-antigens. However, in the response 
to infection, inflammation or tissue damage, DC migration increases enabling a specific 
T-cell response. DCs are the only immune cells that are able to migrate to the LN and 
interact between the innate and adaptive immune system47. There are thought to be 
different subtypes of DCs, including a non-migratory subtype that remains in 
peripheral tissues and acts as an inflammatory mediator47. DCs can also interact with 
other immune cells, such as B-cells and NK cells. In addition, DC associated cytokines 
include IFN-α, IL-6 and IL-1047.  
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Neutrophils are active, phagocytic cells that, in addition to macrophages and DCs, 
make up the first line of defence within innate immunity46. These cells are highly 
mobile and are mainly located in circulating blood. Upon inflammatory stimuli, 
neutrophils rapidly migrate to the site of infection or tissue-damage, being drawn by 
chemo-attractants such as pro-inflammatory cytokines46,51.  The main function of these 
cells is to engulf and degrade foreign organisms. One vital component that enables 
their function is Nox246. Subsequent production of ROS, such as O2
•-, enables an 
oxidative burst within the phagosome, in turn destroying the engulfed material. 
Furthermore, neutrophils can also influence the inflammatory response by migrating 
to the LNs, where they can interact with other immune cells such as other APCs and 
lymphocytes52,53. For example, in the case of T-cells, neutrophils have the ability to 
enhance and direct the T-cell response in addition to suppressing the T-cell response 
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all together144. More recent research has highlighted the potential for distinct subtypes 
of neutrophils, which may possess unique biological and functional implications145.  
 
1.3.2 Adaptive immune cells 
The adaptive immune system comprises of antigen-specific lymphocyte populations, 
which bear a wide-variety of distinct antigen receptors in order to elicit a response to 
any pathogen encountered44. There are two types of antigen-specific lymphocytes, T- 
and B-cells, which play quite distinct roles within the immune system. 
 
1.3.2.1 B-cells 
B-cells contain an antigen-specific B-cell receptor (BCR) on their cell membrane. The 
antigen-binding region of the BCR is highly variable and encoded by variable region-
encoding gene segments (V(D)J segments)54. During B-cell development, these genes 
undergo complex rearrangement that enables B-cells to recognise a wide variety of 
antigens. Due to this, the B-cell development pathway incorporates a number of 
checkpoints to prevent self-reactive or defective B-cells within the immune system54. 
Immature B-cells migrate to peripheral lymphoid organs where they maturate55. When 
the BCR is activated, this allows proliferation of the antigen-specific B-cell population 
and differentiation into plasma cells55. These effector B-cells are capable of releasing 
the antigen-specific receptor, known as an antibody or immunoglobulins (Ig), which 
are capable of binding to pathogens, marking them for destruction. B-cells also have 
the capacity to act as APCs to T-cells as part of the adaptive response55. They can 
influence T-cell differentiation by cytokine production in addition to regulating DC 
responses and even anti-inflammatory processes55. Further B-cell subsets can be 
defined by their cytokine production, location and function55.  
B-cell subtypes with a regulatory phenotype (Breg) have also been observed56. They 
may play a role in early regulation of the immune response by secreting anti-
inflammatory molecules (Figure 1-6). These include IL-10, IL-35, TGFβ and forkhead 
box P3 (FoxP3), which are thought to be expressed by individual Breg subtypes56,57, 151. 
  37  
Hence inhibiting pro-inflammatory cytokines, inflammatory cells and supporting 
regulatory T-cell (Treg) differentiation58. Different subtypes of Bregs are thought to 
exist, which may arise at different points within the B-cell development58,59. 
 
 
Figure 1-6: Regulatory B-cell functions. Adapted from Rosser et al 2015 (Immunity)57. 
 
1.3.2.2 T-cells 
T-cells initially develop in the bone marrow before final maturation within the thymus. 
Naïve T-cells are double negative (CD4-CD8-) but can be activated by their T-cell 
receptor (TCR), which causes the cell to proliferate and differentiate into a number of 
different effector T-cells (Teffs). Initially, activated T-cells progress through a number 
of different ‘double negative’ (DN, CD4-CD8-) stages before becoming ‘double positive’ 
(DP, CD4+CD8+), Figure 1-760. Positive selection then occurs to ensure that the T-cell 
recognises MHC class I (CD4-CD8+) or class II (CD4+CD8-), and negative selection 
ensures that the T-cells do not respond to self-antigens60.  
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Figure 1-7: T-cell differentiation process. Adapted from D'Acquisto et al60. 
 
In the periphery there are two different subsets of Teff cells; CD4+ T-cells and CD8+ T-
cells, which are activated upon recognition of antigen bound to MHC class II or MHC 
class I respectively. Both subtypes require co-stimulation to enable their activation. 
This second signal is provided by non-specific molecules on the surface of both cells, 
for example between CD28 upon T-cells and either CD80 or CD86, on the APCs. These 
two subtypes of Teff cells have distinct functions within adaptive immunity. 
Cytotoxic T-lymphocytes (CTLs) kill cells infected with intracellular pathogens and 
viruses. They are derived from naïve CD8+ T-cells and proliferate in the presence of IL-
261. Compared to other T-cell subtypes, CTLs undergo dramatic clonal expansion due to 
easy activation by the Ag-MHC class 1 complex, as co-stimulation is not required, and 
they survive more efficiently within circulation61. Cytotoxicity requires contact with the 
target cell, antigen recognition and release of cytolytic granules. There are two 
different cytotoxic pathways; Ca2+ dependent perforin/granzyme-mediated apoptosis 
and Ca2+ independent Fas ligand/Fas-mediated apoptosis61. 
T-helper (Th) cells are derived from naïve CD4+ T-cells and have a number of different 
subtypes based on their cytokine expression, producing distinct responses. Th1 cells 
are mainly driven by the T-bet transcription factor and produce IFN-γ, IL-2, TNF-α and 
lymphotoxin61. Their function is to enhance pro-inflammatory cell-mediated immunity, 
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for example Th1 cells can induce B-cell production of IgG61. Th2 cells are driven by the 
transcription factor GATA3 (which binds to the GATA DNA sequence) and mainly 
secrete IL-4, -5, -6, -10 and -13 and play a role in non-inflammatory immediate immune 
responses such as instigating B-cell production of IgA and IgE61. Th17 cells mainly 
secrete IL-17 and their master transcription factor is the retinoid-related orphan 
receptor-γt (RORγt)62. They are the first subset generated during infection, enabling 
recruitment of macrophages and neutrophils61. They enhance the innate acute 
inflammatory response but are also implicated in a number of inflammatory diseases61. 
Th9 cells, a recent addition, are distinct due to their production of IL-9 however their 
implication in the immune response requires further investigation61.   
Finally, Tregs that have anti-inflammatory properties are another CD4+ T-cell subset, 
which is discussed in more detail in section 5.1.1. Recent research has highlighted the 
potential plasticity of Th lineages and cytokine production, making Th populations 
more complicated to define (Figure 1-8)62-64.  
 
 
Figure 1-8: T-cell lineage differentiation and plasticity. Adapted from Zhou et al 
200963. 
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T-cell plasticity describes the ability of T-cells to shift between different lineages rather 
than obeying a traditional lineage differentiation62,64. As described above, unique 
master transcription factors T-bet, GATA3 and RoRγt were found to be sufficient, and 
necessary, for the induction of signature cytokines, eliciting differentiation into Teff 
cells (Th1, Th2 and Th17 respectively)65. Cytokines produced by distinct Th subtypes 
tend to inhibit progression of other lineages. For example Th1 and Th2 cytokines, IFN-γ 
and IL-4, suppress the expression of each other, and together inhibit production of IL-
1763. However, commitment to the Th lineages may be compromised, particularly with 
regard to Th17 and Tregs63. TGFβ is required for the differentiation and maintenance 
of Tregs, however this cytokine was also found to be essential for Th17 differentiation, 
hence suggesting a link between the two subtypes63. Mice deficient in TGFβ showed 
depletion of Th17 and Tregs in addition to overwhelming autoimmunity due to an 
enhanced Th1 response66,67. In addition, TGFβ can induce upregulation of both RoRγt 
and FoxP3 in naïve CD4+ T-cells, and cells that co-express both RoRγt and FoxP3 have 
been identified63. These cells may act as a transient population that can differentiate 
into either lineage depending on environmental cues68.  Tregs can also co-express a 
number of other transcription factors, including T-bet, GATA3 and signal transducer 
and activator of transcription 3 (STAT3), further demonstrating their plasticity64. 
Recent research also suggests the implication of further transcription factors and 
processes within the Th differentiation pathways65. For example STAT3 has also been 
shown to be important for Th17 differentiation69. These addition factors are not 
lineage-specific and hence understanding their role may elucidate Th differentiation 
and plasticity65. Moreover, evidence suggesting that Th cells can acquire suppressive 
functions is accumulating70. For example, Th1 cells have the capacity to produce IL-10, 
an anti-inflammatory cytokine in order to modulate their own response71. 
Inflammation has been implicated in the progression of hypertension and associated 
changes in heart structure and function.  
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1.4 Hypertension 
1.4.1 Clinical basics 
Hypertension refers to elevated levels of arterial blood pressure and is defined by a 
systolic or diastolic blood pressure that is persistently above 140mmHg and 90mmHg 
respectively72.  There are two main types of hypertension; primary and secondary. 
Primary hypertension is the most common type exhibiting high blood pressure as the 
main symptom, with no underlying conditions found72. Genetic variation and a number 
of environmental factors such as obesity, high salt intake, age and stress all contribute 
to primary hypertension72. In comparison, secondary hypertension occurs due to 
another defect such as renal failure, renovascular disease, aldosteronism, and other 
primary causes72. 
Blood pressure is regulated by several different pathways, among which two well-
established mechanisms are the RAAS that is a hormone-regulated system73, and the 
baroreceptor reflex that elicits responses via the autonomic nervous system74. Here, 
we are interested in the RAAS, which is discussed in more detail in the following 
sections.    
 
1.4.2 Regulation of blood pressure 
The RAAS plays a vital homeostatic role in maintaining blood volume and systemic 
vascular resistance, thereby influencing cardiac and vascular function, as illustrated in 
Figure 1-9. Activation of this hormone-controlled system initiates the release of renin 
from the kidneys, allowing the cleavage of angiotensinogen73. Secretion of renin from 
the juxtaglomerular (JG) cells, within the renal glomerulus, is stimulated by a decrease 
in perfusion pressure, sodium chloride (NaCl) delivery or increases in sympathetic 
nerve activity75. Renin is described as the rate-limiting step of the RAAS cascade75. 
Initial synthesis of renin produces a precursor, which requires proteolytic cleavage of 
amino acids from the N-terminus of pro-renin, generating mature, activated renin76. 
Mature renin is then stored in granules in JG cells within the kidney, which are 
released by exocytosis76. 
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Meanwhile, the liver constitutively secretes angiotensinogen, so plasma levels remain 
consistent73. Renin regulates the cleavage of circulating liver-derived angiotensinogen, 
by removing ten amino acids from the N-terminus generating angiotensin I (AngI), an 
inactive decapeptide that serves solely as a precursor to angiotensin II (AngII) 77 73,76.  
Angiotensin-converting enzyme (ACE) then hydrolyses AngI, removing the C-terminal 
dipeptide to form an active octapeptide, AngII73. ACE is a membrane bound enzyme 
that is highly expressed on the luminal side of the vascular endothelium73. AngII is the 
primary active product of RAAS, however both AngI and AngII are thought to have 
short half-lives and hence AngII is potentially synthesised very close to its site of 
action. It is thought that renin may serve as a circulating hormone signal with the 
ability to initiate RAAS pathway at local sites where AngII is required73,76,78.  
AngII can elicit a number of different responses mediated by the angiotensin II 
receptor 1 (AT1R), which provides a negative feedback loop in order to control the 
system, as shown in Figure 1-973. AT1R is responsible for the modulation of a number 
of processes in the cardiovascular system such as vasoconstriction, increases in blood 
pressure, cardiac contractility, and cardiovascular hypertrophy79. In addition, due to its 
wide distribution in a range of tissues, AT1R elicits responses in the kidney, to reabsorb 
sodium (Na2+) and inhibit renin release, sympathetic nervous system and the adrenal 
cortex, to stimulate synthesis of aldosterone73,76,78,79. Aldosterone is a hormone that 
binds to the mineralocorticoid receptor to induce ion and water reabsorption into the 
kidney. This further increases blood volume and hence blood pressure.  
Although AT1R is the main receptor that allows AngII to elicit a response, there are also 
3 other reported receptors AT2R, AT3R and AT4R that can be bound by AngII
79. AT2R is 
present in the brain, kidney and other organs during foetal life73. Low levels of AT2R 
expression are also found in adults and may aid vasodilation, anti-proliferative and 
apoptotic effects in VSMCs73. Upregulation of AT2R has been observed during injury 
and once activated may mediate anti-fibrotic and anti-inflammatory effects. Therefore 
AT2R is thought to oppose AT1R responses and act as a protective arm of the RAAS 
pathway80. The importance of any of these AT2R responses remains uncertain. AT4R is 
thought to mediate the release of plasminogen activator inhibitor 1 (PAI1) by AngII, 
but AT3R functions remain unknown
73. 
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The classical RAAS cascade, as described above, is viewed solely as a circulating 
peptide system involved in blood pressure regulation, salt and fluid homeostasis. 
However there are a number of recent findings that demonstrate homeostasis by the 
RAAS cascade that lie outside this traditional view73,78,80. For instance, metabolites of 
AngI and AngII may function biologically in different tissues81. Moreover, AngII 
synthesis can be stimulated by adrenocorticotrophic hormone (ACTH), norepinephrine, 
endothelin and serotonin, and can be inhibited by atrial natriuretic peptide and NO73.  
In a number of different pathological settings, enhanced activation of the RAAS can 
lead to hypertension and play an important role in the pathogenesis of cardiovascular 
disorders. Increasing the level of AngII within the system, a method commonly used 
within research, can also induce hypertension. 
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Figure 1-9: Physiological response of the classical renin-angiotensin-aldosterone 
system (RAAS). 
 
1.4.3 Tissue-specific RAAS 
In addition to this classical RAAS pathway, which occurs mainly in the circulatory 
system, recent evidence has also suggested a tissue-specific RAAS cascade. AngII 
precursors have been identified in numerous other tissues, including the brain, 
placenta, adrenal gland, ovary, visceral adipose tissue and even the heart and vascular 
tissues73. However the purpose of these precursors and their generation within these 
tissues are poorly understood. Accumulating evidence supports the synthesis of RAAS 
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components in many different tissues, suggesting that tissue-specific AngII levels can 
be controlled independently from circulating RAAS76. 
Due to the identification of Ang receptor subtypes and signal transduction pathways, 
truncated Ang peptides and specific cell surface receptors for renin and prorenin, it is 
thought that the RAAS may also function as a tissue paracrine/autocrine system82, 13. 
Local AngII synthesis may occur by tissue-uptake of circulating renin or 
angiotensinogen, or independent AngII-generating systems. This is thought to be the 
case in tissues such as the heart, peripheral blood vessels, kidney, brain, adrenal 
glands, pituitary, adipose tissue, testes, ovaries and skin.  
The cardiac RAAS system is required to maintain cellular balance of inhibiting and 
inducing cell growth and proliferation in addition to mediating adaptive responses to 
myocardial stretch. AngII within cardiac tissue is mainly produced by conversion of 
locally produced AngI into AngII. It has also been postulated that local production of 
renin and additional proteolytic enzymes may also be involved in this setting. 
Especially as all the components required for AngII production are present in the 
heart76,83. In addition to this, although ACE is the main enzyme generating AngII, in the 
heart it has been postulated that this is mainly regulated by chymase. Therefore, new 
mechanisms allowing local tissue-specific RAAS cascades are coming to light and 
suggest independent pathways to that of the circulating RAAS components. A similar 
local generation of AngI and AngII is found in VSMCs, endothelial and endocardial cells. 
This vascular RAAS exerts an effect on cardiovascular homeostasis by stimulating VSMC 
and fibroblast proliferation via AT1R and AT2R
76. 
Collectively, this evidence suggests that AngII can be synthesised locally within tissues, 
encouraging tissue-specific regulation in addition to circulatory RAAS mechanisms. 
Within the cardiovascular system AngII is heavily involved in cardiac remodelling 
processes with are further investigated in section 1.5. 
Te Riet et al contradict these ideas in their recent review, suggesting that local AngII 
generation does occur, but that this is still dependent on renal-renin and hepatic-
angiotensinogen78. These precursors diffuse into the interstitium where they are 
locally used to generate AngII via ACE. AngII can then bind directly to local AT1R to 
elicit a response, and such binding results in internalisation of AngII, hence explaining 
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intracellular AngII levels78. Therefore the specifics of local tissue-RAAS still remain 
plausible but yet undetermined.   
Further to this, AngII can impact immune cell recruitment, migration and function, 
which are discussed in later chapters.  
 
1.4.4 RAAS dysregulation and clinical inhibition 
Dysregulation of the RAAS cascade has been identified in the pathogenesis of a 
number of hypertensive disorders. This includes essential hypertension, in addition to 
the cardiovascular and renal tissue responses to hypertensive and non-hypertensive 
injury. For example increases in the rate-limiting renin levels can be a cause of primary 
hypertension by overstimulation of the RAAS, leading to excessive AngII production 
and hence increased blood pressure. This also causes increased levels of aldosterone 
production, which further contributes to this problem.  
There are many stages within the RAAS that have been identified to target with 
pharmacological inhibitors to prevent the formation, or block the effects of, AngII and 
aldosterone. These include renin inhibitors, ACE inhibitors, AT1R antagonists and 
mineralocorticoid receptor antagonists78.  
Renin was a clear target, being the rate-limiting step of the RAAS cascade. Inhibition of 
plasma renin-levels by both renin antibodies and synthetic renin inhibitors showed a 
significant decrease in plasma renin levels, AngI, AngII and aldosterone. This 
consequently produced a decrease in systolic blood pressure; however initial renin 
inhibitors required intra-venous administration. In 2007, an oral direct renin inhibitor 
(DRI) was developed (named aliskiren), which is an effective anti-hypertensive drug 80. 
Beta-blocker therapy (e.g. propranolol) can also be used to block sympathetic (beta1)-
mediated renin release by the kidney thereby lowering plasma renin and AngII levels78. 
In addition, this method has also shown a potential to prevent conversion of prorenin 
into mature renin. All in all, these therapies produced decreased blood pressure and 
are beneficial for treating hypertension.  
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ACE inhibitors (e.g. captopril) prevent the conversion of AngI into AngII, therefore 
reducing circulating and local levels of AngII as well as aldosterone, hence reducing 
blood pressure78. However, by blocking AngI to AngII conversion there is consequently 
an increase in renin release and AngI, which may progress AngII synthesis via different 
pathways. They are also thought to exert beneficial effects due to activation of the 
ACE2-Ang1-7-MAS1 axis. Despite this, ACE inhibitors remain the first-line therapy for 
patients with hypertension and heart failure, successfully managing blood pressure 
and left-ventricular hypertrophy (LVH).  
Angiotensin receptor blockers (ARBs) prevent the binding of AngII to the AT1R receptor 
(e.g. losartan) and hence limit the downstream effects of AngII. ARBs are used in a 
similar context to ACE inhibitors, to manage hypertension, heart failure and renal 
protection84. However blocking AngII binding to the AT1R also prevents the negative 
feedback loop resulting in higher levels of AngII. Similar to ACE inhibitors, ARBs can 
activate the ACE2-Ang1-7-MAS1 axis potentially giving further beneficial effects78,80.  
These RAAS blockers discussed so far are all related to the traditional RAAS cascade, 
however as more components of the RAAS pathway are being identified further 
potential targets emerge80. 
 
1.5 Cardiac remodelling associated with hypertension 
Cardiac remodelling is a process that involves modification of both cardiac structure 
and function. Processes involved in cardiac remodelling include cardiomyocyte 
hypertrophy, interstitial fibrosis, ventricular dilation, cell death and contractile 
dysfunction42,75. Although there are a number of causes with different aetiologies, that 
lead to cardiac remodelling, they all share similar pathways for molecular, biochemical 
and mechanical events85. Cardiac remodelling is thought to initiate as an adaptive 
mechanism compensating for stress or trauma in order to maintain stroke volume75. 
For instance cardiac hypertrophy allows a greater cardiac contraction per heartbeat, 
observed by fractional shortening, and hence increased volumes of blood ejected per 
heartbeat, determined by ejection fraction. Therefore higher blood pressures are 
managed due to initial cardiac remodelling. However, sustained haemodynamic 
overload progresses into a transition from compensatory cardiac changes to heart 
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failure75,85. This is characterised by left ventricular dilation, contractile dysfunction and 
impaired survival.  
Ventricular dilation defines a process whereby the chambers of the heart become 
stretched and thinned, occurring mainly in response to pressure overload86. The 
specific events that lead from compensatory cardiac remodelling into a maladaptive 
state of ventricular dilation and heart failure require further investigation86.  
 
1.5.1 Hypertrophy 
1.5.1.1 Hypertrophy basics and the cellular response 
Cardiac hypertrophy denotes a thickening of the myocardium, which results in an 
increased chamber mass and wall thickness, often associated with a decreased 
chamber volume87,88. At the cellular level, it involves an increase in the volume of 
individual cardiomyocytes, enhanced protein synthesis and a higher organisation of 
the sarcomere88. Hypertrophy is regarded as a cardiac remodelling process to 
compensate for temporary increases in biomechanical stress75,89. 
Hypertrophy occurs in response to chronic exercise training or even pregnancy, and in 
these instances is described as physiological rather than pathological hypertrophy89,90. 
This type of hypertrophy occurs without interstitial fibrosis, apoptosis or cardiac 
dysfunction, usually associated with pathological hypertrophy85,90. Physiological 
hypertrophy is thought to be beneficial or even protective, rather than detrimental85. 
Therefore the differences between pathological and physiological hypertrophy are 
important to study in order to understand how pathological hypertrophy switches to a 
maladaptive process and progresses to heart failure90. Going forward specific 
processes involved in pathological hypertrophy only will be discussed. 
Hypertrophies are further subdivided into concentric or eccentric hypertrophy 
depending on the initiating stimuli and the effect this has on cell shape85,91. Increases 
in relative wall thickness and cardiac mass but without changes in chamber volume 
denote concentric hypertrophy91. This is usually visualised by a parallel sarcomere 
addition pattern and hence an increase in cardiomyocyte width85,91. For example, 
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stimuli resulting in pressure overload, such as hypertension and aortic stenosis90. In 
comparison eccentric hypertrophy encompasses increases in cardiac mass with 
increased chamber volumes85,91. For example stimuli resulting in volume overload, 
such as aortic regurgitation and arteriovenous fistulas90. In this setting, sarcomeres are 
usually added in series leading to increased cardiomyocyte length7, 90. 
At the cellular level, cardiac tissue is composed mainly of cardiomyocytes (muscle 
cells), non-myocytes that include fibroblasts, endothelial cells, mast cells and VSMCs, 
and extracellular matrix, which surrounds these cells90,92. Proliferation of 
cardiomyocytes within mammalian hearts occurs up until birth, after this any cardiac 
growth results from increases in cardiomyocyte size22. Cardiomyocytes themselves are 
composed of myofibril bundles that contain myofilaments. These myofilaments consist 
of sarcomeres, which are the main contractile unit of the muscle22. The left ventricle is 
composed of cardiomyocytes that are arranged in a circular and spiral orientation22. To 
ensure a normal heart rhythm cardiomyocytes need to contract simultaneously, hence 
cellular coordination is important. Cell-to-cell adhesion is maintained by intercalated 
discs at the bipolar ends of cardiomyocytes22. This allows the synchronicity of 
contractile force between adjacent cardiomyocytes. 
Hypertrophy involves the activation of a highly complex web of intracellular signalling 
pathways that activate gene expression, promote protein synthesis and stability, in 
turn leading to an increase in cardiomyocyte size, as shown in Figure 1-1088,90.  
Pathological hypertrophy is associated with elevated levels of AngII, catecholamines 
and endothelin-1 (ET-1) and their subsequent effects are elicited from GPCR 
signalling93,94. In addition to this, pathological hypertrophy has also been associated 
with abnormalities leading to enhanced PI3K, mitogen activated protein kinases 
(MAPKs), protein kinase C (PKC) and D (PKD), and calcineurin85,93.  
 
  50  
 
Figure 1-10: Intracellular signal-transduction pathways mediating the cardiac 
hypertrophic response. From Bernardo et al, 201090. 
 
1.5.2 Interstitial Fibrosis 
Most cardiac diseases are associated with interstitial fibrosis, which contributes to the 
progression of heart failure. Over-activation of fibroblasts, in response to specific 
stressors such as hypertension, causes an increase in collagen secretion42,75. Secreted 
collagen occupies the space between cardiomyocytes causing increased myocardial 
stiffness, impaired cardiac diastolic function and potentiates cardiac arrhythmias. 
Therefore fibrosis is a key component of cardiac remodelling.  
There are two distinct stages of fibrosis, initial reactive interstitial fibrosis and 
replacement fibrosis95. Reactive fibrosis is a mechanism that occurs in response to 
cardiac stressors, such as hypertension, whereas replacement fibrosis is a response to 
cardiomyocyte cell death95. Here, fibrosis maintains tissue structure by replacing 
cardiomyocytes, which have undergone apoptosis. Cell types involved in the 
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development of fibrosis include; fibroblasts, cardiomyocytes, inflammatory cells, 
endothelial cells and other circulating cells4,42. Cardiomyocyte hypertrophy, as 
described in section 1.5.1, is determined solely by the growth of cardiomyocytes, this 
can also be accompanied by growth of non-cardiomyocytes and interactions in tissue 
structure, distorting organ architecture and function92,95.  
 
1.5.2.1 Basic development and cellular responses resulting in fibrosis 
Cardiac fibroblasts play an important role in maintaining normal cardiac function. In 
healthy cardiac tissue the extracellular matrix (ECM) forms a network that surrounds 
and interconnects cells providing a 3D structure for myocytes and other cells within 
the heart96. This not only provides a scaffold, maintaining structural integrity of the 
tissue, but also allows distribution of mechanical forces through the myocardium in a 
cell-to-cell manner96. Fibroblasts, derived from mesenchymal origins, are the main 
cellular component implicated in synthesis and deposition of the ECM; they also have 
the ability to interact on a cell-to-cell basis with other fibroblasts, myocytes and 
endothelial cells95. They thereby take a regulatory standing, ensuring the appropriate 
response is mediated, to changes in chemical, mechanical and electrical signals in the 
heart96. Fibroblasts themselves are flat, spindle-shaped connective tissue cells that lack 
a basement membrane96. They have the ability to produce a variety of ECM 
components including collagen and fibronectin in addition to cytokine and growth 
factor secretion, (Figure 1-11). 
Tissue fibrosis arises when the normal regulation of wound healing fails. Therefore in 
addition to their tissue-homeostatic function, fibroblasts also contribute to cardiac 
remodelling. It is the complex interaction of pro-fibrotic and anti-fibrotic cytokines and 
secreted proteins that regulate the appropriate response. Research has demonstrated 
phenotypic heterogeneity among fibroblasts. In particular a modified form of the 
fibroblast, specific to wound-sites, termed myofibroblasts have the ability to express α-
smooth muscle actin (α-SMA) and an enhanced ability to contract ECM, which is 
necessary for wound closure96. These cells secrete other specific growth factors and 
cytokines that are vital for their roles in growth, development, fibrosis and the repair 
of numerous tissue types. The differentiation from a fibroblast into a myofibroblast is 
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promoted by TGFβ, cytokines, the surrounding ECM and other growth factors. Other 
origins for fibroblasts include endothelial cells, by endothelial-mesenchymal transition, 
or from bone marrow-derived circulating progenitor cells, monocytes and 
fibrocytes95,97.  
Fibroblasts have the ability to sense changes in the microenvironment and elicit an 
appropriate response to preserve organ function. After injury, synthesis of new 
connective tissue involves activated fibroblasts with the ability to proliferate and 
migrate around the wound98. In this setting, synthesis of new ECM proteins such as 
collagen and fibronectin occurs98. One such response occurs due to pathological 
stimuli, such as hypertension99. In addition, matrix metalloproteinases (MMPs), that 
are required for collagen degradation, are greatly upregulated by fibroblasts99. This 
causes excessive ECM degradation, which has a knock-on effect for cardiac function. 
During the process of cardiac injury, fibroblasts are influenced by a number of different 
factors that alter their gene expression. Fibroblast activation and differentiation into a 
myofibroblast is heavily upregulated within this pathological setting. This in turn is 
associated with increased secretion of fibronectin and fibrillary type collagens I and III.  
As pathological remodelling continues, further increases in cytokines and growth 
factors stimulate myofibroblast proliferation, migration and remodelling of the cardiac 
insterstitium99. In addition, activated fibroblasts may have a direct influence on 
cardiomyocyte hypertrophy by paracrine mechanisms, hence further contributing to 
impaired cardiac function. The abundance of myofibroblasts present during fibrosis 
contributes heavily to excessive tissue scarring observed in fibrotic disease. At the 
same time cardiac fibroblasts also secrete increased levels of growth factors and 
cytokines including IL-1β, IL-6 and TNF-α, which in turn activate MMPs stimulating 
further cardiac remodelling99.  
Similar to the hypertrophic response, initial stages of fibrosis are beneficial and critical 
for tissue-repair. As this process continues, it becomes maladaptive leading to 
interstitial fibrosis, increased mechanical stiffness and hence reduced cardiac function. 
Although cardiac fibroblasts are non-excitable cells, their coupling to myocytes allows 
electrical signal transduction, giving a uniform tissue response. However in the setting 
of fibrosis, excessive levels of collagen provide an insulating layer separating 
cardiomyocytes. This in turn disrupts their electrical-coupling, preventing synchronicity 
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of electrical signals and hence increasing the risks of arrhythmias. Cardiac fibroblasts 
also have the ability to induce or inhibit angiogenesis; however their distinct 
mechanism here requires further investigation.  
 
 
Figure 1-11: Functions of cardiac fibroblasts. Adapted from Krenning et al 2010 and 
Souders et al 200995,99. 
 
1.5.2.2 Signalling pathways involved in fibrosis development 
 Within healthy cardiac tissue the ECM is synthesised and degraded by cardiac 
fibroblasts in a coordinated, regulatory manner. However during heart failure there is 
a disruption of these regulatory pathways, which result in an imbalance of ECM 
synthesis and degradation. This is thought to account for the severity of cardiac 
remodelling and hence this section is concentrating on understanding these specific 
signalling processes. A number of different growth factors, cytokines and hormones 
are responsible for the fibrotic response. These include TGFβ, connective tissue growth 
factor (CTGF); platelet derived growth factor (PDGF), AngII and ET-196. 
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TGFβ is the main factor promoting the fibrotic response. There are three TGFβ ligands 
(TGFβ-1, -2 and -3), of which TGFβ-1 mechanisms are the most clarified96,100. TGFβ-1 is 
upregulated in normal tissue repair in addition to the progression of pathological 
fibrosis. Upon activation, TGFβ binds to a heteromeric receptor consisting of one TGFβ 
type I, and one TGFβ type II receptor, both of which possess tyrosine kinase activity. 
TGFβ type I is also known as activin-linked kinase (ALK) -5 within fibroblasts, whose 
signalling is mediated by the Smad family of transcriptional activators96. For instance 
Smad-3 enables procollagen type III, tenascin-C, collagen lattice contraction and α-
SMA expression. ALK-5 inhibitors, developed as a potential anti-fibrotic agent, allow 
decreased TGFβ activity, reduced fibrosis and collagen messenger ribonucleic acid 
(mRNA) expression in a model of myocardial fibrosis in vivo96. However this was 
associated with an increased inflammatory response and did not have any benefits on 
myocyte hypertrophy, blood pressure or systolic function.  
TGFβ also has the ability to activate other signalling pathways, such as MAPK 
pathways, which allows modification of gene expression and hence contributes to 
cardiac fibrosis. In addition this MAPK signalling can link back into the TGFβ/Smad 
signalling cascade to enable a regulatory feedback mechanism96. Upregulation of ECM 
and the tissue inhibitors of matrix metalloproteinases (TIMP) gene expression by TGFβ 
promote ECM deposition. This in conjunction with the suppression of MMP gene 
expression, and promotion of fibroblast to myofibroblast differentiation, allows TGFβ 
to stimulate fibrosis in response to pathological stimuli. Hence this interplay between 
MAPK and Smad signalling pathways mediate and control ECM expression98. 
Several proteins downstream of TGFβ are required to enhance the cellular response 
and hence prolong the wound healing process. These can either prolong the 
contractile response of fibroblasts, closing wound-sites, or to prolong ECM production. 
Such proteins include CTGF and the ED-A form of fibronectin101. CTGF is a protein that 
is upregulated in fibroblasts in response to TGFβ, promoting fibroblast proliferation, 
ECM production (including collagen and fibronectin), adhesion, migration and 
granulation tissue formation. CTGF is also thought to help TGFβ to bind to its receptors 
when at lower concentrations. Taken together, CTGF is implicated in the TGFβ-driven 
fibrotic response however the specific signalling process involved remains to be 
elucidated. In addition, recent published data has questioned the role of this factor as 
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a mediator of the pro-fibrotic response. A conditional CTGF-knock out (KO) mouse 
subjected to transverse aortic constriction (TAC), a model of chronic pressure 
overload, maintained a normal hypertrophic and fibrotic phenotype102.  
Counteractive responses are also present to dampen down the fibrotic process, 
mediated by cytokines such as TNF-α and IFN-γ. TNF-α is a pro-inflammatory cytokine 
that is produced by macrophages during the wound healing process. In addition, TNF-α 
has an anti-fibrotic phenotype with the ability to suppress ECM expression and the 
TGFβ induction of collagen and CTGF. Similarly IFN-γ possesses anti-fibrotic responses, 
it is a cytokine produced mainly by T-cells and NK cells, which orchestrates responses 
by the Janus kinase (JAK)-STAT pathway.  
PDGF encompasses a family of homodimeric or heterodimeric growth factors (e.g. 
PDGF-A, -B, -C and –D). PDGF-A and –D are increased in endothelial cells, macrophages 
and fibroblasts after cardiac injury, which is also associated with cardiac responses 
such as angiogenesis, inflammation and fibrosis. In terms of fibrosis, PDGF is thought 
to act via elevating TGFβ levels, thereby contributing to the remodelling process.  
Hormonal stimuli also have the ability to affect the progression of fibrosis. As 
described previously, AngII is increased in response to cardiac stress. AngII can be 
expressed and activated by both macrophages and myofibroblasts in the setting of 
pathological cardiac remodelling. By binding to the AT1R, AngII can induce TGFβ-1 
expression and in turn TGFβ is required for AngII to induce both cardiac hypertrophy 
and fibrosis. AngII induces collagen expression by the TGFβ/Smad3 pathway and via IL-
6 mechanisms, which potentially involve NF-kB activation. ET-1 can also be stimulated 
in response to cardiac stress, or even induced by AngII. ET-1 activates the endothelin -
A (ETA) and –B (ETB) receptors and is mainly produced by endothelial cells but can also 
be produced by cardiomyocytes, fibroblasts and macrophages. Responses instigated by 
the ETA receptor include decreased DNA synthesis and collagen production in 
fibroblasts.  
Another aspect that is vital in the response to cardiac stress and the resultant 
remodelling process are ROS. A number of signalling pathways involved in cardiac 
remodelling consist of redox sensitive proteins, suggesting that ROS are implicated in 
the activation and regulation of theses response cascades103.  
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1.5.3 Apoptosis 
1.5.3.1 General implications of apoptosis 
Another key component in cardiac remodelling is the loss of cardiomyocytes, which is a 
progressive mechanism leading to the development of heart failure104. Cardiomyocyte 
death can occur by two means; necrosis, the premature death of a cell due to injury or 
toxicity, or by apoptosis, a programmed cell death mechanism105,106. Apoptosis is an 
evolutionarily conserved suicide process, that occurs when regulated biochemical 
changes within the cell leads to alterations in cell morphology and eventually cell 
death105,106. Characteristic morphological changes include nucleosomal DNA 
fragmentation and cell shrinkage, without the loss of membrane integrity107. Apoptosis 
plays critical roles in homeostasis, remodelling, surveillance and host defences106. Both 
internal and external stimuli enable the removal of cells that are damaged, genetically 
unstable or were inappropriately produced during development107. Therefore 
apoptosis is involved in essential biological processes; however dysregulation of 
apoptosis has been implicated in cardiac remodelling and heart failure106. For instance, 
as adult cardiomyocytes cannot self-renew after injury the loss of cardiomyocytes due 
to apoptosis potentially influence cardiac structure and function107.  
 
1.6 Pathological role of Nox2 in cardiac remodelling 
Nox proteins are major sources of ROS within the cardiovascular system and the 
expression of different Nox isoforms is very complex, not only within different cell 
types but in different regions of the vascular system. Nox2 is expressed in 
cardiomyocytes, endothelial cells, VSMCs and adventitial fibroblasts. Nox2-dependent 
ROS is capable of modulating intracellular signalling pathways, which lead to cardiac 
hypertrophy, fibrosis, apoptosis and contractile dysfunction (Figure 1-12)42. The 
intricate pathways leading to development of these maladaptive changes were 
previously described in section 1.5, here we look at how these pathways can be altered 
by Nox2-dependent ROS, hence demonstrating the integral role of Nox2 in the cardiac 
remodelling process.  
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Figure 1-12: Nox2-derived ROS involvement in cardiovascular remodelling. Adapted 
from Nabeebaccus et al. 2011, illustrating the main signalling complexes involved in 
cardiac remodelling42. 
 
Nox2 activation is implicated in cardiomyocyte hypertrophy induced by GPCR, such as 
AngII and α1-adrenoreceptor agonists4,42. Nox2KO mice treated with a subpressor dose 
of AngII show less LVH compared to WT controls, which is confirmed further by a lower 
increase in molecular markers for hypertrophy108. Furthermore, NADPH oxidase 
activity increases during AngII treatment whereas in the Nox2KO this response is 
inhibited, suggesting a role for Nox2 within this setting3.  Mice deficient in ACE2 exhibit 
exaggerated pressure-overload-induced hypertrophy, however when generated on a 
p47phox-/- background the level of hypertrophy improves109. Nox2 is implicated in a 
number of different signalling pathways resulting in cardiac hypertrophy (Figure 1-13), 
such as Ca2+, MAPK and protein kinase signalling.  
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Figure 1-13: Redox -modulated cardiac hypertrophy signalling cascades. Burgoyne et 
al 20124. 
 
Most cell types involved in the development of fibrosis express Nox2; fibroblasts, 
cardiomyocytes, inflammatory cells, endothelial cells and other circulating cells4,42. 
Global Nox2KO mice treated with a sub-pressor/pressor dose of AngII or aldosterone 
infusion, to induce cardiac remodelling, show a significant decrease in interstitial 
fibrosis when compared to WT controls4,42. Similarly mice globally deficient in proteins 
tightly linked to Nox2, Rac-/- and apoptosis signal-regulating kinase 1 (ASK1)-/-, also 
show a significant decrease in interstitial fibrosis4,42,110,111. In a number of cases where 
Nox2-dependent ROS production is reduced in mice, interstitial fibrosis is 
concomitantly reduced. In contrast, the level of hypertrophy remains similar to the WT 
controls, implying distinct signalling pathways leading to these two processes involved 
in remodelling4,42.  
Cardiomyocyte apoptosis is an important element in the development of fibrosis, 
contractile dysfunction and the progression to heart failure. Nox, more specifically 
Nox2, have been associated with apoptosis in different settings of AngII- and 
aldosterone-induced cardiomyopathy4,87. Potentially, ASK-1 and P38MAPK reduction of 
B-cell lymphoma 2 (Bcl2), and induction in Blc2 associated X protein (Bax) and caspase-
3, plays a role in mediating Nox-dependent apoptosis in the setting of aldosterone and 
AngII infusion respectively4,87.  
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ROS can also modulate proteins involved in ECC, such as RyR2 and Ca2+/Calmodulin-
dependent protein kinase II (CAMKII)87. It appears that Nox2-dependent CaMKII 
oxidation causes apoptosis of sinoatrial (SA) cells in a mouse model of AngII infusion. 
The exact role of Nox2 in AngII-related cardiac dysfunction still needs further 
clarification.  
Nox2 has also been implicated in AngII-specific cardiovascular remodelling, which is 
discussed in more detail in section 1.8. In addition to Nox2, inflammation has also been 
linked to cardiovascular disease (CVD) and may play a pertinent role in the associated 
remodelling process. 
 
1.7 Inflammatory response in cardiovascular remodelling 
The inflammatory response plays a major role in the progression of CVD. Within the 
heart, an immune-mediated response provides a short-term adaptation to stress in an 
attempt to ultimately restore tissue homeostasis and cardiovascular function. 
However, if these abnormal conditions are sustained and inflammation progresses this 
can contribute further to myocardial damage leading to progressive LV dysfunction 
and remodelling112.  
Immune responses in cardiac tissue are initiated by pathogen-associated molecular 
patterns (PAMPs) or damage-associated molecular patterns (DAMPs), which are both 
detected by pattern recognition receptors (PRRs). PAMPs arise from foreign material 
such as glycolipids from mycobacterium or double-stranded ribonucleic acid (dsRNA) 
from viruses. In comparison DAMPs arise from endogenous host material that can be 
released by injured or dying myocardial cells. Upon recognition of PAMPs and DAMPs, 
PRRs stimulate signalling cascades that in turn activate NF-κB, activator protein-1 (AP-
1) and interferon regulatory factor (IRF) transcription factors112. These enable the 
modulation of target genes that encode pro-inflammatory cytokines and interferons 
within the heart. Hence kick starting an innate immune response, further discussed in 
section 1.3.  
Activation of neurohormonal systems such as the RAAS is sufficient in triggering 
cardiac inflammation, and the associated pro-inflammatory cytokines have an 
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extensive role in the pathophysiological response113.  Inflammatory mediators, which 
are upregulated in this setting, are instigated in several cardiovascular remodelling 
processes including hypertrophy, fibrosis and apoptosis114. There is a complex, cell-
specific response to numerous pro-inflammatory cytokines by cardiomyocytes, 
fibroblasts and inflammatory cells (Figure 1-14); such cytokines include TGFβ, TNF-α, 
IL-1β and IL-6115. The concentration of these cytokines within patients with heart 
failure has been found to correlate to disease severity, and hence may play a role in 
disease progression116. However the complexity of ascertaining the source and target 
of these cytokines is increased by the temporal changes in the inflammatory response 
to cardiovascular injury115. 
 
 
Figure 1-14: Interactions between cardiomyocyte and non-cardiomyocytes during 
cardiac remodelling. Adapted from Frieler et al 2015115. 
 
TGF-β is a major pro-fibrotic cytokine that is heavily upregulated in hypertrophied and 
fibrotic hearts resulting from hypertension115. With the ability to modulate a range of 
responses in cardiomyocytes, immune cells and fibroblasts; TGF-β signalling pathways 
are context dependent115. Previous research demonstrates that overexpression of TGF-
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β is sufficient to induce cardiac hypertrophy and fibrosis117. Similarly inhibition of TGF-
β signalling and TGF-β KO models demonstrate reduced levels of fibrosis and prevent 
cardiac dysfunction118,119.  
Previous studies investigating TNF-α in relation to pressure overload-induced cardiac 
remodelling have highlighted its importance in this setting120. An in vivo study 
increasing the systemic level of TNF-α, to that found during heart failure, showed that 
this resulted in cardiac dysfunction121. Furthermore, the overexpression of cardiac-
specific TNF-α leads to the progression of cardiac hypertrophy and fibrosis122. This was 
further confirmed by a TNF-α KO model that prevented cardiac hypertrophy, fibrosis 
and dysfunction in response to pressure-overload120.  
Pressure-overload induced cardiac hypertrophy and dysfunction is blunted in IL-1β 
deficient mice, highlighting a role in cardiac remodelling123. Furthermore, healthy mice 
treated with IL-1β induced cardiac dysfunction and reduced exercise tolerance124. An 
IL-1 receptor agonist (anakinra) also confirms the pathological properties of IL-1β, by 
producing beneficial responses in terms of cardiovascular remodelling and exercise 
tolerance125,126.  
During hypertension levels of IL-6 tend to increase, however it also has a direct role in 
associated cardiovascular remodelling127. Rats infused with IL-6 for a week displayed 
cardiac hypertrophy, fibrosis and dysfunction127. In addition IL-6 KO models have been 
shown to prevent AngII-induced cardiac remodelling and associated signalling 
pathways128,129. However, similar studies using pressure overload, show no differences 
in IL-6KO models in terms of hypertrophy and fibrosis115. Therefore the specificity of IL-
6 signalling is yet to be ascertained115.    
As described above, the inflammatory response is a key process for the progression of 
CVD, here we have focused on inflammatory signalling however the immune cell 
activation and prevalence are also implicated within this setting and are discussed 
later.  
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1.8 Nox2 and inflammation in AngII-induced hypertension 
The individual impacts of Nox2 and inflammation on CVD have been discussed in 
sections 1.6 and 1.7. However there are also collaborative effects that aid the 
progression of cardiovascular remodelling.  
There is a key role for Nox in the ROS-dependent increase in blood pressure, 
suggesting its implication in hypertensive signalling. The RAAS plays a vital homeostatic 
role in maintaining blood volume and systemic vascular resistance (section 1.4), 
thereby influencing cardiac and vascular function, as illustrated in Figure 1-9. In order 
to prevent tissue damage and initiate the healing process, in response to stress, the 
immune system mediates an inflammatory response. Initial inflammation involves 
activation of tissue resident immune cells, such as macrophages, leading to the release 
of inflammatory mediators. These in turn cause vasodilation and increased 
permeability of blood vessels to enable leukocytes, such as T-cells, to migrate into the 
tissue and aid the inflammatory response130. 
Inflammation is potentially implicated in hypertension as summarised in Figure 1-15. A 
number of different research groups have highlighted the presence of inflammatory 
immune cells and cytokines within this setting. AngII and other components of RAAS 
are able to stimulate Nox and the production of ROS. ROS in turn activate pro-
inflammatory transcription factors such as Nrf2, NF-κB and AP-1, enabling the 
expression of adhesion molecules and chemokines131,132. In addition, oxidative stress 
or injury can trigger inflammation by oxidising lipoproteins that can interact with toll-
like receptors (TLRs); initiating a number of inflammatory responses131. A variety of 
inflammatory cells also express Nox133, potentially adding to hypertension by 
increasing ROS levels further. Moreover, ROS may mediate signalling within immune 
cells and therefore influence their phenotype within this setting; this is discussed in 
more detail later. Furthermore, ROS contribute to hypertension directly by inducing 
vasoconstriction, enhancing water and Na2+ retention within kidneys and encouraging 
sympathetic outflow from the central nervous system (CNS)131. 
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Figure 1-15: Role of Nox-dependent ROS in angiotensin II induced hypertension. 
Adapted from Harrison et al131. 
 
The involvement of T-cell Nox2 in the setting of AngII-induced hypertension has also 
been highlighted by Guzik et al134. T-cells express Nox2, which is essential for full 
development of AngII-induced hypertension133,134. Recombination-activating gene 
(RAG)-/- mice, which lack T- and B-cells, showed a blunted response to AngII in terms of 
hypertension. Furthermore, the adoptive transfer of T- (but not B-) cells was able to 
restore this response134.  Adoptive transfer of T-cells lacking p47phox, an essential Nox2 
subunit were only partially able to restore the expected AngII-induced phenotype. 
Moreover, mice globally lacking p47phox eliminated the recruitment, activation and 
infiltration of T-cells within the aorta in response to AngII134. Infusion with AngII in 
C57Bl/6 mice increased expression of T-cell Nox2 subunits whilst enhancing O2
•- 
production134. AngII activation of T-cells was verified in vitro where apocynin, an 
NADPH oxidase inhibitor blunted this effect134. 
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Nox2 may therefore have an important endogenous role in T-cells but has also been 
implicated in the development of blood pressure and inflammation by Lob et al135. 
Specific deletion of p22phox, a vital Nox subunit, in the subfornical organ (SFO) in the 
brain prevented inflammation and decreased accumulation of ROS within this region in 
AngII treated mice135. p22phox is vital for both Nox2 and Nox4 activation, which have 
been shown to orchestrate opposing responses in vivo. Hence this research highlights 
the general role of Nox in the SFO, but not individual functions and effects in response 
to AngII infusion.  
AngII is primarily involved in the inflammatory response during hypertension by 
modulating different pro-inflammatory transcription factors and chemokines132. AngII-
dependent activation of Nox2 is well recognised to be an important contributor to 
many AngII responses136.  
 
1.9 Research aim and objectives  
As described above, Nox2 and inflammation have separately been identified to have an 
important role in the pathophysiology of AngII-induced cardiovascular remodelling. 
Furthermore, T-cell Nox2 within this setting has previously been implicated in the 
generation of vascular remodelling. However, the specific role of T-cell Nox2 and 
specific T-cell subtypes in the cardiovascular response to AngII requires further 
investigation.   
Therefore the aim of this thesis was to identify the role of T-cell Nox2 and its capacity 
to regulate cardiovascular remodelling in the setting of increased RAAS activation.  
In order to achieve our aim, our objectives were to:  
1. Determine the pattern of T-cell infiltration in the heart during RAAS activation. 
2. Investigate the role of Nox2 in AngII-induced infiltration of T-cells into 
cardiovascular tissues. 
3. Analyse the specific role of Nox2 in regulatory T-cell function.  
4. Develop a novel in vivo mouse model of CD4+ T-cell-specific Nox2 knockout and 
study the response to chronic RAAS activation.  
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2.1 Animal husbandry 
All mice were housed and maintained in a designated facility in accordance with the 
Code of Practice for the Housing and Care of Animals Used in Scientific Procedures 
issued by the UK Home Office. Up to 6 mice were housed per cage with unlimited 
access to food and water with 12 hours of light/day. All animal procedures were 
performed in accordance with the Guidance on the Operation of the Animals (Scientific 
Procedures) Act, 1986 (UK Home Office) and local institutional guidelines. 
 
2.2 Murine models 
Male mice aged 6-8 weeks were used for all experiments. C57Bl/6 mice were 
purchased from Harlan UK Limited and both global Nox2KO and CD4-Nox2KO mice 
were bred at our institution as described in sections 4.3 and 6.3 respectively.  
 
2.3 Angiotensin II infusion model 
Subcutaneous mini-osmotic pumps (Alzet® Micro-osmotic pump, model 1002) 
containing a pressor dose (1.1mg/kg/day) of AngII were implanted into mice. 
Treatment continued up to 14-days, as illustrated in Figure 2-1.  
 
 
Figure 2-1: Experimental design. 
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Mini-osmotic pumps were prepared as per the manufacturer’s instructions (Figure 2-2) 
and pumps were weighed before and after being filled to ensure correct loading. The 
concentration of AngII (CAngII) used to fill the mini-osmotic pump was calculated using 
the following equation: 
𝐶𝐴𝑛𝑔𝐼𝐼 (µ𝑔/µ𝑙) =
𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝑑𝑜𝑠𝑒 (µ𝑔/𝑘𝑔/ℎ𝑟)𝑥 𝑚𝑊(𝑘𝑔)
𝑀𝑃𝑅 (µ𝑙/ℎ𝑟)
 
Where the desired dose was 45.83µg/kg/hr (1.1mg/kg/day), the mean pump rate 
(MPR) was 0.25±0.05μL/hr and the mouse weight (mW) was determined on the day of 
surgery. The MPR is calculated by the manufacturer during performance tests, using 
the following calculation: 
𝐾 = 𝑄 𝑥 𝐶 
 
Here, ‘K’ is the mass delivery rate (μg/hr), ‘Q’ is the volume delivery rate (µL/hr) and ‘C’ 
is the concentration (μg/μL) of the agent in the vehicle. Finally, the maximum amount 






Where ‘D’ is the duration (hrs), ‘V’ is the reservoir volume (µL) of the mini-osmotic 
pump and ‘Q’ is the pumping rate (µL/hr). Therefore based on the mean fill volume of 
110.7µL, and a MPR of 0.25µL/hr, the maximum amount of time the drug will defuse 
for is 442.8 hours (18.5 days). As shown in Figure 2-1 mini-osmotic pumps were 
removed prior to the maximum time limit, after 14-days of infusion.  
 
With the mini-osmotic pump held in an upright position, a 1mL syringe was used to 
inject the solution into the top of the mini pump, ensuring the pump reservoir was full 
and all air had been displaced (Figure 2-2B). Finally the flow modulator was inserted to 
displace any remaining trapped air and prevent leakage (Figure 2-2C).  Mini-osmotic 
pumps were then kept in sterile saline until surgical implantation. Animals from the 
sham group were implanted with empty mini-osmotic pumps.   
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Figure 2-2: Mini-osmotic pump filling procedure. 
 
Mice were anaesthetised using 2% isoflurane in medical O2 at 2L/minute, and then 
anaesthesia was maintained at this concentration using a nose cone. Fur was removed 
from the surgical area using an electric razor (Wella) and the area was cleaned with 
iodine and chlorhexidine (Vetasept). Abolition of the toe pinch reflex was used to 
confirm deep anaesthesia, 1U vetergesic (0.03mg/mL, buprenorphine) and 5U 
finadyne (1mg/mL, flunixin meglumine) were administered, by subcutaneous and 
intramuscular injections respectively, to provide long-lasting analgesia. An incision was 
then made at the top of the mouse dorsum in line with the scapula using surgical 
scissors (Figure 2-3). The skin plane and muscle plane were separated by blunt 
dissection with surgical scissors to create a subcutaneous pocket into which the mini-
osmotic pump was inserted. The incision was closed using 5.0 polyglactin coated vicryl 
sutures (W9442, Ethicon®). Mice were closely monitored for 3-days post-surgery to 
ensure recovery. 
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Figure 2-3: Surgical implantation of subcutaneous mini-osmotic pumps. (A) Maintain 
anaesthetic using a nose cone, (B) fur is removed and area cleaned and (C) a small 
incision made at the top of the mouse dorsum. (D&E) A subcutaneous pocket is then 
made and (F&G) the mini-osmotic pump is inserted. Finally, (H&I) the incision is sutured 
to close the wound.  
 
2.4 Harvesting organs 
2.4.1 Histology 
Animals were submitted to terminal anaesthesia (3% isoflurane in 2L/minute of O2) 
and culled by cardiac arrest in diastole induced by injection of 0.5% potassium chloride 
(KCl) directly in the LV and, followed by excision of the heart. The LV was then 
dissected as shown in Figure 2-4 and treated as described in section 2.8 for 
cryosections and paraffin sections. Heart samples for RNA and protein extraction were 
snap-frozen in liquid nitrogen and stored at -80°C. 
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Figure 2-4: Heart dissection for analysis. 
 
2.4.2 Flow Cytometry 
All animals were submitted to terminal anaesthesia (3% isoflurane in 2L/minute of O2) 
before performing splenectomy. Whole hearts were then perfused with 0.9% NaCl 
through the LV before harvesting to eliminate residual blood. Both the heart and 
spleen were stored in isolation buffer (500mL phosphate buffered saline (PBS) w/o 
Ca2+ and Mg2+, 2mL 5M ethylenediaminetetraacetic acid (EDTA), 2mL foetal calf serum 
(FCS)) on ice before preparation for flow cytometry (section 2.6). In experiments where 
the kidney was used, the whole left kidney was removed and placed in isolation buffer. 
For experiments where aorta was required, the aorta was carefully removed after 
cardiac excision, and placed in isolation buffer as before.  
 
2.4.3 Immune cell isolation 
Animals were culled using increasing levels of carbon dioxide (CO2) prior to removal of 
LNs and spleen. Peripheral lymph nodes (PLNs) were removed first followed by 
mesenteric lymph nodes (MLNs) and finally the spleen, as illustrated in Figure 2-5. All 
lymphatic organs were placed in complete media (500ml RPMI with L-Glutamine, 
10,000U Penicillin, 10,000μg/ml streptomycin, 10% FCS, 1% HEPES, 500μl β2-
mercaptoethanol) on ice until next step. For the initial immune cell characterisation in 
Chapter 6:, PLNs and MLNs were kept separate in order to analyse individually.  
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Figure 2-5: Location of lymphoid organs within murine models, adapted from Dunn et 
al 1954. Lymphoid organs isolated for our experiments are highlighted in yellow. 
 
2.5 Physiological measurements 
2.5.1 Blood pressure 
Blood pressure recordings were measured on conscious mice by tail cuff 
plethysmography using either CODA™ (Kent Scientific Corporation) or MK-2000ST 
monitor (Muromachi Kikai, Japan), non-invasive blood pressure systems. Mice were 
acclimatised for 3-days prior to recordings; this entailed placing the mice into the 
restraint (Figure 2-6) for 10 minutes followed by 6-8 blood pressure measurements. 
The acclimatisation period reduces animal stress during future recordings, preventing 
any anomalies.  For the CODA™ system, the occlusion and volume-pressure recording 
(VPR) cuffs determine the blood volume within the tail in order to measure systolic, 
diastolic and mean blood pressure. For this method an average of 20 blood pressure 
recordings per mouse were taken. For the MK-2000ST the cuff-pulse sensor is an all-in-
one system enabling accurate measurement of systolic, diastolic and mean blood 
pressure. For this method an average of 8-10 recordings per mouse were taken.  Heart 
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rate was maintained between 600-700 beats per minute (bpm) by allowing mice to 
rest in-between recordings.  Blood pressure recordings were taken at baseline (prior to 
surgery) and at 3-, 7- and 14-days after surgery. Extra measurements were taken in 
between recordings to maintain acclimatisation of the mice to the procedure.  
 
 
Figure 2-6: Tail cuff plethysmography set up to record blood pressure. (A) Image 
showing mouse in a restraint with the cuff-pulse sensor around the tail, which is 




Echocardiography was performed at baseline (prior to surgery) and at 3-, 7- and 14-
days after surgery using the Visualsonics Vevo® 2100 imaging system (FUJIFILM, 
Canada). Mice were initially weighed and anaesthetised with 5% isoflurane (IsoFlo®) in 
medical O2 at 1L/minute, then maintained on a nose cone at 1.25-1.5% isoflurane on a 
heated platform in the supine position. Fur was removed from the abdomen using a 
topical depilatory agent (Veet) and residual cream was thoroughly removed using 
water. Limbs were taped to copper tabs on the heating platform that act as the 
electrocardiogram gating (Figure 2-7). Body temperature was measured using a rectal 
temperature probe, which was maintained between 36°C and 37°C using the heating 
platform and a heating lamp to further increase body temperature. In addition, heart 
rate was maintained above 400bpm by maintaining body temperature and adjusting 
isoflurane levels appropriately. Ultrasound transmission gel (Skintact ultrasonic gel) 
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was then applied to the abdomen before lowering the transducer into position using a 
mechanical arm to maintain stability during recording. 
A linear transducer of 32-56MHz (Visualsonics MS550) was used to obtain parasternal 
long axis (PLAX) and parasternal short axis (PSAX) views (Figure 2-7). Both motion-
mode (M-mode) and brightness-mode (B-mode) images in PLAX and PSAX were used 
to measure the left ventricular end diastolic (LVED) and systolic (LVES) diameter 
(Figure 2-8). From these measurements LVED and LVES volume, ejection fraction (EF) 
and fractional shortening (FS) were automatically determined by Visualsonics Vevo® 
software. In addition PLAX M-mode was used to measure the interventricular septum 




Figure 2-7: Obtaining PLAX and PSAX echocardiography images. 
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Figure 2-8: Measurements for cardiac structure and function. Echocardiography 
provides physiological measurements in both systole and diastole to analyse heart 
function. 
 
Echocardiography images were analysed using Visualsonics Vevo® 2100 1.5.0 software. 
Measurements from B-mode images involved tracing around the LV, as shown in 
Figure 2-8. For M-mode images the posterior and anterior LV walls were traced over at 
least three contractions and measurements were generated automatically by the 
software (Figure 2-9). Three measurements were recorded per image, for B-mode and 
M-mode, and the average was calculated between all PLAX and PSAX images.   
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Figure 2-9: Echocardiography analysis of M-mode images. Images to show analysis of 
(A) parasternal long axis (PLAX) and (B) parasternal short axis (PSAX).  
 
2.6 Flow cytometry 
2.6.1 Principles of flow cytometry 
Flow cytometry uses fluorophore-bound antibodies in order to analyse the different 
cell types within a single cell suspension. The cell suspension is hydro-dynamically 
focused to intersect an argon-ion laser (Figure 2-10), with a specific wavelength, and 
scattered light is detected in terms of forward scatter (Fsc) and side scatter (Ssc) 
indicating cell surface area and granularity respectively. There are three parameters to 
detect scattered light; height (H), width (W) and area (A). Detectors are also present 
for fluorescent light emitted from fluorophores bound to specific antibodies. These 
allow detection of specific cells dependent on their distinct cell surface markers. 
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Figure 2-10: Schematic of a flow cytometer. Single cell suspensions are focused hydro-
dynamically with sheath fluid to intersect a laser. Emitted signals are detected by a 
forward light scatter detector, side light scatter detector (1) and multiple fluorescence 
emission detectors (1-4). Detected signals are then amplified and converted into a 
digital signal for analysis. Adapted from Brown et al 2000 (clinical chemistry)137. 
 
Within this thesis three flow cytometry machines are used, BD FACS Calibur™, BD FACS 
Canto II™, and BD LSRFortessa™. All of these machines are multi-parameter systems. 
The Calibur™ is a basic flow cytometry machine that utilises two lasers to enable 
detection of up to 4 fluorophores whereas the Canto II™ contains three lasers and 
allows detection of up to 8 fluorophores at once (Table 2). Finally the Fortessa™ 
utilises five lasers and detects up to 18 fluorophores at once (Table 3). All machines 
analyse Fsc and Ssc, however the Calibur™ measures only Fsc-H and Ssc-H whereas the 
Canto II™ and Fortessa™ can measure all Fsc and Ssc parameters (H, W and A) enabling 
elimination of doublets. Doublets occur when two cells become physically attached to 
each other or when two cells pass through the laser beam close together, so that they 
are recorded as a single event. The Calibur™ was initially used to carry out preliminary 
experiments that are shown in section 2.6.3.1, these were then repeated on the Canto 
II™ instrument, fully analysed and are discussed in section 3.3. The Fortessa™ was used 
only for the immune composition analysis of lymphoid organs of the CD4-Nox2KO 
model at baseline in section 6.4.3.  
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Table 2: BD FACS Calibur™ and Canto II™ laser specifications. 
 
  78  
 
Table 3: BD LSR Fortessa™ laser specifications. 
 
2.6.2 Preparation of samples 
Single cell suspensions were prepared from whole organs. Fibrous tissues, such as 
heart and aorta, were digested for 30 minutes at 37°C in digestion solution (Ca2+/Mg2+ 
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free PBS, 0.5% bovine serum albumin (BSA), 1mg/mL collagenase, 1mM EDTA, 
100U/mL deoxyribonuclease I (DNase I) 500U/mL hyaluronidase IV-S). All samples 
were then triturated and filtered separately through a 70μm nylon mesh, followed by a 
second filtration through a 30μm nylon mesh. Cell suspensions were then washed in 
isolation buffer (200mM EDTA, 0.4% FCS in Ca2+/Mg2+ free PBS) and centrifuged at 
1800rpm for 5 minutes at 4°C. Spleen samples were treated for 3 minutes with 1x red 
cell lysis buffer (Biolegend) at room temperature followed by a final wash in isolation 
buffer. Samples were re-suspended in 500μL of isolation buffer and 30-40μL of each 
sample was used for ‘fluorescence-minus one’ (FMO) controls for each antibody used. 
The FMOs are prepared in the same way as the samples and contain all but one 
antibody, in Table 4 and Table 5, therefore allowing clear identification between 
positively and negatively stained cells. 
Cell suspensions and FMOs were FcRγ-blocked for 15 minutes on ice, using anti-mouse 
CD16/CD32 antibody (BD pharmingen, 10μg/mL, 1:50) followed by staining (30 min, on 
ice) with a combination of antibodies in Table 4 and Table 5, depending on the flow 
cytometry machine being used. The samples were then washed in 2mL isolation buffer, 
centrifuged (5 mins, 1800rpm, 4°C) and the pellet was re-suspended in 500µL isolation 
buffer.  
Samples that included anti-FoxP3 antibody staining required a further fixation and 
permeabilisation step before incubation with this antibody. All other antibodies were 
incubated as previously stated, however prior to re-suspending the cell pellet in 500μL 
isolation buffer; cells are incubated with 200μL fixation buffer (Biolegend) for 20 
minutes at 4°C before being washed twice in 1mL 1x permeabilisation washing buffer 
(Biolegend). Samples were then incubated with anti-FoxP3 antibody, at concentrations 
shown in Table 4, for 15 minutes before a final wash in permeabilisation buffer. 
Before running samples through the BD FACS Canto II™ machine they were filtered 
through a 30μm nylon mesh. For fixed samples a Zombie aqua™ dead cell stain (1:100, 
ebioscience) is incorporated into the initial antibody staining step before fixation, 
however unfixed samples were incubated for 3-5 minutes with Sytox®Blue Dead Cell 
Stain (Invitrogen, 2μM, pacific blue) instead.  
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Table 4: Antibodies used for flow cytometry with the Calibur™. 
 
 
Table 5: Antibodies used for flow cytometry with the Canto II™ and Fortessa. 
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2.6.3 Compensation 
When using multiple fluorophores in an experiment, spectral overlap can occur. This is 
where the fluorescence emitted from one fluorophore is detected within the specific 
wavelength channel designed to measure the signal from a different fluorophore138. 
Compensation is a process that enables the spectral overlap between different 
fluorophores to be mathematically eliminated, so that acquired data are accurate139.  
 
BD FACS Calibur™ 
Compensation for the BD FACS Calibur™ was performed manually on the flow 
cytometer, comparing single stained samples and removing spectral overlap between 
the channels being used.  
 
BD FACS Canto II™ and BD LSR Fortessa™ 
The BD FACS Canto II™ and BD LSR Fortessa™ automatically perform compensation on 
single stained samples; for this compensation beads (BD™ CompBeads, BD biosciences) 
were used. To prepare the beads, 1 drop of the anti-Rat and anti-hamster Ig κ solution 
and 1 drop of the negative control solution were added to 120μL isolation buffer for 
each antibody being used, in addition to an unstained beads control. Beads were then 
incubated for 30 minutes at room temperature with individual antibodies, shown in 
Table 4 and Table 5. Finally, the beads were washed in 2mL isolation buffer and 
centrifuged (1800rpm, 5mins). Supernatants were removed and beads were re-
suspended in 500μL isolation buffer. Beads stained individually for each antibody and 
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2.6.3.1 Flow cytometry protocol development 
 
Figure 2-11 shows the gating strategy used for flow cytometry on the Calibur™ in order 
to identify T-cells and different T-cell subpopulations. Initially this method was also 
used to identify a number of other inflammatory cells such as macrophages and B-
cells. Preliminary experiments showed an increase in total leukocytes (CD45+ cells), 
macrophages, B-cells and T-cells after 3-days of AngII treatment, as demonstrated in 
Figure 2-12. T-cell subpopulations also tended to increase with AngII, with a peak after 
3-days of treatment as shown in Figure 2-13. In addition, a similar trend was observed 
in isolated spleens from these animals (Figure 2-14). However these results showed a 
lot of variation and false positives, therefore we investigated the best way to analyse 
our samples using flow cytometry.  
 
 
Figure 2-11: Single cell suspensions prepared from whole hearts and analysed using 
the Calibur™. (A) T-cells were identified at CD45+TCRβ+ and further T-cell subsets 
analysed using CD4 and CD8. (B) Tregs (CD25+FoxP3+) were identified from CD4+ T-cells 
(CD45+CD4+). 
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Figure 2-12: Preliminary results showing an altered immune cell infiltration into the 
heart during AngII treatment. The effect of AngII treatment on (A) CD45+ cells, and 
more specifically (B) macrophages (CD11b+F4/80+), (C) B-cells (B220+CD19+) and (D) T-
cells (TCRβ+). All cells are represented as a percentage of total cells acquired using the 
Calibur™.**p <0.01, N=3 per group. 
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Figure 2-13: Preliminary results showing altered T-cell subtype profile infiltrating the 
heart during AngII treatment. (A) Double negative  T-cells (CD4-CD8-) (B) CD8+ T-cells 
(CD4-CD8+), (C) Double positive T-cells (CD4+CD8+), (D) CD4+ T-cells (CD4+CD8-) and (E) 
regulatory T-cells (CD4+CD25+FoxP3+). All data is represented as a percentage of total 
cells acquired on the Calibur™. N=3 per group. 
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Figure 2-14: Preliminary results showing an altered infiltration of immune cells within 
the spleen during AngII treatment. The percentage of (A) CD45+ cells, (B) T-cells 
(CD45+TCRβ+) and (C) T-cell subtypes, identified by expression of CD4 and CD8, in 
response to AngII treatment up to 14-days. All data is represented as a percentage of 
total cells acquired on the Calibur™. N=3 per group. 
 
Results using the Calibur™ looked promising, especially concerning T-cells, however 
one can argue the accuracy of the T-cell subsets in the spleen in the sham treated 
mice. Here the CD8+ T-cells were three times more numerous than their CD4+ 
counterparts whereas a lower ratio is found in the literature, of 1:2 (CD4+:CD8+ T-
cells)140,141.  
FMO controls were introduced later, which enable accurate positive and negative 
gates to be placed for flow cytometry analysis as described in section 2.6.1 however 
this highlighted further limitations with the method. Figure 2-15 illustrates a specific 
gating strategy for a heart sample from a mouse treated for 3-days with AngII. When 
identifying T-cells (CD45+TCRβ+) there is a high amount of background staining due to 
auto-fluorescent dead cells and doublets, which are visualised as a bright diagonal line, 
panel 3 of Figure 2-15. Using the Calibur™ method, this background material needs to 
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be gated out of the results; however there are also correctly stained cells that fall 
amongst this group, making analysis difficult and unreliable. Figure 2-15B further 
highlights this point; this is an FMO control for CD8-APC in which there should not be 
any CD8+ cells. This figure shows background staining making it impossible to place a 
reliable CD8-APC positive/negative boundary. 
 
 
Figure 2-15: Limitations of the Calibur™ method. The (A) gating strategy for a WT 
heart sample treated with AngII for 3-days shows significant background staining 
clearly seen in CD45/TCRβ and CD4/CD8 panels. The (B) CD8-APC FMO shows 
significant background staining above the boundary between positive and negatively 
stained cells. 
 
Due to the low amount of immune cells in the heart this method, which lacked 
sufficient specificity, was inadequate to confidently identify specific immune cells 
infiltrating the heart. In order to verify these preliminary results the Canto II™ was 
used, enabling dead cell and doublet exclusion, as shown in Figure 2-16. This method 
also allows a higher number of events to be acquired as the heart sample can be 
stained for all antibodies at once whereas the Calibur™ method required samples to be 
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split in order to analyse each cell type. This is important when analysing more specific, 
rare cells such as Tregs.  
 
 
Figure 2-16: Single cell suspensions prepared from whole hearts and analysed using 
the Canto II™. (A) T-cells were identified at CD45+TCRβ+ and further T-cell subsets 
analysed using CD4 and CD8. (B) Tregs (CD4+CD25+) were identified from T-cells 
(CD45+TCRβ+). 
 
Figure 2-17 shows the CD8-APC FMO where one can clearly distinguish the negative 
cells below the horizontal line. There are no cells that occur across the positive-
negative boundary showing a clearer and more reliable analysis method for both heart 
and spleen samples. As results with the CantoII™ proved more reliable, we carried out 
our main flow cytometry experiments using this method, in addition to using controls 
such as FMOs and compensation beads to ensure correct compensation of 
fluorescence spill over. These preliminary flow cytometry results are repeated and 
analysed in more detail in chapter 3.  
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Figure 2-17: Improvement with the Canto II™ when analysing CD8-APC FMO. CD8-
APC FMO for (A) heart samples and (B) spleen samples are clearer using the Canto II™. 
 
2.7 RNA extraction and qPCR 
2.7.1 RNA extraction 
RNA was extracted according to the manufacturer’s technical datasheet from whole 
tissues (RNasy® fibrous mini kit, Qiagen) or isolated cells (RNeasy® mini kit, Qiagen). 
Tissues were disrupted and homogenised using 300µL buffer RLT (Qiagen, with 
addition of 10µL β-mercaptoethanol (β-ME) per 990µL of RLT) by pipetting repetitively. 
Ribonuclease (RNase)-free water (590µL) and proteinase k (10µL, Qiagen) were then 
added and samples were incubated at 55˚C for 15 minutes. Tissue samples were then 
centrifuged for 3 minutes at 11,000rpm and transferred to a new tube. Half the total 
volume of 96% ethanol (EtOH) was then added to the sample and mixed. Isolated cells 
were disrupted by adding 350µL (for <5 x 106 cells) or 600µL (for <1 x 107 cells) buffer 
RLT. The lysate is then pipetted directly into a QIAshredder™ spin column (Qiagen) 
placed above a 2mL collection tube and centrifuged for 2 minutes at full speed. One 
volume of 70% EtOH was then added to each sample and mixed well by pipetting.  
Lysates from both methods above were then treated as follows. 700µL of the sample 
was then transferred to the RNeasy mini column (placed in a 2mL collection tube) and 
centrifuged at 11,000rpm for 15 seconds. The flow-through was discarded and this 
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step repeated until the entire sample was used. Then, 350µL of buffer RW1 (Qiagen) 
was added to the RNeasy mini column and centrifuged for 15 seconds at 11,000rpm. 
Once again, the flow-through was discarded before adding 80µL of DNase, diluted in 
buffer RDD (Qiagen), (10µL DNase mg/mL + 70µL buffer RDD) directly to the 
membrane for each sample. After incubating for 15 minutes, 350µL of buffer RW1 was 
added to the RNeasy mini column and the sample was centrifuged for 15 seconds at 
11,000rpm. The flow-through was discarded and this process was repeated with 500µL 
of buffer RPE (Qiagen) twice, discarding flow-through in between washes, and the 
second centrifuge was extended to 2 minutes at 11,000rpm. The RNeasy column was 
then placed into a new 2mL collection tube and centrifuged at full speed for 1 minute 
to remove any excess EtOH and then placed into a new 1.5mL Eppendorf. 30µL of 
RNase-free water was then added directly to the membrane and left for 2 minutes at 
room temperature to allow release of RNA from the membrane. Samples were then 
centrifuged for 1 minute at full speed and this elution step was repeated using the RNA 
eluate collected in the 1.5mL Eppendorf.    
 
2.7.1.1 Measuring RNA concentration 
RNA concentration was then measured for all samples by using a NanoDrop-1000 (ND-
1000). The sample type, nucleic acid, was selected on the ND-1000 software and the 
pedestal cleaned with water in preparation. 1µL of RNase-free water was then loaded 
onto the pedestal of the ND-1000 to set and blank the machine. Then, 1µL of each 
sample was loaded individually onto the pedestal and the absorbance detected at 
260nm (for nucleic acid). The following calculation is used by the ND-1000 software to 





) = 𝐴260 × 𝐶𝑜𝑛𝑠𝑡𝑎𝑛𝑡(40 𝑓𝑜𝑟 𝑅𝑁𝐴) 
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2.7.2 Reverse transcription 
A thousand nanograms (1000ng) of RNA were used for reverse transcription (RT) and 
added to 7µL of the super-mix (Omniscript® reverse transcription kit, Qiagen), 
components of which are shown in Table 6, and the volume was rounded up to a total 
of 20µL with RNase-free water. Samples were incubated at 37˚C for 60 minutes using a 
thermocycler. After the polymerase chain reaction (PCR) cycle is complete, 
complementary DNA (cDNA) samples are diluted with 50µL of RNase-free water. 
 
 
Table 6: Reverse transcription super-mix components. 
 
2.7.3 Quantitative PCR 
DNA generated from the RT-step was then used for a quantitative PCR (qPCR). All 
primers used are shown in Table 7 and are reconstituted with RNase-free water to 
generate 100mM stock solutions. 1mM aliquots were then made by diluting these 
stocks with RNase-free water as a “working” stock to be used for experiments. A 
master mix was made up for each PCR primer being used with the components in 
Table 8. 18µL of the master mix was then added into the correct wells of a 96-well 
plate in addition to 2µL of the cDNA generated from the RT-PCR in the previous step. 
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Table 8: Super mix for qPCR. 
 
2.8 Sample preparation and tissue staining 
Tissue samples for paraffin sections were fixed for 2-4 hours in 2% paraformaldehyde 
(PFA), washed and stored in 70% EtOH. Tissues were then embedded in paraffin wax 
and 6µm thick sections were cut using a microtome. Paraffin sections were mounted 
onto glass slides (Superfrost® plus, Thermo scientific) with at least 4 sections per slide 
and stored at room temperature. Before tissue staining, paraffin sections were 
rehydrated in xylene followed by a series of EtOH dilutions (100%, 100%, 95%, 75%, 
50%, 25%) and double-distilled water (ddH2O) for 1 minute each. 
Tissue samples for cryosections were mounted on cork with tragacanth gum (4% 
tragacanth gum, 1% thymol m/v in ddH2O) and frozen in liquid nitrogen-cooled 
isopentane. Samples were stored at -80°C. Transverse sections (6µm thick) were cut 
using a cryostat and 3 sections were mounted onto each glass slide (Superfrost® plus, 
Thermo scientific) and air-dried before being stored at -80°C. Prior to tissue staining, 
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cryosections were thawed at room temperature for 30 minutes and fixed using 4% PFA 
in PBS for 5 minutes. 
 
2.8.1 Haemotoxylin and eosin Staining 
Haemotoxylin and eosin (H&E) staining was performed after rehydration of paraffin 
sections, the tissues were incubated in 1% aqueous eosin for 10 seconds and then 
rinsed for 5 minutes under running tap water. Samples were then treated in Harris 
haematoxylin for 30 seconds before a further 5 minute rinse under running tap water. 
Stained tissue sections were then dehydrated in successive baths of EtOH and xylene 
(25%, 50%, 75%, 95%, 100%, 100% EtOH, Xylene) for 1 minute each before mounting 
with DPX (distyrene, a plasticizer and xylene, Sigma Aldrich) and a coverslip.  
 
2.8.2 Wheat germ agglutinin staining 
Wheat germ agglutinin (WGA) is a lectin that binds to residues of N-acetyl-D-
glucosamine and sialic acid, which are highly expressed on cell surface membranes142. 
When conjugated with rhodamine, a fluorescence dye, cell membranes can be 
visualised as red fluorescence.  
Rehydrated paraffin transverse sections were treated steamed in antigen unmasking 
solution (Vector H3300) for a total of 30 minutes to retrieve antigens. Sections were 
then washed three times for 5 minutes in 1x PBS with agitation before individual 
sections were isolated with a water repelling marker (Dako, DakoPen). Samples were 
blocked for 45 minutes with 10% goat serum in PBS (Vector) at room temperature in a 
humidity chamber. Sections were then incubated for 2 hours at room temperature, in 
a humidity chamber, with avidin-FITC (1:100) and WGA-rhodamine (1:50) both diluted 
together in 10% goat serum. Samples were then washed 3x 5 minutes in PBS with 
agitation. Sections were then stained for 5 minutes with DAPI (1:10,000) and washed 
as before. Finally slides were mounted using mowiol (10% mowiol 4-88, 25% glycerol 
and 100mM Tris, pH 8.5). 
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2.8.3 Picrosirius red 
Picrosirius red (PSR) is a strong, linear anionic dye that contains six sulfonate groups 
that can associate to collagen fibres, which are cationic143. This staining therefore 
identifies fibrillary collagen, such as collagen I and III fibres, and can be visualised as 
red staining under brightfield microscopy143. 
Following rehydration the paraffin slides were incubated in 0.2% phosphomolybdic 
acid (Fluka) for 2 minutes. Sections were then washed in ddH2O before 2-hour 
incubation in 0.1% PSR (Fluka). Samples were then washed in two changes of acidified 
water (10% acetic acid) for 10 seconds each, before being dehydrated through a series 
of 25%, 50%, 75% and 100% EtOH for 1 minute each followed by two immersions in 




H&E and PSR slides were analysed by light microscopy using a Leica DM2000 LED 
brightfield microscope (Leica). Immunohistochemistry (chapter 3) and WGA slides 
were analysed using bright-field or wide-field fluorescence on an IX81-2 microscope 
(Olympus).  
Three images were taken for each of the heart sections on the slide. Images were 
acquired using velocity software (PerkinElmer) and analysed using either velocity or 
ImageJ (MacBiophotonics). For WGA staining, images were taken at 40x magnification 
and analysed using velocity software (PerkinElmer). The average of 10 cardiomyocytes 
were calculated per image taken by tracing the cardiomyocyte membrane of cells 
where DAPI stain (nucleus) was central and the cell appeared full and rounded. PSR 
images were taken at 20x magnification and were analysed using ImageJ software by 
estimating the area containing red picrosirius stain. For immunohistochemistry and 
H&E staining, three images were taken at 20x magnifications per section and 
representative images displayed to show the level of immune cell infiltration.  
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2.9 Statistical analysis 
All values were expressed as means the standard error of the mean (SEM) and 
significance was accepted when p≤0.05. Level of significance was stated as follows in 
figures: * P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. Graphpad Prism (Version 6) 
was used for all graphs and statistical analysis. 
Unpaired two-tailed t-tests were used for data comparing two distinct groups such as 
qPCR results showing different mRNA levels of a particular target gene between AngII 
and Sham animals. Where a f-test revealed significant difference in variances between 
groups, an unpaired t-test with Welch’s corrections was used. 
Data containing multiple groups where one variable is being analysed were statistically 
examined using a one-way analysis of variance between groups (ANOVA) test for 
differences between groups. This was followed by Bonferroni’s multiple comparison 
tests to compare individual groups. For example, data comparing cardiomyocyte 
surface area over different time points were analysed using this method.  
A two-way ANOVA, followed by a Bonferroni multiple comparison tests, was used for 
data where more than one variable was being analysed such as systolic blood pressure, 
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 Wild-type response Chapter 3:
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3.1 Introduction 
Chronic AngII infusion in animals is extensively used as a model of RAAS-dependent 
hypertension. Pressor doses of AngII significantly increase systolic blood pressure and 
lead to changes in vascular and cardiac function and morphology83, 134. 
 
3.1.1 Pathophysiological response to AngII 
AngII is the main effector peptide within the RAAS, which facilitates blood pressure 
homeostasis as described in section 1.4.  AngII and related RAAS components circulate 
in the blood to act on different organs and cell types involved in blood pressure 
regulation. For instance, AngII can target the brain to increase sympathetic nerve 
activity, allowing blood pressure maintenance144. In addition, AngII stimulates 
aldosterone production from adrenal glands, promoting water retention within the 
kidneys, hence increasing blood volume. Moreover, AngII can directly act on VSMCs 
that express AT1R, to induce vasoconstriction and remodelling, hence increasing blood 
pressure145.   
During treatment with AngII, the haemodynamic load increases therefore the heart 
morphology changes in order to maintain cardiac function89,90. These remodelling 
processes include cardiac hypertrophy, interstitial fibrosis and apoptosis that are 
discussed in detail in section 1.5. Direct effects of AngII on the heart also contribute to 
these effects. Briefly, increased cardiomyocyte size, and hence heart size, allows 
increased heart function and efficiency in order to maintain the increase in blood 
pressure89,90. Interstitial fibrosis enables maintenance of tissue structure and required 
rigidity to withstand higher pressures95. Finally, apoptosis is a homeostatic process 
enabling removal of injured cells106. These changes in cardiac structure prove 
beneficial to compensate for short-term increases in haemodynamic load. In contrast, 
as the pathological stimulus remains, cardiac remodelling develops a maladaptive 
stance contributing to cardiac dysfunction and progressing towards heart failure86.   
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3.1.2 Angiotensin II and inflammation 
In addition to being a major mediator of cardiovascular remodelling, AngII is also 
implicated in the inflammatory response (section 1.7 & 1.8). Recent studies have 
described AngII as a pro-inflammatory molecule with the ability to orchestrate an 
immune response146. Initially, AngII increases vascular permeability, by prostaglandins 
and vascular endothelial growth factor (VEGF), which initiates the immune 
infiltration147. In addition to this, within organs such as the kidney, heart and 
vasculature, AngII has been found to stimulate inflammation by mechanisms involving 
pro-inflammatory cytokines and chemokines148.  This leads to the accumulation of 
immune cells within these tissues. Furthermore, many immune cells contain the 
components required to synthesise AngII, hence potentially contributing to and 
amplifying the pathophysiological response. During initial stages of cardiac 
remodelling, inflammation is beneficial as a mechanism that enables damaged or dying 
cells to be cleared away with the aim to restore tissue homeostasis after injury. As the 
pathological stimulus remains the inflammatory response progresses and contributes 
to further cardiac damage. 
The underlying mechanism enabling immune-cell recruitment by AngII involves the 
induction of NF-κB and AP-1 transcription factors (in cells such as VSMCs, endothelial 
cells, fibroblasts and resident or circulating immune cells) that are involved in pro-
inflammatory responses149,150,151-153. These transcription factors activate genes 
encoding pro-inflammatory mediators such as IL-1, IL-6, IL-8, IL-12, TNF-α, IFN-γ, 
monocyte chemotactic protein-1 (MCP-1), C-C chemokine receptor 2 (CCR2), TGF-β, 
CCL5 and adhesion proteins such as vascular cell adhesion molecule-1 (VCAM-1) and 
intercellular adhesion molecule-1 (ICAM-1) 149,150. NF-κB is the main transcription 
factor enhanced during hypertension154. Inactive NF-κB is associated with nuclear 
factor κ light polypeptide gene enhanced in B-cells inhibitor alpha (IκB-α) in the 
cytoplasm of a wide range of cells types155. Activation involves the phosphorylation 
and subsequent degradation of IκB-α, thereby permitting NF-κB translocation into the 
nucleus and allow gene activation155. Zhang et al established a new cellular signalling 
pathway within VSMCs whereby AngII stimulation activates a Ras-MEK1-ERK-ribosomal 
S6 kinase (RSK) pathway leading to sequential phosphorylation and activation of NF-
κB156. AngII can also stimulate Nox, and subsequent ROS production may act as a signal 
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transduction messenger for numerous transcription factors, including NF-κB and AP-1, 
hence enhancing an inflammatory response153.  
AngII therefore increases the levels of cytokines, chemokines and adhesion molecules 
in cardiovascular tissues, which all aid the recruitment and infiltration of immune cells. 
These include macrophages, DCs, B-cells, T-cells and NK cells. Often this recruitment 
process in turn amplifies cytokine and chemokine production within these specific cell 
types enabling the inflammatory response to continue and progress. In addition, AT1R 
is also expressed on these immune cells, which can therefore be activated directly by 
AngII157-159. 
 
3.1.2.1 Innate immune cells implicated in AngII response 
Spontaneous hypertensive rats (SHRs), which have elevated levels of AngII, have a 
significantly higher level of macrophages infiltrating the aorta compared to WT rats158. 
When SHRs were treated with AT1 antagonists the observed inflammation, associated 
hypertension and aortic remodelling were attenuated158. Similarly, rats treated with 
AngII directly exhibited an infiltration of immune cells, which included macrophage 
recruitment160. Furthermore, macrophage infiltration is instigated in the setting of 
increased aldosterone, ET-1, salt and even double transgenic rat (dTGR) models 
expressing both angiotensinogen and renin genes151,152,154,161-163.  In vitro experiments 
also confirm these chemotactic properties of AngII in terms of monocyte migration164. 
Increased levels of inflammatory mediators occur concomitantly with cellular 
infiltration. NF-κB induction of chemokine MCP-1 and its receptor CCR2 are key 
components that enable the recruitment of macrophages, and elicit an inflammatory 
response158,165. These markers were increased in animals treated with AngII, 
aldosterone or salt, and accompanied the inflammatory process158, 160-163,166. AT1R 
antagonists and ACE inhibitors reduced expression of both MCP-1 and CCR2; in 
addition CCR2 deficient mice displayed a diminished macrophage infiltration in 
response to AngII167, 158,168. Similarly, AngII prompts production of cytokines and 
chemokines within macrophages and monocytes, such as MCP-1, CCR2, TNFα, IL-1, IL-
6, IL-8, IL-12, which further amplifies and progresses the inflammatory response 158,165. 
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DCs are also implicated in the AngII-inflammatory response. Being major mediators 
between the innate and adaptive immune responses they potentially play an 
important role in this setting169. In a rat model of chronic kidney fibrosis, AT1R 
blockade by valsartan eliminated the marked local increase in DCs and attenuated 
renal tubulo-interstitial damage170. DC activation and stimulation was also confirmed 
in mice with either AngII- or deoxycorticosterone acetate (DOCA) salt- induced 
hypertension169. The chemotactic properties of AngII in DC recruitment are also 
confirmed in vitro157. Human DCs treated with AngII display up-regulation of pro-
inflammatory cytokines, which are important in recruiting an adaptive immune 
response. Similar to macrophages, this involved the activation of NF-κB by AngII 
treatment, accompanied with higher levels of TNFα and IL-6 production from DCs 171. 
Furthermore AngII stimulates upregulation of CD80 and CD86 upon DCs, which 
enhances antigen-presentation to T-cells via CD28172. This process is critical to the 
development of hypertension, as inhibition of this costimulatory signal prevented T-
cell recruitment and the onset of experimental hypertension172.  
Although innate immune cells are important in the initial stages of the inflammatory 
response and are upregulated with AngII treatment, accumulating evidence implicates 
the adaptive immune response in the setting of AngII induced hypertension and 
cardiac remodelling.  
 
3.1.2.2 Adaptive immune cells implicated in response to AngII 
Hypertension is prevented in a number of different settings where the adaptive 
immune response is perturbed. For instance blockade of components involved in 
instigating the adaptive immune response, such as DCs, reduced hypertension in 
addition to cardiac and renal damage within SHRs173,174.  
As seen by Vinh et al, T-cells are potentially key components in the progression of 
hypertension172. Preventing T-cell activation by blocking B7/CD28 costimulation 
prevented T-cell accumulation in the vasculature and the subsequent development of 
experimental hypertension was attenuated172. This was initially highlighted by Guzik et 
al who demonstrated a key role for T-cells in the progression of AngII-induced 
hypertension134. WT mice treated with AngII had a significant infiltration of T-cells, 
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specifically CD4+ and DN T-cell subpopulations, within the aorta134. Furthermore, RAG 
deficient mice, which lack T- and B-cells, displayed a blunted hypertensive response to 
AngII134. Adoptive transfer of T-cells restored the pathophysiological responses 
observed in WT counterparts. Although B-cells also tend to increase during AngII 
treatment, the adoptive transfer of B-cells into RAG-/- mice did not restore AngII-
induced hypertension134.  
Binding of AngII to AT1 receptors upon T-cells stimulates proliferation and triggers the 
release of specific cytokines and chemokines by activating transcription factors such as 
NF-κB and AP-1, including IL-1, IL-2, IL-17, TNF-α, TGFβ, CCR5, CD44134,146. These 
inflammatory mediators further potentiate T-cell recruitment146. Human T-cell 
proliferation assays, in the presence of anti-CD3 antibody, showed that T-cells are 
more proliferative in the presence of AngII compared to anti-CD3 antibody alone157. 
When NK cells were depleted from isolated T-cells, prior to proliferation, this 
enhanced proliferative effect by AngII was diminished, suggesting this may be 
orchestrated by NK cells157.  
Together these results suggest that adaptive immunity, and more specifically T-cells, 
are implicated in the generation of AngII-induced hypertension. Moreover, increasing 
baseline levels of Tregs, with the ability to suppress CD4+ T-cell responses, also 
protects the cardiovascular system from AngII- and aldosterone-induced hypertension 
and cardiovascular remodelling. 
Overall, AngII is implicated in hypertension and cardiovascular remodelling as well as 
being a key component in the inflammatory response. These processes appear to be 
intricately entwined in an overactive system, leading to further amplification and 
hence the progression of organ damage. Published research highlights the importance 
of inflammation, specifically adaptive immunity, to the development of hypertension. 
Previous studies have concentrated on T-cell infiltration within the vasculature and 
shown its importance in the setting of AngII-induced hypertension. As discussed above 
and in chapter 1, AngII activates Nox2 (which is present in all immune cells) and it 
seems likely that this would affect the function of immune cells. However the specific 
role of endogenous Nox2 in T-cells during AngII-induced hypertension and cardiac 
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remodelling has not been studied. Furthermore, the pattern of T-cell infiltration in the 
heart during RAAS activation requires further investigation.   
 
3.2 Aims and objectives 
The main aims of this chapter were to characterise the pattern and time-course of 
cardiac T-cell infiltration in the progression of AngII-induced physiopathology in a 
model of chronic AngII infusion.   
 
3.3 Methods  
3.3.1 Experimental model 
Male C57Bl/6 mice aged 6-8 weeks (Harlan) were used for all experiments within this 
chapter. Most methods used are described in the general methods chapter. Briefly, 
subcutaneous mini-osmotic pumps containing a pressor dose of AngII (1.1mg/kg/day) 
were surgically implanted into mice for up to 14-days, as described in section 2.3. 
Blood pressure and haemodynamic function were analysed by tail cuff 
plethysmography and echocardiography respectively (section 2.5). Another group of 
C57Bl/6 mice were also treated with a pressor dose of AngII but for 3-days, before 
organs were harvested for flow cytometry or for immunohistochemistry to analyse 
immune cells.  
 
3.3.2 Treatment of samples 
Harvested hearts were treated as described in section 2.3. RNA was extracted and 
reverse transcribed to enable analysis by qPCR (section 2.7). Fibrosis-related markers 
were analysed as described in section 2.7. Histological analysis involved staining of 
harvested hearts for WGA, H&E and PSR (section 2.8). Further identification of immune 
cell infiltration was observed using immunohistochemistry for CD45 and CD3, 
described below (section 3.3.3). 
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Flow cytometry was performed on whole hearts and spleens using the BD FACS 
CantoII™ as described in section 2.6. The level of leukocytes, T-cells and T-cell subsets 
were determined based on expression of CD45, TCRβ, CD4, CD8, CD25 and FoxP3. 
Further confirmation of immune cell infiltration was determined by qPCR (section 2.7) 
using primers for CD3, CD25, FoxP3, IL-10, IL-35, CD73, CD37, cytotoxic T-lymphocyte 
associated protein-4 (CTLA-4), glucocorticoid-induced tumour necrosis factor receptor 
(TNFR) family related gene (GITR), neuropilin (NRP), CCL1, CCR8, CCL17, CCL22, CCR4, 
cMet, STAT-3 and CXCR3 (primer sequences shown in Table 9). 
 
 
Table 9: Immune-related primer sequences used for qPCR. All sequences are shown as 
5’-3’. 
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3.3.3 Immunohistochemistry 
Samples were treated as described in the general methods (section 2.8) before being 
stained for either CD45 or CD3, described below, to observe total leukocyte infiltration 
and T-cell infiltration respectively.   
Cryosections were thawed and fixed using 4% PFA in PBS for 5 minutes, then washed 
for 5 minutes in 1x Tris-buffered saline (TBS)-0.02% Triton (0.05M Tris base, 0.15M 
NaCl, 0.02% Triton, pH 7.4) with agitation and incubated for 15 minutes in methanol 
containing hydrogen peroxide (3% H2O2, in methanol). Sections were then washed 
three times for 5 minutes in TBS-0.02% Triton with agitation and each individual 
section was isolated with DakoPen (Dako). Sections were blocked in normal serum 
(1:40 diluted in TBS-0.02% Triton, Vectorstain universal quick kit), for 45 minutes at 
room temperature. Samples were then incubated overnight with an anti-CD45 
antibody (1:100 in normal serum, BD Pharmingen) or with anti-CD3 antibody (1:100 in 
normal serum, BD Pharmingen), both diluted in TBS-0.02% Triton, at 4°C. Slides were 
washed three times for 5 minutes each in TBS-0.02% Triton with agitation before being 
incubated with diluted universal biotinylated antibody (1:10 diluted in normal serum, 
Vectorstain universal quick kit in a humidity chamber at room temperature for 10 
minutes. Cryosections were then washed three times for 5 minutes each in TBS-0.02% 
Triton with agitation and incubated with streptavidin-peroxidase complex (1:40 in 
normal serum, Vectorstain universal quick kit) for 5 minutes in a humidity chamber 
before a final set of washes in TBS-0.02% Triton with agitation. Slides were incubated 
with ImmPACT DAB (3,3'-Diaminobenzidine, Vector) for 2-5 minutes and washed for 1 
minute under running tap water. Harris haematoxylin counter staining was then 
performed for 30-60 seconds and then slides were rinsed for 15 minutes under running 
tap water. Cryosections were then dehydrated with successive baths of EtOH and 
xylene as described previously and mounted using DPX and a coverslip. One section 
per slide was kept as a negative control, which was submitted to secondary antibody 
but not primary. 
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3.4 Results 
3.4.1 Angiotensin II induces hypertension and cardiac remodelling 
3.4.1.1 Haemodynamic response to AngII 
C57Bl/6 mice were treated with a pressor dose (1.1mg/kg/day) of AngII over a 14-day 
period, a well-established model of cardiomyocyte hypertrophy and fibrosis83,134,175. 
Blood pressure was recorded by tail cuff plethysmography and cardiac morphology 
and function were analysed using echocardiography at time points illustrated in Figure 
2-1.  
With AngII treatment there was a rapid increase in systolic blood pressure by 47% after 
3-days (p=0.007), which was sustained over the 14 day treatment period, as shown in 
Figure 3-1. Statistical analysis using a 2-way ANOVA revealed a significant difference 
between the AngII treated group and the sham group (p=0.010). In comparison to 
control mice, AngII treated mice showed no difference in left ventricular end-diastolic 
and end-systolic volume (LVEDV, LVESV respectively) after 14-days of treatment. LVESV 
tended to slowly decrease over the 14-day treatment period; however this did not 
reach significance at day 14. These results consequently lead to a gradual increase in 
ejection fraction with AngII treatment without reaching significance after 14-days.   
This demonstrates that AngII infusion for 2 weeks in this model induced hypertension 
and that cardiac function remained well compensated over this period. 
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Figure 3-1: Physiological response to AngII after 14-days of treatment. Increased (A) 
systolic blood pressure, accompanied by similar levels of (B) end-diastolic and (C) end-
systolic volume and hence (D) ejection fraction. **p<0.01, N=3 per group. 
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3.4.1.1 AngII induced cardiac remodelling: hypertrophy and fibrosis 
Body weight (BW), heart weights (HW) and tibia length (TL) were recorded upon culling 
and the heart weight-to-body weight (HW/BW) and heart weight-to-tibia length 
(HW/TL) ratios were calculated for each animal (Figure 3-2). As expected, HW/BW ratio 
gradually increased over the treatment period, reaching significance after 7 days 
(p=0.003), which is maintained after 14-days (p<0.001). HW/TL also significantly 
increased after 7 days, reaching 9.98±0.49 (p=0.005), which is preserved up to 14-days 
(p=0.004). This increase in heart size was also accompanied by an increase in IVS 
thickness that gradually progressed from 0.68±0.03mm to 1.05±0.04mm, suggesting 
organ-level hypertrophy.   
 
Figure 3-2: Development of organ-level hypertrophy after AngII treatment. After 14-
days AngII treatment (A) heart weight-to-body weight (HW/BW) and (B) heart weight-
to-tibia length (HW/TL) significantly increased, accompanied by an increase in (C) IVS 
thickness.**p<0.01, ***p<0.001, N=3 per group. 
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Remodelling was then studied at the tissue level. In order to verify the documented 
effect of AngII on cardiomyocyte hypertrophy, heart cryosections prepared from AngII 
and sham treated mice were stained with WGA in order to identify cell membranes 
(Figure 3-3). AngII treated mice showed a significant increase in the cardiomyocyte 
surface area, rising from an average of 434±14.8μm2 in the sham group to 
518±12.3μm2 after 14-days treatment (P=0.001).  
 
 
Figure 3-3: Onset of tissue-level hypertrophy with AngII treatment. WGA staining 
observed in negative control, sham, day 3 AngII, day 7 AngII and day 14 AngII confirms 
enlarged cardiomyocyte cross-section. Scale bar represents 25µm, **p<0.01, N=3-7 per 
group. 
 
Cardiac cryosections were also stained with PSR in order to identify collagen. The 
percentage of collagen increased slowly over the treatment period from 0.12% in sham 
mice to 6.2% after 14-days of AngII treatment (p<0.0001), as highlighted in Figure 3-4. 
Collagen was located in the interstitium, suggesting interstitial fibrosis. This was 
verified by significant increases in mRNA levels of fibrotic markers identified by qPCR 
from sham and day 14 tissue samples. Both collagen1α1 (col1α1, p=0.005) and 
collagen3α1 (col3α1, p=0.022) mRNA levels significantly increased after 14-days of 
treatment (Figure 3-5). However, fibronectin, CTGF and TGFβ mRNA levels remained 
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unchanged. These findings confirm the development of interstitial fibrosis after 14-
days of systemic treatment with AngII.  
Taken together these results indicate that, in line with previous results using this 
model, AngII induces significant cardiac remodelling marked by organ-level and 
cardiomyocyte hypertrophy, and development of interstitial fibrosis, with well 
compensated cardiac function.  
 
 
Figure 3-4: Progression of interstitial fibrosis within the heart in response to AngII 
treatment. Picrosirius red staining highlights increased collagen from sham to day 14 
AngII treatment. Scale bar represents 25µm, ****p<0.0001, N=6-7 per group. 
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Figure 3-5: Increase in collagen-related mRNA levels with AngII. A marked increase of 
(A) collagen1α1 and (B) collagen3α1 further corroborates these findings. (C) 
Fibronectin, (D) CTGF and (E) TGFβ mRNA levels are unchanged.*p<0.05, **p<0.01, 
N=5-6 per group.  
 
3.4.2 Infiltration of immune cells in response to AngII 
3.4.2.1 Visualising cardiac inflammation 
General tissue structure and cellular infiltration was observed by H&E staining in heart 
cryosections prepared from sham or AngII treated animals up to 14-days. Infiltration of 
small cells was observed after 3-days of AngII treatment and these tended to reside up 
until day 14 (Figure 3-6). Cryosections were also stained for CD45 and CD3 to analyse 
changes in total leukocytes and T-cells respectively. Figure 3-6 illustrates an increase in 
both CD45+ and CD3+ cells, observed by brown DAB staining, in response to AngII 
treatment; this appears to be maintained up to 14-days. After 14-days, leukocytes 
mainly reside within the interstitium, rather than forming clear peri-vascular clusters 
as observed at day 3 and 7. 
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Figure 3-6: Inflammation within the heart of AngII treated mice. General tissue 
structure and cellular infiltration observed by H&E staining. Leukocyte (CD45+) and T-
cell (CD3+) infiltration was visualised using brown DAB staining performed on 
cryosections from sham, 3-, 7- and 14-days after AngII treatment. Scale bar represents 
25µm.  
 
3.4.2.2 Quantifying AngII-induced inflammation 
Flow cytometry was used in order to better quantify the infiltrating T-cells, identify 
specific subsets involved in the cardiac response to AngII and to define the time-course 
of infiltration. Single cell suspensions were prepared from whole hearts obtained from 
mice treated with AngII for up to 3-days (Figure 3-7). Spleens were also isolated from 
respective animals and used to analyse the general immune status. All samples were 
analysed using the BD FACS CantoII™. Representative flow cytometry dot plots for 
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heart samples (Figure 3-7) display a higher level of total leukocytes (CD45+ cells), T-
cells (CD45+TCRβ+ cells) and T-cell subpopulations with AngII treatment after 3-days.  
 
 
Figure 3-7: Representative dot plots showing cardiac T-cell infiltration. The effect of 
AngII treatment on infiltrating leukocytes and T-cells represented as visual flow 
cytometry dot plots. Acquired on BD FACS CantoII™. 
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Upon quantitative analysis, a marked increase in leukocytes (CD45+ cells) from 
40.6±5.11 cells/mg to 166±38.5 cells/mg of cardiac tissue (p=0.007) was observed after 
3-days of AngII treatment (Figure 3-8). However, this reduced back to sham-levels after 
7-14-days of AngII treatment. A similar effect was observed with T-cell infiltration 
(CD45+TCRβ+ cells) increasing to 80.4±24.1 cells/mg after 3-days of AngII compared to 
sham (p=0.005) before reducing back to baseline after 7-14-days.   
 
 
Figure 3-8: Altered cardiac T-cell infiltration during AngII treatment. Individual 
analysis of (A) CD45+ cells and (B) T-cells (CD45+TCRβ+) infiltration. Individual T-cell 
subpopulations, (C) double negative (CD4-CD8-), (D) double positive (CD4+CD8+), (E) 
CD8+ and (F) CD4+ T-cells, were also altered by AngII treatment. All data is represented 
as cells per mg of cardiac tissue acquired on the CantoIITM. *p<0.05, **p<0.01, N=5-12 
per group.  
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T-cell subtypes were also analysed from prepared cardiac samples using the CantoII™, 
shown in Figure 3-8. After 3-days of treatment with AngII, DP T-cells (CD4+CD8+) 
tended to increase, accompanied by a significant increase in DN T-cell (CD4-CD8-) 
(p=0.011), CD8+ T-cells (CD4-CD8+) (p=0.009) and CD4+ T-cells (CD4+CD8-) (p=0.002) 
compared to sham.  CD8+ T-cells and CD4+ T-cells, after 3-days of AngII, were 
approximately 4 and 8 times higher than sham levels respectively. As treatment 
progressed to 7 and 14-days the level of all T-cell subtypes decreased back to baseline.  
Due to the systemic nature of the AngII treatment, spleen samples were also analysed 
to ascertain the general immune status of the mice (Figure 3-9). All immune cell 
subpopulations in the spleen remained unaltered throughout treatment with AngII.  
 
 
Figure 3-9: Splenic levels of T-cells remain unchanged during AngII infusion. Splenic 
levels of (A) CD45+ cells, (B) T-cells and (C) T-cell subpopulations. All data are 
represented as a percentage of total cells, acquired on the BD FACS CantoII™. N=5-12 
per group. 
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Tregs were also affected by AngII treatment, as shown in Figure 3-10. Initial numbers 
of CD4+CD25+ Tregs per mg of heart tissue significantly increased after 3-days 
(p=0.013) of AngII, before decreasing back to baseline levels after 7 and 14-days of 
treatment. FoxP3 staining further verified the increase in Tregs after 3-days of AngII by 
displaying a 2.4 fold increase compared to sham levels (p=0.024). This cardiac peak in 
Tregs was not seen within treated spleens, where Treg-levels remained unchanged 
over the treatment period.  
 
 
Figure 3-10: Influx of regulatory T-cells in response to AngII treatment. Increase in 
cardiac (A) CD4+CD25+ Tregs and (B) CD4+CD25+FoxP3+ Tregs (N=9 per group). (C&D) 
Splenic levels of Tregs do not differ in response to AngII. Cardiac samples represented 
as cells per mg of heart tissue; splenic samples represented as a percentage of total 
cells. All samples acquired on BD FACS CantoII™, *p<0.05, N=5-12 per group. 
 
Cardiac infiltration of T-cells and Tregs, after 3-days of treatment, was verified by qPCR 
analysis of mRNA levels (Figure 3-11). CD3 (p=0.006), CD25 (p=0.001) and FoxP3 (p 
<0.001) mRNA levels significantly increased after 3-days of AngII treatment. The Treg-
specific cytokine, IL-10 (p=0.025) was also increased after 3-days of AngII. 
Quantification of Treg-specific surface markers that aid Treg function176-178, showed a 
significant increase for CD73 (p=0.032), CD39 (p=0.025) and CTLA-4 (p=0.027) whereas 
GITR remained the same between sham and AngII treated samples. These data further 
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corroborate our findings using flow cytometry. NRP, a marker identifying thymus-
derived natural Tregs179,180, was similar between sham and AngII treated samples.  
 
 
Figure 3-11: AngII increased levels of immune cell mRNA markers.  Quantification of 
(A) CD3, (B) CD25, (C) FoxP3, (D) IL-10, (E) IL-35, (F) CD73, (G) CD39, (H) CTLA-4, (I) 
GITR and (J) NRP mRNA levels by qPCR also support Treg infiltration.*p<0.05, **p<0.01, 
****p<0.0001, N=8-9 per group.  
 
Due to increases in total leukocytes, T-cells, CD4+ T-cells and Tregs, analysis of cell 
populations as a percentage of their parent population was necessary to investigate 
changes in cell ratios. For example, Tregs as a percentage of CD4+ T-cells were 
analysed. Figure 3-12 demonstrates that even though there are increases in each of 
these individual cell types with AngII treatment, the proportion of cells and balance 
between subpopulations is unaltered.  
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Figure 3-12: AngII effect on immune cell proportions. For both (A-D) heart and (E-F) 
spleen samples (A&E) T-cells as a percentage of CD45+ cells, (B&F) CD4+ T-cells as a 
percentage of total T-cells, (C&G) CD4+CD25+ Tregs as a percentage of CD4+ T-cells and 
(D&H) CD4+CD25+FoxP3+ Tregs as a percentage of CD4+ T-cells all remain stable with 
AngII treatment. N=12 per group.  
 
In order to assess factors that might promote the migration of Tregs to AngII treated 
hearts after 3-days, mRNA levels of associated chemokines and their receptors were 
investigated (Figure 3-13). After 3-days of AngII treatment, CCL1 tended to increase, 
with a significant increase in its chemokine receptor CCR8 (p=0.041). A marked rise in 
CCL17 (p=0.025), CCL22 (p=0.042) and their chemokine receptor CCR4 (p=0.048) also 
suggests Treg migration to the heart181,182. Similarly, significant increases in cMet 
(p=0.022), STAT-3 (p=0.021) and CXCR3 (p=0.051), recently found to be involved in 
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Figure 3-13: AngII treatment increases levels of cardiac-specific chemokines. After 3-
days of AngII treatment (A) CCL1 tends to increase, (B) CCR8, (C) CCL17, (D) CCL22, (E) 
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3.5 Discussion 
AngII is extensively used to induce hypertension in murine models. In this study, the 
efficacy of the agent in initiating both hypertension and subsequent cardiac 
remodelling in C57Bl/6 mice was verified. In our hands, treatment with AngII led to 
hypertension as well as cardiomyocyte hypertrophy and interstitial fibrosis, in a time-
dependant manner, confirming previous published reports83, 134.  
The novelty of this study was to investigate immune cell infiltration in the heart during 
treatment with AngII. An important finding within this study is that AngII induces 
cardiac inflammation in a time-dependent manner. Initial infiltration within the 
myocardium occurs around the vessels, which is the point of entry, but as treatment 
continues inflammatory cells are dispersed throughout the tissue. This diffusion of 
inflammatory cells within the myocardium may be a mechanism that impacts on 
cardiac remodelling processes, in particular fibrosis. Furthermore the type of immune 
cells infiltrating the myocardium during AngII treatment was pin pointed towards T-
cells.  
Until now, other groups have concentrated on the repercussion of hypertension on the 
vasculature, with a focus on inflammation134,146,148,167. Guzik et al observed an 
infiltration of T-cells within the aorta in response to AngII and carefully characterised 
the T-cell subsets involved in this particular tissue134. Interestingly, the heart seams to 
respond to AngII in a similar fashion, as highlighted by a major increase in T-cells. The 
time-course of leukocyte infiltration during AngII treatment was also investigated and 
revealed a peak after 3-days of AngII infusion. Within the aorta, the same authors 
identified that all subpopulations were affected by AngII treatment, with a significant 
increase in DN (CD4-CD8-) and CD4+ T-cells. This group chose to concentrate on DN T-
cells as this cell type increased seven-fold in the aorta during AngII treatment.  
Similar to Guzik et al in the vasculature, we showed an increase in all T-cell subtypes, 
including DN T-cells in the heart. However, the other T-cell subtypes investigated were 
affected to a greater extent by AngII treatment.  
Using specific KO models Laroumanie et al demonstrated that CD4+, but not CD8+, T-
cells were associated with cardiovascular remodelling after TAC184. This therefore 
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highlights the impact of CD4+ T-cells within the setting of cardiac remodelling. Here, 
the profile of both CD8+ and CD4+ T-cells in the heart were affected by AngII, with a 
significant increase after 3-days of treatment.  
CD4+ group encompasses a versatile subpopulation of T-cells. This is composed of pro-
inflammatory Th cells, namely Th17, Th1 and Th2, in addition to anti-inflammatory 
Tregs. Interestingly, Th17 subsets of CD4+ T-cells, which produce IL-17, are markedly 
increased in the aorta during AngII treatment185. IL17-/- mice treated with AngII 
displayed hypertension, which was not sustained for the duration of AngII treatment, 
preserved vascular function and decreased T-cell infiltration185. Cytokines produced by 
Th1 (IFN-γ, TNF-α and IL-2) and Th2 (IL-4, 6, 10, 13), have also been implicated in the 
setting of AngII induced cardiac remodelling. Both IFN-γ receptor and TNF receptor-1 
KO mice treated with AngII exhibit reduced levels of cardiac hypertrophy, fibrosis and 
inflammation186-188. In comparison, Th2 cells may arise after the Th1 pro-inflammatory 
response and produce cytokines involved during the development of fibrosis such as 
IL-6, acting as a pro-fibrotic mechanism188.  
T-cell subtypes are difficult to analyse within the heart, especially at baseline, due to 
initial low numbers and further depletion caused by the treatment of tissues required 
for flow cytometry. Therefore, until more sensitive techniques are established, pooling 
heart samples or even analysing immune-cells within the LNs draining the heart may 
provide further detail into immune cell recruitment. This could enable more in-depth 
analysis of Th subpopulations, associated cytokines and chemokines. 
Here, a two-phase response in T-cell infiltration was observed, characterised by an 
initial increase at day 3, followed by a decrease in cell number on day 7. The observed 
decrease in T-cells within the heart could be linked to the expression of anti-
inflammatory factors. Therefore, by concentrating on anti-inflammatory T-cells, which 
could be responsible for this phenomenon, potential therapeutic targets may be 
identified. Within the CD4+ T-cell subset, results show the level of Tregs 
(CD4+CD25+FoxP3+) significantly increased after 3-days of AngII treatment. This was 
validated by a marked increase in mRNA expression in the Treg transcription factor, 
FoxP3, in addition to Treg cytokines (IL-10 and IL-35) and functional surface makers 
(CD25, CD73, CD39, CTLA-4, GITR) 3-days after treatment. These results demonstrate a 
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clear infiltration of Tregs within the myocardium during AngII treatment, as supported 
by a number of published papers189-193. 
Tregs have been implicated in the pathophysiology of AngII-induced hypertension and 
vascular injury. Barhoumi et al highlighted the protective effects of Tregs by 
performing an adoptive transfer of these cells followed by AngII treatment for 14-
days190.  Treg (CD4+CD25+) adoptive transfer blunted the pathological effects induced 
by AngII compared to vehicle or Teff cells (CD4+CD25-)190. This included attenuation of 
AngII-induced Nox activity190. A similar response was observed with the adoptive 
transfer of Tregs into mice later treated with aldosterone192.  
Komarowska et al studied T-cell migration to cardiac allografts and highlighted specific 
chemokines that promote recruitment to the heart183. The hepatocyte growth factor 
(HGF) receptor (cMet), CCR4, and CXCR3 were identified as important cardiac-
recruitment factors for T-cells183. In addition, other studies investigating Treg 
recruitment to cardiac allografts highlighted CCR4 and CCR8 to be important 
chemokine receptors involved in this process182. Our results fall in line with these 
findings, as the T-cell and Treg increase observed here was accompanied by increased 
mRNA expression of cMet, CCR4, CCR8, STAT-3 and CXCR3. In addition to chemokine 
receptors, increases in associated ligands (CCL1, CCL17 and CCL22) were also observed.  
These data suggest that Tregs might be involved in cardiac remodelling associated with 
experimental hypertension. Hence the infiltration of Tregs during AngII treatment, 
observed in the present study, may support this further. The initial influx of Tregs 
observed within the heart may be an attempt to supress inflammation. The percentage 
of Tregs reduces to baseline after 7-days and hence this may allow the inflammatory 
response of other T-cell subtypes to resume, aiding the progression of cardiac 
remodelling. The un-sustained Treg level could potentially lead to the later attenuation 
of T-cell infiltration in the heart.  
Overall, the data presented in this chapter confirm the involvement of AngII in both 
cardiovascular remodelling and inflammation. T-cells, specifically CD4+ T-cells and 
Tregs, may potentially play an important role in this setting in a time-dependent 
manner. ROS have been implicated in the AngII response both within cardiovascular 
remodelling and inflammation. The role of Nox2 within cardiomyocytes and 
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endothelial cells has been well established in the setting of AngII-induced cardiac 
remodelling, but its specific role in infiltrating immune cells in this setting requires 
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 The response of Chapter 4:
global Nox2KO mice to chronic 
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4.1 Introduction 
Previous research has implicated Nox2 in AngII-induced cardiovascular remodelling42. 
Nox2 is involved in intracellular signalling pathways that modulate cardiac 
hypertrophy, fibrosis, apoptosis and contractile dysfunction. As discussed in section 
1.6, a number of studies where Nox2 levels are depleted demonstrate an attenuated 
response to RAAS overstimulation. Furthermore, Nox2 has also been identified in the 
modulation of hypertensive signalling as discussed in section 1.8.   
 
4.1.1 Role of Nox2 in AngII-induced inflammatory response 
Nox2 is the main source of ROS within immune cells, and a number of different aspects 
within the immune system require Nox2194. The importance of Nox2 in immunity is 
clearly highlighted in cases of chronic granulomatous disease (CGD) where patients 
suffer from severe and recurrent bacterial and fungal infections. This is due to a 
deficiency in their innate immune response, which is potentially related to a defect in 
neutrophil phagocytic function195. Furthermore, CGD patients with a Nox2 deficiency 
display an increase in inflammatory genes encoding inflammatory mediators such as 
CD11b, CD14, CD54, TLR5, CCR1 and many more, which prolong inflammation196. In 
addition, during a phagocytic response, there is a lack of pro-apoptotic proteins such 
as Bcl-associated X protein synthesis (BAX), leading to defective apoptosis after 
phagocytosis that may delay resolution during an inflammatory response to 
infection196. Furthermore, CGD patients have  an increased prevalence of concurrent 
autoimmune diseases194. 
Nox2-derived ROS are implicated in different cellular signalling pathways affecting 
proliferation, differentiation and/or activation of different immune cells. They are also 
involved in chemotaxis194, microbicidal activity within phagocytes17,42 and antigen 
presentation by DCs197. 
Mice in which p47phox has been knocked-out presented more severe arthritis that is 
blunted in the presence of Nox2 pharmacological activators198. These models also 
express a higher autoimmune phenotype, suggesting a role for Nox2 in regulating 
autoimmunity and certain cases of inflammation194. Furthermore Nox2KO mice 
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develop spontaneous age-related arthritis as well as displaying an altered CD4+ T-cell 
profile, with a tendency towards a Th17 phenotype in the periphery199.  
However, the role of Nox2 within immunity is still not fully understood. The capability 
of Nox2-derived ROS to enable communication and interaction of different 
components of the immune system is extensive, and the implication of this in 
inflammation related to CVD requires further investigation. 
 
4.1.1.1 Nox2 within innate and adaptive immunity 
Nox2 was initially identified in immune cells during the phagocytic respiratory burst. 
This process occurs in the neutrophil phagosome, where ingested pathogens are killed 
by a rapid increase in Nox2-derived ROS. ROS can directly damage pathogens and 
produce optimal conditions for neutrophil proteases to function, pH ~6.5-7200. ROS 
have also been implicated in neutrophil chemotaxis; both the direct inhibition of Nox2 
or absence of the gene impairs neutrophil chemotaxis194. 
In a similar way to neutrophils, Nox2 provides an oxidative burst to enable digestion of 
pathogens in the macrophage phagosome. This requires a lower pH (4-5) than 
neutrophils, which is specific for the activation of the macrophage proteases200.  
Nox2-derived ROS production is implicated in intracellular signalling that can mediate 
inflammatory responses. Within macrophages, NF-κB activation is critical in the 
production of cytokines, chemokines and adhesion genes that are essential for the 
inflammatory response, and ROS have a function in this setting201. Recent published 
data has shown that ROS production is essential for macrophage differentiation (into 
M1 or M2 cells)202. Inhibition of O2
•- production prevents differentiation of monocytes 
into M2 cells202. In this setting, O2
•- was shown to be essential for biphasic ERK 
activation that is involved in macrophage differentiation202. 
Nox2 has also been implicated in the cellular migration of macrophages in response to 
CSF-1, a common tissue chemo-attractant203. Nox2KO bone-marrow derived 
macrophages did not display a chemotactic response to a source of CSF-1, and showed 
a reduced level of ERK1/2 phosphorylation after CSF-1 stimulation203. Nox2 regulation 
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of NF-κB activation also impacts the expression of other chemokines, such as MCP-1 
and CCR2, which are key components in macrophage recruitment158,165,194.  
DCs express Nox2 to a lesser extent compared to macrophages; however Nox2-derived 
ROS still have important roles within this cell type. Human DCs show a requirement for 
Nox2 activity to aid antigen cross-presentation204. Nox2KO mice produce an increased 
level of acidification within the phagosome of DCs. This causes a higher level of protein 
degradation, hence impairing antigen cross-presentation to cells of the adaptive 
immune system204,205. Therefore Nox2 is thought to contribute towards alkalinisation 
in DCs in order to mediate an efficient level of protein degradation for antigen 
presentation to occur204,206. Furthermore, Nox2 in DCs has been linked to cytokine 
production; Nox2KO DCs express a higher level of cytokines compared to WT 
controls207. Lack of Nox2 also prevents apoptosis so cells have higher viability, enabling 
a higher production of TNFα in addition to promoting IFNγ production from T-cells and 
encouraging differentiation into Th1 cells207. Moreover, Nox2KO DCs tend to be less 
mature, expressing lower levels of CD83, the maturation marker and CD86, the DC 
costimulatory marker207.  
Within B-cells, stimulation of the BCR results in a significant production of ROS, with 
initial generation being dependent on Nox2208. Deletion of Nox2 does not impair BCR 
signalling or B-cell activation and these cells elicit a normal, if not enhanced 
response208. The later generation of ROS, thought to be of mitochondrial origin, has a 
more pertinent role. Treatment of B-cells with a ROS scavenger, N-acetylcysteine 
(NAC), abrogated BCR-dependent PI3K signalling and altered successive activation and 
proliferation of B-cells208. In this case the presence of Nox2-derived ROS does not seem 
to function to enhance the B-cell response; however other sources of ROS are 
important in this setting. 
Endogenous Nox2 within macrophages and DCs has the ability to alter T-cell activation, 
proliferation and even orchestrate the type of adaptive immune response. However, 
intrinsic expression of Nox2 in T-cells may also direct T-cell polarisation and cytokine 
production, discussed in more detail in section 4.5. 
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4.2 Aims and objectives 
Nox2 has a great impact on a variety of cells within the cardiovascular system that are 
reflected in its ability to modulate cardiovascular remodelling in response to AngII. The 
effects of Nox2 on individual immune cells is apparent, however the specific role of T-
cell Nox2 in the setting of AngII-induced cardiac pathophysiology has not been studied.  
The aim of the studies in this chapter was to define the overall impact of Nox2 on 
immune cell infiltration into the heart during chronic RAAS activation, using studies in 
global Nox2KO mice.  
 
4.3 Methods 
4.3.1 Maintenance of global Nox2KO line 
Male Nox2KO mice were bred on a C57Bl/6 background at our institution209. 
Heterozygous females were crossed with C57Bl/6 (Harlan UK limited) males, or 
C57Bl/6 females (Harlan UK limited) were crossed with gp91-/- males to generate 
homozygous gp91-/- (Nox2KO) male mice and WT littermate controls. Nox2KO mice, 
WT littermates and C57Bl/6 mice were used for experiments between 6-8 weeks of 
age.  
 
4.3.2 Global Nox2KO genoyping 
Ear biopsies were treated with 300µL of 50mM sodium hydroxide (NaOH) at 95°C for 
30 minutes. Samples were vortexed to homogenise and 25µL 1M Tris-HCl (pH 8.0) 
added and incubated at room temperature for 30 minutes. Next, 2µL of sample 
(~56ng/µL) was added to 23µL of the PCR master mix (Figure 4-1), where primers are 
shown in Table 10. All samples were run alongside a no-template sample and known 
WT and Nox2KO samples on the PCR cycle shown in Figure 4-1.  
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Figure 4-1: Gp91 genotyping PCR Cycle. 
 
Samples (20µL) were then run on a 2% agarose gel (150mL 1 x TAE (Tris base, acetic 
acid and EDTA) and 3g agarose) infused with ethidium bromide (0.5µL/mL) at 180v for 
30 minutes. The gel was then photographed under ultraviolet (UV) light using a 
transluminator machine. Figure 4-2 shows the identification of global Nox2KO animals 
(e.g. 1812-1820) that have a lower band (~200bp) compared to WT littermates (e.g. 
1825, 1827-1828), which display a higher band (~300bp) and heterozygotes express a 
double band (e.g. 1821- 1824). 
 
Figure 4-2: Nox2 (Gp91) genotyping example.  
 
 
Table 10: Genotyping Primer sequences. 
  128  
4.3.3 Experimental model 
Male Nox2KO mice ages 6-8 weeks were bred at our institution and used for 
experiments in this chapter along with WT littermate controls. Subcutaneous mini-
osmotic pumps containing a pressor dose of AngII (1.1mg/kg/day) were surgically 
implanted into mice for up to 14-days, as described in section 2.3. Blood pressure and 
haemodynamic function were analysed by tail cuff plethysmography and 
echocardiography respectively (section 2.5).  A second group of mice were also treated 
with a pressor dose of AngII for 3-days, before organs were harvested for flow 
cytometry.   
 
4.3.4 Treatment of samples 
Whole hearts were harvested and treated as described in section 2.4.1, RNA extraction 
and reverse transcription was performed as described in section 2.7 to enable analysis 
of fibrosis-related markers by qPCR. Histological analysis involved staining of harvested 
hearts for WGA and PSR (section 2.8).  
Immune cell quantification was performed on whole hearts and spleens by flow 
cytometry using BD FACS CantoII™ as described in section 2.6. The level of leukocytes, 
T-cells and T-cell subsets were determined based on expression of CD45, TCRβ, CD4, 
CD8, CD25 and FoxP3.  
 
4.4 Results 
4.4.1 Global Nox2KO mice have a blunted response to AngII  
4.4.1.1 Physiological responses to AngII 
We confirmed the efficacy of AngII in inducing hypertension in both naive C57Bl/6 
mice and the C57Bl/6 WT littermates of Nox2KO animals (Figure 4-3). Unlike these 
groups, the Nox2KO animals did not exhibit a significant increase in blood pressure 
when treated with AngII for 14-days (p<0.001). These data confirm results found in 
previous studies108,175. HW/BW and HW/TL tended to be lower in Nox2KO animals 
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compared to WT littermates and C57Bl/6 mice following AngII treatment for 14-days, 
however this was not significant.  
 
 
Figure 4-3: Blunted AngII response in Nox2KO model. Global Nox2KO response to 
AngII analysed by (A) systolic blood pressure, (B) HW/BW, (C) HW/TL. *Nox2KO vs. 
C57Bl/6. # Nox2KO vs. WT littermates. *p<0.05, ***p<0.001, ****p<0.0001, N=6-9 per 
group. 
 
WGA staining was performed on paraffin sections from Nox2KO mice and WT 
littermate controls treated for 14-days with AngII. WGA revealed that Nox2KO treated 
animals had a significantly smaller cardiomyocyte cross-sectional area (p=0.001) 
compared to WT littermates treated with AngII, consistent with previous data108. This 
can clearly be observed in Figure 4-4, where representative images display smaller 
cardiomyocytes within Nox2KO treated groups with a cross-section of 245±13.8μm2 
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compared to 396±13.4μm2 observed for WT littermate samples. Previous published 
data report no difference at baseline between WT and Nox2KO mice108,210.  
 
 
Figure 4-4: Nox2KO prevents AngII-induced cardiomyocyte hypertrophy. WGA 
staining to analyse cardiomyocyte cross-section for Nox2KO and WT littermate 
animals. Scale bar represents 25µm, **p<0.01, N=8 per group. 
 
Paraffin sections stained with PSR (Figure 4-5) highlighted a high percentage of 
interstitial collagen within WT littermate controls treated with AngII, which was 
attenuated in Nox2KO treated animals (p <0.0001). The percentage of collagen reduces 
from 2.64±0.36% in WT littermates to 0.24±0.05% in Nox2KO animals. This was verified 
by analysis of mRNA levels of fibrotic markers via qPCR, as shown in Figure 4-6. After 
AngII treatment Nox2KO mice had significantly lower mRNA levels of col1α1 (p=0.029), 
col3α1 (p=0.004) and TGFβ (p=0.023) further confirming blunted levels of interstitial 
fibrosis, consistent with published reports175.  Fibronectin and cTGF mRNA levels were 
similar between Nox2KO and WT animals. No differences were observed in collagen 
deposition between WT and Nox2KO mice at baseline175.  
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Figure 4-5: Global Nox2KO blunts AngII-induced fibrosis. Picrosirus red staining for 
Nox2KO and WT littermate animals. ****p<0.0001, N=8 per group.  
 
 
Figure 4-6: Marked decrease in mRNA levels of pro-fibrotic-markers. Quantitative PCR 
analysis of pro-fibrotic markers (A) collagen1α1, (B) collagen3α1, (C) TGFβ, (D) 
fibronectin and (E) cTGF.*p<0.05, **p<0.01, N=8 per group. 
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Here, the lack of Nox2 prevents AngII-induced hypertension, cardiomyocyte 
hypertrophy and interstitial fibrosis, in line with previous published results25. 
 
4.4.1.2 Altered composition of cardiac-resident T-cells 
Global Nox2KO animals at baseline presented no evidence of infection, both clinically 
and during routine screening for pathogens (appendix), but had enlarged lymphoid 
organs. Figure 4-7 shows that the LNs (142% bigger, p=0.025), spleen (21% bigger, 
p=0.008) and thymus (34% bigger, p=0.043) are larger in Nox2KO, compared to WT 
littermate mice. This suggests they may also have an altered immune cell composition 
at baseline and a potentially altered inflammatory response199. Hearts were a similar 
size between the Nox2KO and WT littermates (Figure 4-8). 
 
 
Figure 4-7: Enlarged lymphoid organs in Nox2KO animals at baseline. (A) Images of 
freshly harvested lymphoid organs and analysed by (B) lymph node weight-to-tibia 
length (LNW/TL), (C) spleen weight-to-tibia length (SW/TL) and (D) thymus weight-to-
tibia length (ThyW/TL) ratios. Scale bar represents 0.5cm. *p<0.05, **p<0.01, N=6-10 
per group.  
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Figure 4-8: Heart weights are the same in Nox2KO compared to WT littermates. (A) 
Images of freshly harvested hearts and analysed by (B) heart weight-to-tibia length 
(HW/TL) ratios. Scale bar represents 0.5cm. N=3 per group.  
 
Flow cytometry was used to quantify the basal levels of cardiac immune cells, using 
spleen samples as a control. Within the heart, global Nox2KO mice had a significantly 
higher level of total leukocytes, T-cells and T-cell subpopulations at baseline as 
illustrated in Figure 4-9, where cells are represented by dots.  
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Figure 4-9: Higher levels of cardiac-resident immune cells in Nox2KO mice. 
Representative dot plots show an increased level of immune cells in the heart at 
baseline. Analysed on BD FACS CantoII™.  
 
Quantitative analysis highlighted an increase of 130% in total leukocytes (p=0.0001, 
CD45+ cells), of which T-cells (p=0.006, CD45+TCRβ+) also showed a marked increase 
from 10.2±1.67 cells/mg in WT littermates compared to 18.8±1.99 cells/mg in Nox2KO 
hearts (Figure 4-10). T-cell subpopulations were also altered by the lack of Nox2 at 
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baseline with a significant increase in CD8+ (p=0.003) and CD4+ T-cells (p = 0.005), both 
being two-fold higher in Nox2KO compared to WT littermate. 
 
 
Figure 4-10: Altered levels of cardiac-resident immune cells with Nox2 deficiency. 
Baseline immune cell levels of (A) total leukocytes (CD45+ cells), (B) T-cells (CD45+TCRβ+ 
cells) and T-cell subpopulations (C) CD4-CD8-, (D) CD4+CD8+, (E) CD8+ and (F) CD4+ T-
cells. All data represented as cells per mg of tissue, analysed on BD FACS CantoII™. 
**p<0.01, ***p<0.001, N=8-11. 
 
In comparison, the immune cell levels within the spleen remained similar between the 
WT littermates and Nox2KO mice, as shown in Figure 4-11. This was true for total 
leukocytes (CD45+ cells), T-cells (CD45+TCRβ+ cells) and each of the T-cell 
subpopulations (CD4-CD8-, CD4+CD8+, CD8+ and CD4+).  
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Figure 4-11: Immune cells within the spleen are comparable in Nox2KO. (A) Total 
leukocytes (CD45+ cells), (B) T-cells (CD45+TCRβ+ cells) and (C) T-cell subpopulations 
remain consistent between both genotypes. All data represented as a percentage of 
total cells, acquired on BD FACS CantoII™. N=8-11. 
 
Of the CD4+ T-cell population observed within the heart, Tregs (p=0.042) were also 
significantly higher in the Nox2KO compared to WT littermate controls (Figure 4-12). 
Analysis showed that Nox2KO hearts contain about four times more Tregs compared 
to WT samples at baseline. However, the opposite was observed within the spleen, 
with a lower level of CD4+CD25+ Tregs (p=0.021) but similar levels of CD4+CD25+FoxP3+ 
Tregs. 
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Figure 4-12: Cardiac and splenic Tregs at baseline may alter between WT and 
Nox2KO mice. Analysis of cardiac immune cells by (A) CD4+CD25+ Tregs and (B) 
CD25+FoxP3+ Tregs suggest altered levels between the two genotypes. However, spleen 
levels of (C) CD4+CD25+ Tregs and (D) CD25+FoxP3+ Tregs respond differently. Cardiac 
samples represented as cells per mg of tissue; spleen samples represented as a 
percentage of total cells acquired. Analysed on BD FACS CantoII™. *p<0.05, N=8-11.  
 
To determine any differences in T-cell proportions, the percentages of parent 
populations were calculated (Figure 4-13). Looking at the heart samples, T-cells as a 
percentage of CD45+ cells remained identical between the two groups, as did CD4+ T-
cells as a percentage of total T-cells. Meanwhile, CD4+CD25+ Tregs (p=0.034) and 
CD25+FoxP3+ Tregs (p=0.028), represented as a percentage of CD4+ T-cells, were both 
significantly higher in the Nox2KO heart at baseline. In comparison all T-cell 
proportions within the spleen were equivalent between the two groups. This suggests 
that in Nox2KO hearts the ratio of Tregs to T-cells is higher than that in WT littermate 
controls. This higher ratio could potentially alter the immune-response as Tregs should 
be able to suppress inflammation.  
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Figure 4-13: T-cell proportions in heart and spleen at baseline. (A&E) T-cells as % of 
CD45+ cells, (B&F) CD4+ T-cells as a percentage of total T-cells, (C&G) CD4+CD25+ Tregs 
as a percentage of CD4+ T-cells and (D&H) CD25+FoxP3+ Tregs as a percentage of CD4+ 
T-cells. Analysed on BD FACS CantoII™.*p<0.05, N=8-11,  
 
4.4.1.3 Blunted AngII-induced infiltration of cardiac immune cells in Nox2KO 
mice 
Next, the effect of AngII on immune cell infiltration in Nox2KO and WT littermate mice 
was studied. Single cell suspensions were prepared from hearts of mice that had 
received AngII by mini-osmotic pump (or a sham mini-osmotic pump) for 3-days, and 
were analysed using the CantoII™. Representative flow cytometry dot plots highlight 
lower infiltration of immune cells within Nox2KO animals compared to WT littermates 
(Figure 4-14). This was observed for total leukocytes (CD45+ cells), T-cells (CD45+TCRβ+) 
and each of the T-cell subpopulations (CD4-CD8-, CD4+CD8+, CD8+ and CD4+ T-cells). 
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Figure 4-14: Global Nox2KO prevents AngII-induced cardiac inflammation. Flow 
cytometry dot plots showing representative examples of WT and Nox2KO both treated 
with AngII. Analysed by BD FACS CantoII™. 
 
Analysis, as shown in Figure 4-15 showed that total leukocyte infiltration significantly 
increased in WT littermate controls treated with AngII (p=0.0001), as previously 
observed in chapter 3. This increase was significantly blunted in Nox2KO animals 
treated with AngII (p=0.005), where leukocytes were twofold lower than their WT 
counterparts. In addition, no significant increase occurred in Nox2KO animals when 
treated with AngII. A similar response was observed with T-cell infiltration, where the 
WT littermate treated hearts contained 37.4±5.69 cells per mg, compared to 12.8±2.16 
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cells per mg in the Nox2KO treated hearts (p<0.001). All T-cell subpopulations tended 
to be lower in the Nox2KO treated hearts compared to WT littermate hearts treated 
with AngII, with a significantly lower level of CD8+ T-cells (p=0.004) and CD4+ T-cells 
(p<0.0001). Interestingly, no difference was observed between Nox2KO sham and 
AngII treated mice, demonstrating a blunted response to AngII in the absence of Nox2. 
The immune-cell differences observed at baseline between Nox2KO and WT 
littermates is still present in sham groups analysed here, however the 2-way ANOVA 
with Bonferroni post-test is not suitable to highlight these differences. In comparison, 
splenic levels of T-cells were not affected by AngII treatment in either Nox2KO or WT 
littermates (Figure 4-16). 
 
Figure 4-15: Blunted immune cell infiltration in response to AngII with Nox2 
deficiency. Analysis showing (A) total leukocytes (CD45+), (B) T-cells (CD45+TCRβ+) and 
T-cell subpopulatons including (C) CD4-CD8-, (D) CD4+CD8+, (E) CD8+ and (F) CD4+ T-
cells. *WT AngII vs. WT, +Nox2KO AngII vs WT AngII. Results are represented as cells 
per mg of heart tissue. Acquired on BD FACS CantoII™, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001, N=4-8 per group.  
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Figure 4-16: Splenic levels of T-cells remain unchanged after AngII infusion. (A) total 
leukocytes (CD45+), (B) T-cells (CD45+TCRβ+) and T-cell subpopulatons including (C) CD4-
CD8, (D) CD4+CD8+, (E) CD8+ and (F) CD4+ T-cells. Results are represented as a 
percentage of total cells acquired on BD FACS CantoII™, N=4-8 per group.  
 
Finally, CD4+CD25+ Tregs significantly increased in the myocardium of WT animals 
treated with AngII (p=0.002) compared to sham, as observed previously, however this 
was significantly blunted in Nox2KO treated animals (p=0.002). Treg levels were then 
confirmed with a FoxP3 marker showing a significant reduction by 84% 
(CD4+CD25+FoxP3+, p=0.049) in the AngII-treated Nox2KO, compared to the AngII-
treated WT littermate (both treated with AngII for 3-days) (Figure 4-17). In comparison 
Treg levels were not affected by AngII treatment within analysed spleen samples.  
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Figure 4-17: Treg infiltration is blunted in Nox2 deficient animals. Cardiac Treg 
infiltration was blunted by Nox2 deficiency as by analysis of (A) CD4+CD25+ Tregs and 
(B) CD25+FoxP3+ Tregs. However, Tregs within the spleen remains consistent shown in 
(C) CD4+CD25+ Tregs and (D) CD25+FoxP3+ Tregs. Cardiac data represented as cells per 
mg of tissue; splenic data represented as a percentage of total cells. Acquired on BD 
FACS CantoII™. *WT AngII Vs WT sham, +Nox2KO AngII Vs WT AngII. *p<0.05, 
**p<0.01, N=4-8 per group.  
 
The proportions of T-cells, CD4+ cells and Tregs were analysed by representing values 
as a percentage of parent populations (Figure 4-18). No significant differences were 
observed between the four groups by a 2-way ANOVA. Within Nox2KO sham heart 
samples, there tends to be a higher level of Tregs as a percentage of CD4+ T-cells 
compared to WT littermates, as observed previously with mice at baseline. This trend 
was maintained after 3-days of AngII treatment, suggesting a potential protective 
phenotype against cardiac inflammation.  
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Figure 4-18: Proportion of Tregs to CD4+ T-cells tends to be altered in cardiac samples 
of Nox2KO mice. (A&B) T-cells as a percentage of CD45+ cells, (C&D) CD4+ T-cells as a 
percentage of total T-cells, (E&F) CD4+CD25+ Tregs as a percentage of CD4+ T-cells and 
(G&H) CD25+FoxP3+ Tregs as a percentage of CD4+ T-cells. Acquired on BD FACS 
CantoII™. N=4-8 per group. 
 
Collectively, these data suggest a protective phenotype within the global Nox2KO 
animals identified by attenuated AngII-induced hypertension, hypertrophy, and 
interstitial fibrosis and associated cardiac inflammation. The baseline immune 
phenotype suggests that global Nox2KO animals have a different composition of 
cardiac immune cells, including an increased level of Tregs and Treg:T-cell ratio. 
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4.5 Discussion 
Previous research has demonstrated the overall role of Nox2 in the development of 
cardiac remodelling. Nox2KO mice show significantly reduced interstitial fibrosis, 
compared with WT controls, after AngII or aldosterone infusion, myocardial infarction 
(MI) or pressure overload induced by aortic banding4,108,175. Initial results within this 
chapter verify these findings as a blunted response to AngII in terms of hypertension, 
hypertrophy and interstitial fibrosis was observed. Therefore this demonstrated that 
the global Nox2KO model works efficiently in our hands. However, the novelty of this 
chapter is in understanding the role of Nox2 in regulating the function of T-cells in this 
setting. 
At baseline, Nox2KO mice displayed LN, thymus and spleen hyperplasia without any 
signs of infection, which is confirmed in the literature from a study investigating age-
induced arthritis in these animals199. This may suggest an augmented development of 
immune cells that may influence the inflammatory response in this murine model199.   
Interestingly, published data suggest increased levels of inflammatory cells within 
Nox2KO animals199; therefore it is important to clarify whether this would alter the 
level of cardiac-resident immune cells. These results have shown a significantly higher 
level of total leukocytes, T-cells and more specifically CD8+ and CD4+ T-cells at baseline 
residing in the heart.  In contrast, Lee et al carefully analysed LNs of mice aged 15-18 
weeks where they saw higher levels of B-cells, macrophages and monocytes in 
comparison to a lower level of T-cells.  As this is a different tissue and time point from 
experiments in this chapter, where the mice have high incidence of arthritis, it is 
unreasonable to determine a trend. However one may suggest a cardio-tropism for T-
cells within Nox2KO animals, recruiting more T-cells to the heart and away from LNs at 
baseline.  
Background data using spleen samples showed an equivalent level of T-cells between 
Nox2KO and WT control mice. In comparison, published results have seen a reduction 
in splenic T-cell levels, including CD8+ and CD4+ T-cells, from mice aged 15-18 weeks199. 
This difference in results could be attributed to the older age of animals used, where 
the onset of arthritis is at 60% therefore tissue compositions may alter.  
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Within CD8+ T-cells, Nox2 is implicated in NF-κB signalling pathways leading to 
production of TNF-α, IFN-γ and IL-2, pro-inflammatory cytokines211. Treatment with 
apocynin, a Nox2 inhibitor, significantly decreases these inflammatory mediators. Bai 
et al also demonstrated that inhibition of Nox2 (gp91phox) in CD8+ T-cells prevents ROS 
generation, in turn modulating c-Jun N-terminal kinase (JNK) and NF-κB signalling 
leading to decreased IFNγ and CD39 expression212. Similar investigations have 
identified a reduction in TNF-α production by CD8+ T-cells lacking Nox2213. CD4+ Th 
differentiation can also be affected by Nox2 levels, where the absence of Nox2 
promotes Th1 and Th17 differentiation. Nox2KO mice with spontaneous age-induced 
arthritis displayed an increase in Th17 cells and a decrease in Tregs (analysed by FoxP3 
expression) within LNs199.  
Moreover, the production of Nox2-derived ROS within APCs can also affect T-cell 
activation and function. During DC antigen presentation to T-cells, bidirectional 
communication instigates the mediation between innate and adaptive immunity. Both 
cell types in this setting produce ROS, and ebselen (an antioxidant) is able to inhibit 
this production197. Presence of ebselen in a DC/T-cell coculture inhibits the DC-
dependent proliferation by T-cells and has the potential to abrogate sequential 
adaptive immune responses197. The antioxidant also inhibits production of cytokines, 
suggesting the involvement of ROS within DC and T-cell signalling. 
Furthermore, the basal levels of cardiac-resident Tregs in Nox2KO mice were 
somewhat elevated compared to WT littermate controls and give rise to an increased 
Treg:T-cell ratio. One could imagine that the higher level of Tregs in the Nox2KO heart 
provides a local protection to experimental hypertension and its pathological 
responses. However, one limitation of this model is the absence of Nox2 in all cell 
types, which makes it difficult to verify this hypothesis. For example, immune 
infiltration may also be influenced by endothelial cells or by factors released by 
cardiomyocytes or fibroblasts – all cell types that express Nox2. Results presented here 
have shown that splenic levels of Tregs remained the same between WT and Nox2KO 
mice. This was confirmed by a study investigating the effect of Nox2 (p47phox) on Treg 
development, where the baseline levels of Tregs within the spleen were similar 
between both genotypes214. Intriguingly, Lee et al identified a lower level of Tregs 
within LNs of Nox2KO mice compared to WT in mice aged 12-14 weeks199. 
  146  
Nox2 has also been implicated in the direct suppression of CD4+ T-cells by Tregs214. 
Both Tregs from the neutrophil cytosolic factor-1 (Ncf1, p47phox)–deficient mice, which 
lack Nox2 activity, and normal Tregs treated with Nox inhibitors have shown a 
decreased ability to suppress CD4+ effector T-cells in vitro214. Hence, suggesting that 
Nox2 may play a role in regulating the suppressive abilities of Tregs. Further in vitro 
work demonstrated that the suppressive attribute of Tregs is partially dependent on 
TGFβR signalling within these cells214. Within the periphery of Nox2KO mice there are 
reported to be fewer Tregs compared to WT animals, naïve CD4+ T-cells isolated from 
the periphery are also less efficient at differentiating into Tregs199.  
Furthermore, production of Nox2-derived ROS upon macrophage activation can 
stimulate Tregs, and consecutive suppression of T-cells215. Co-culture of T-cells and 
macrophages saw an increase in CD4+CD25+FoxP3+ Tregs, which was diminished in the 
presence of apocynin, a Nox2 inhibitor215. This was also confirmed in vivo.  
Dexamethasone, an immunosuppressive drug, also increases ROS levels and T-cell 
suppressive activity within M2 cells216. Nox2 deficient macrophages from CGD patients 
lacked the ability to produce ROS. The capacity of these Macrophages to suppress T-
cell responses was diminished and the levels of Tregs induced were significantly 
reduced compared to healthy controls215.   
Research investigating human M2 cells indicated the different capacities of ROS 
production and function between M2 subpopulations. M2 cells appear to produce ROS 
to a higher capacity, compared to M1, however the different subtypes of M2 cells 
(M2a, M2b and M2c) also vary in their capacity to produce ROS and ability to induce T-
cell activation49. M2a has lower ROS production and a better ability at inducing T-cells 
whereas M2b and M2c are the opposite and also have the ability to induce Tregs49. 
The effect of Nox2 on CD4+ T-cells and Tregs creates an essential balance that can 
switch between a pro-inflammatory or anti-inflammatory response, which is vital 
within a variety of diseases outcomes.  
In addition, Lee et al examined the differentiation of naïve CD4+ T-cells and reported a 
skewed phenotype towards Th17 cells and a reduced level of Treg differentiation, 
suggesting Nox2 alters the Th17/Treg balance199. However, cells used were also 
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isolated from lymphoid organs of mice aged 12-18 weeks; therefore in younger 
animals, such as those used here, this T-cell skewing and Treg levels may be different.  
Madhur et al investigated T-cell infiltration into the aorta of WT mice in response to 
AngII, and highlighted that IL-17 was a potent cytokine upregulated in this setting185. 
They also identified that IL-17, and hence the Th17 CD4+ T-cell subtype, are critical for 
the maintenance of AngII-induced hypertension and vascular remodelling185. Within 
the Nox2KO cardiac environment, where a significantly higher level of Tregs were 
observed at baseline, different modulators such as TGFβ that can promote Treg 
maintenance and differentiation217, may alter the Treg:Th17 balance towards Tregs. 
Previous research has implicated Tregs within cardiac remodelling associated with 
experimental hypertension. Hence, our findings here may partially explain the blunted 
response of Nox2KO mice to AngII-induced cardiac remodelling. Therefore Tregs may 
be a key cellular-modulator within this process.  
As global Nox2KO mice display a blunted response to AngII-induced hypertension and 
cardiac remodelling, in addition to an altered baseline level of immune cells within the 
heart, this led to the investigation of immune cell infiltration with AngII within these 
global Nox2KO mice. AngII treatment within WT littermates initiated the typical 
inflammatory response previously observed; however this was significantly blunted in 
Nox2KO animals. The cardiac infiltration of total leukocytes, T-cells, CD8+ and CD4+ T-
cells were all significantly lower in Nox2KO treated animals compared to their WT 
counterparts.  
One could postulate that as AngII contributes to hypertrophy and fibrosis, the 
concomitant stimulation of the inflammatory response further aggravates cardiac 
remodelling and damage. Therefore Tregs may be activated in order to restrain 
inflammation and hence limit the remodelling process. This supports the idea that the 
increase in Tregs observed in WT mice after 3-days of AngII treatment could be a 
transient compensatory mechanism. Thus if AngII treatment persists the inflammatory 
response may progress. However, as global Nox2KO animals exhibit a higher level of 
Tregs at baseline, this may keep inflammation at bay as AngII treatment is initiated, 
and in part protect the heart against AngII-induced pathophysiology.  
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Overall, data within this chapter have shown that global Nox2KO animals have an 
increased level of cardiac-resident immune cells at baseline, including an enhanced 
Treg:T-cell ratio. AngII-induced cardiac immune cell infiltration is obliterated in these 
Nox2KO animals suggesting a potential protective response of the initial elevated Treg 
levels in the heart. This in part may contribute to the favourable AngII response of 
Nox2KO mice. However the impact of CD4+ T-cells, and more specifically Tregs, within 
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 Role of Nox2 in the Chapter 5:
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5.1 Introduction 
5.1.1 Regulatory T-cells 
Tregs are driven by their master transcriptional regulation, FoxP362. They suppress the 
activity of other immune cells, such as CTLs, B-cells and Th subsets, in order to control 
immune responses218,219. They play a critical role in peripheral tolerance, to dampen 
down the amplitude of an immune response, which is pertinent in preventing 
autoimmune diseases.  
Treg differentiation and classification remains controversial, within the literature 
numerous terms are given to describe Treg subtypes. Tregs that are derived from the 
thymus are known as natural Tregs (nTregs), or thymic-derived Tregs (tTregs), whereas 
peripheral-derived Tregs are known as inducible Tregs (iTregs), or peripheral-derived 
Tregs (pTregs)220. iTregs within the secondary lymphoid organs (SLO) are also termed 
central Tregs that, when activated, differentiate into effector Tregs178,220. This 
differentiation process is initiated by TCR signalling and CD28178. Effector Tregs then 
produce different cytokines and chemokines, depending on the type of inflammatory 
response, in order to specialise their suppressive function (Figure 5-1)178. Hence, 
central Tregs serve as a quiescent pool of Tregs, which recirculate through SLO, 
differentiating into faster-lived, highly proliferative effector Tregs eliciting an anti-
inflammatory response. One must bear in mind that this is one view of the Treg 
classification, however this still remains controversial and further research is required. 
In addition, tissue-resident Tregs are also present that possess a unique phenotype 
specific to their location and homeostatic functions178,220. Their origin is not yet 
defined; however they may propagate from effector Tregs.  
CD4+CD25+FoxP3+ naturally occurring Tregs, derived from the thymus, represent 10% 
of the total CD4+ population and have been the focus of recent studies218. 
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Figure 5-1: Specialisation and diversity of Treg subtypes. Rothstein et al 2015 (current 
opinion organ transplantation)178. 
 
There are four basic mechanisms thought to be used by Tregs to enable suppression: 
inhibitory cytokines, cytolysis, metabolic disruption and targeting APCs (Figure 5-2)218. 
Firstly, Tregs have the ability to secrete anti-inflammatory cytokines including TGFβ, IL-
10 and IL-35, which enable the indirect suppression of immune cells such as Teff 
cells221. These Treg-associated cytokines also have the ability to stimulate development 
of iTregs, thereby amplifying the anti-inflammatory response218.  
The second mechanism involves cytolysis by the secretion of granzymes that enter 
target cells via a perforin pore218. Perforin is a component of the cytolytic granule that 
enables permeabilisation of the target cell plasma membrane218. Once granzymes have 
entered the target cell they can elicit an apoptotic response by cleaving and activating 
intracellular caspases. A number of studies have implicated granzyme A and granzyme 
B in the Treg-mediated suppression of inflammation222-224. 
Tregs can also mediate metabolic disruption of a target cell by expression of CD25 on 
Treg membranes218. CD25 sequesters IL-2, diminishing local IL-2 levels that are 
required for T-cell survival225,226. In addition, IL-2 has also been found to upregulate 
FoxP3 expression and hence may be involved in Treg activation and amplification of 
suppressive mechanisms221,227. In addition to this, Tregs express CD39 and CD73 on 
their cell membranes that produce adenosine, which in turn suppresses the target 
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cells221. Pericellular adenosine binds to and activates adenosine receptor 2 A (A2AR), 
which in turn inhibits Teff cell function221. Furthermore A2AR activation can enhance 
induction of Tregs by inhibiting IL-6 whilst promoting TGFβ secretion228. TGFβ 
enhances Treg differentiation, thereby further amplifying this regulatory response.  
Finally, Tregs can modulate the inflammatory response by targeting APCs such as DCs. 
The binding of CTLA-4 or the lymphocyte-activation gene 3 (LAG3) on Tregs to their DC 
receptor targets, CD80/86 or MHC class II respectively, inhibits DC maturation and 
function preventing further inflammation221,229. Depletion of CTLA-4 impairs Treg 
suppressive function both in vitro and in vivo177,230.  
 
 
Figure 5-2: Treg suppressive mechanisms. From Vignali et al 2008218. 
 
5.1.2 Role of Nox2 in Treg differentiation, activation and suppressive 
function 
Nox2 has previously been shown to modulate Treg differentiation and function. As 
briefly discussed in section 4.5, Lee et al demonstrated an integral role for Nox2 in the 
differentiation of Tregs199. They observed a lower level of Tregs within the LNs and 
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spleens of global Nox2KO mice compared to WT mice, suggesting a role of Nox2 in 
Treg migration or differentiation199. Furthermore, naïve Nox2KO CD4+ T-cells, isolated 
from LNs, cultured in the presence of anti-IFNγ, anti-IL4, IL-2 and TGFβ were less 
efficient than their WT counterparts at generating iTregs199.  
In addition, Nox2 was identified as an important component in Treg suppressive 
function214. Tregs isolated from of p47phox-/- mice, which lack the p47phox (Ncf1) adaptor 
protein of Nox2, show decreased ability to suppress Teff cells214. This was also verified 
by an in vitro suppression assay analysing WT Treg suppression of Teffs in the presence 
of an Nox inhibitor214.  
Activation of Tregs by macrophages may also be modulated by Nox2. ROS have been 
directly implicated in the activation of Tregs by macrophages198. Gelderman et al 
generated a transgenic (TG) mouse model based on a p47phox-/- background (lacking 
Nox2), whereby only macrophages contain a functional Nox2 enzyme. Global p47phox-/- 
mice are highly susceptible to collagen-induced arthritis; however these TG mice were 
protected to the same extent as WT mice; thereby implicating macrophage Nox2 and 
associated ROS in anti-inflammatory processes198. These findings were validated by in 
vitro analysis of macrophages isolated from CGD patients, lacking Nox2, which were 
unable to suppress T-cells and induced a significantly lower number of Tregs215. 
Therefore these results demonstrate that macrophage Nox2-derived ROS enable the 
suppression of T-cells by inducing Tregs198,215.  
 
5.1.3 Tregs in non-lymphoid tissues 
Current research provides substantial evidence of the implication of Tregs in non-
lymphoid tissues such as visceral adipose tissues (VAT), skeletal muscle and 
cardiovascular tissue231,232. In this non-lymphoid setting Tregs contribute to tissue 
homeostasis and repair. This opens a whole new plethora of Treg functions that go 
beyond the traditional regulation of immune responses. Not only are they vital in 
modulating immune responses, but also have the ability to control non-immunological 
processes in a range of tissues231. Tissue-resident Tregs exhibit a unique phenotype by 
expressing certain transcription factors, chemokines receptors or effector 
molecules231. They may also possess a distinct TCR repertoire, migration patterns and 
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distinct mechanism of action or targets231. Local cues within specific tissues may 
enable this phenotypic and functional specialisation of Tregs in addition to preferential 
survival within the tissue microenvironment231.  
VAT-specific Tregs are the most well defined tissue-specific Treg population. They 
overexpress genes that give rise to chemokine receptors (such as CCR1, CCR2 and 
CCR9), anti-inflammatory cytokines (such as IL-10) and the transcription factor PPAR-
γ233. PPAR-γ interacts with FoxP3 in order to promote VAT Treg-specific 
characteristics233. Absence of PPAR-γ in mice prevents the accumulation of Tregs 
within VAT233. The specific overexpression of these genes enables VAT Tregs to elicit 
their unique functional properties (such as impacting on glucose metabolism)231. In 
addition VAT Tregs express a unique TCR repertoire that is distinct from other Treg 
populations231.  
Skeletal muscle-specific Tregs are upregulated during injury and regeneration of the 
muscle231. They overexpress genes encoding IL-10, growth factors such as 
amphiregulin and the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) 
that regulates macrophage activation231,234. These Tregs also have a unique TCR 
repertoire and phenotypically tend to be more similar to VAT Tregs than splenic 
Tregs231. In this setting, skeletal muscle Tregs have the ability to aid muscle repair by 
satellite cells due to their overexpression of amphiregulin231,234.  
Tissue-specific Tregs are found, albeit in small numbers, within healthy tissues that can 
be upregulated in response to injury or infection231,235. This increase in Treg numbers 
may occur due to chemokine-based recruitment, local expansion or by conversion of 
CD4+ T-cells (Figure 5-3)231. Tissue resident Tregs express distinct chemokine receptors 
and adhesion molecules, which may enable their initial recruitment231. Treg priming 
within the LNs is thought to upregulate these tissue-specific chemokine receptors and 
adhesion molecules in order to direct Treg migration towards the affected tissue and 
elicit a local response231.  
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Figure 5-3: Tissue specific Treg accumulation. Burzyn et al 2013 (nature 
immunology)231. 
 
Research groups investigating Treg recruitment have identified the chemokine 
receptors CCR4 and CCR8 as important mediators of Treg migration181,182. However, 
very few papers have examined the recruitment of Tregs specifically to the heart. In a 
model of cardiac allograft tolerance, the recruitment of Tregs is critical for long term 
graft survival182. This recruitment mechanism was reliant on the expression of CCR4 
chemokine, as CCR4-/- mice were unable to induce tolerance after receiving a cardiac 
allograft182. In addition, CCR5 may play a role in Treg recruitment during MI, as CCR5-/- 
mice showed a significantly higher level of inflammation236. 
Taken together, these results identify a novel, local role for Tregs in non-lymphoid 
tissues, including the myocardium. Local immune responses and Tregs themselves 
have both been recognised as important elements in tissue homeostasis and repair; 
however as research continues it becomes apparent that these two areas are more 
entwined than once thought. Therefore further study into specific cardiac-Tregs may 
elicit new functions and migration patterns that could be harnessed for potential 
therapeutic treatment.  
 
5.1.4 Tregs in cardiovascular pathophysiology 
Little is known about cardiac-specific Tregs, although Tregs have been implicated in a 
number of cardiovascular pathologies including atherosclerosis, MI and AngII-induced 
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abdominal aortic aneurysm232. One main limitation in fully understanding cardiac-
resident Tregs is the limited number of Tregs at baseline, which makes it difficult to 
analyse their cardiac-specific phenotype. Tregs are thought to control the 
development of atherosclerosis, an immune-inflammatory disease characterised by 
the accumulation of lipids within the artery wall237. In this setting Tregs potentially 
reduce atherosclerotic lesion size, prevent rupture and limit progression of 
atherosclerosis238. Ischemic injury to the myocardium is followed by an enhanced 
inflammatory response, however a second phase of resolution and repair also occurs 
that is essential to infarct-healing and prevention of heart failure239. Tregs are thought 
to be involved in this process, and have been shown to expand within the LNs draining 
the heart240. The absence of Tregs in this setting has also been linked to a larger infarct 
size, increased inflammation and impaired resolution of infarct-associated 
inflammation240.  Therefore Tregs enhance cardiac wound healing within the setting of 
MI. Furthermore, recruited Tregs may modulate fibroblast phenotype and function 
within the setting of MI by reducing α-SMA and decreasing MMPs241. Abdominal aortic 
aneurysm (AAA) is a chronic inflammatory aortic disease associated with maladaptive 
vascular remodelling that progress towards aortic rupture242. Antibody depletion of 
Tregs enhances susceptibility of C57Bl/6 mice to AAA and promotes aortic rupture242. 
On the other hand, increased systemic Treg levels provide a protective phenotype 
against AngII-induced AAA243,244.  
 
5.2 Aims 
Nox2 has been identified as a potential modulator of Treg function and development; 
however this still requires further examination. In addition, Tregs have been suggested 
by a number of papers to play an important role in regulating cardiovascular 
remodelling in response to AngII. However, the specific role of Treg-Nox2 within the 
setting of AngII-induced hypertension and cardiac remodelling is unknown.  
Therefore the aim of the studies in this chapter is to identify the effects of Nox2 on 
Treg function both in vitro and in vivo in the setting of AngII-induced cardiac 
pathophysiology.  
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5.3 Methods   
5.3.1 Immune cell isolation and purification 
Immune cells were isolated from fresh spleens and LNs, as described in section 2.4.3, 
from male C57Bl/6 (Harlan UK Limited) or in-house bred global Nox2KO mice (section 
4.3) aged 6-8 weeks. A single cell suspension was created by triturating and passing 
tissues through a 70μm nylon mesh using the plunger of a 1mL syringe. Cells were then 
washed in Roswell Park Memorial Institute (RPMI) media (with L-glutamine, Gibco) and 
centrifuged at 1800rpm for 5 minutes. Spleen samples only were then treated with 1x 
red blood cell lysis buffer (5mL per spleen) for 3 minutes at room temperature before 
washing in RPMI as before. Spleen and LN samples were then re-suspended in a 
suitable volume and pooled together before removing 10μL to count T-cells using a 
haemocytometer (1:10 dilution with trypan blue (Gibco)).  
All immune cell isolations were performed in a laminar flow cabinet (tissue culture 
hood) to provide a sterile environment for use of sterile buffers, where all added 
components were filtered. 
 
5.3.1.1 CD4+ T-cells 
CD4+ T-cells were isolated using the Invitrogen Dynal® CD4+ T-cell isolation kit, 
according to the manufacturer’s protocol. Briefly, splenic cells were incubated in a 
solution of 100μL isolation buffer, 20μL FCS and 20μL of the antibody mix for 30 
minutes at 4˚C under rotation. Samples were then washed and centrifuged as before 
using isolation buffer. Dynabeads® (200μL per 10x106 leukocytes, Invitrogen) were 
prepared by washing twice in 6mL isolation buffer, leaving on a magnet (15mL 
DynaMag™) for 2 minutes and removing the supernatant using a Pasteur pipette. The 
supernatant was removed from centrifuged cells and re-suspended in 800μL isolation 
buffer (per 10x106 leukocytes) and combined with the pre-washed Dynabeads®. The 
cell-Dynabead® solution was then incubated for 30 minutes at 4˚C under rotation. Cells 
bound by beads were then removed by adding up to 6mL isolation buffer and placing 
the solution on a magnet for 2 minutes. The supernatant was then removed and 
placed into a fresh 15mL tube, which was incubated on the magnet for 2 minutes 
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before removing the supernatant again to obtain pure CD4+ T-cells. These cells were 
then washed and centrifuged as before in isolation buffer, the supernatant was 
discarded and cells were re-suspended in a suitable volume before counting using a 
haemocytometer. CD4+ cells were then washed and centrifuged for a final time and re-
suspended at a concentration of 1x106 cells/mL, in complete media.  
 
5.3.1.2 Antigen presenting cells  
Splenic cells were then incubated in a cocktail of CD4 and CD8 depleting antibodies 
(300μL anti-CD4 antibody (YTS-191.1, Lombardi laboratory) and 300µL anti-CD8 
antibody (YTS-169.4, Lombardi laboratory) per spleen) and incubated for 30 minutes at 
4˚C under rotation. Cells were then washed and centrifuged as described previously 
and re-suspended in 1mL isolation buffer per spleen. The cell solution was then 
incubated with 300μL of pre-washed Dynabead® per spleen for 30 minutes at 4˚C 
under rotation. Dynabead® bound cells were then removed as before using a magnet 
and counted using a haemocytometer. APCs were then re-suspended in complete 
media at a concentration of 2x106 cells/mL. 
 
5.3.1.3 Regulatory T-cells  
Spleens and LNs from multiple mice were treated as described above to generate a 
single cell splenocyte suspension. Tregs were isolated, according to the manufacturer’s 
protocol, using an Invitrogen CD4+CD25+ Treg Dynabead® kit, as shown in Figure 5-4. 
Initial single cell suspensions were re-suspended at a concentration of 1x108 cells/mL 
in isolation buffer and incubated with 200μL FCS and 200μL antibody mix (Invitrogen 
Dynal® CD4+CD25+ T-cell isolation kit) per 1 x 108 cells for 30 minutes at 4˚C under 
rotation. Cells were washed using isolation buffer and centrifuged at 1800rpm for 5 
minutes. Cells were then washed, centrifuged and re-suspended in 2mL cold isolation 
buffer (per 1x108 cells). Then mixed with 2mL pre-washed Dynabeads® (per 1x108 cells) 
and incubated for 30 minutes at 4˚C under rotation. Cells bound by beads were then 
removed using a magnet as described previously and the CD4+ Supernatant was 
washed and centrifuged before, resuspending in 250μL isolation buffer per 1x108 cells. 
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25μL FlowComp™ mouse CD25 antibody (Invitrogen) was then added (per 1x108 cells) 
and the cells were incubated again for 30 minutes at 4˚C under rotation. Cells were 
then washed, centrifuged and re-suspended in 250μL isolation buffer per 1x108 cells. 
CD4+ cells were then incubated with 75μL (per 1x108 cells) pre-washed FlowComp™ 
Dynabeads® for 30 minutes at 4˚C under rotation. Beads were re-suspended by 
pipetting and placed on a magnet for 2 minutes. The supernatant was removed and 
kept in a clean 15mL falcon tube; this contains the CD4+CD25- T-cells. Remaining beads 
were washed and reapplied to the magnet twice before resuspending in 0.5mL 
FlowComp™ release buffer and incubated for 30 minutes at 4˚C under rotation. Cells 
were then placed on the magnet for 2 minutes and the supernatant removed to a fresh 
tube, washed and placed back on the magnet for a further 2 minutes and the final 
CD4+CD25+ T-cell suspension was removed to a fresh tube and counted. Cells were re-
suspended to a final concentration of 2x106 cells/mL for the suppression assay, and 5 x 
106 for an adoptive transfer experiment.  
 
 
Figure 5-4: Treg isolation method, adapted from Invitrogen Dynal®. 
 
Remaining CD4+CD25- T-cells and CD4+CD25+ Tregs were analysed using flow cytometry 
to validate efficiency of the isolation process. Figure 5-5 shows a purity of ~ 90-95% of 
isolated CD4+ T-cells expressing CD4, with <5% of cells expressing CD25.  
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Figure 5-5: Verification of isolated CD4+ T-cells. Blue peak represents negative control; 
red peak shows the cell sample. 
 
Similarly, Figure 5-6 shows that ~87-90% of isolated CD4+CD25+ Tregs express CD4, 
where ~93-95% of these CD4+ cells express CD25 and 95-97% express FoxP3.  This 
demonstrates a sufficient purity of isolated cells.  
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Figure 5-6: Validation of isolated CD4+CD25+ Tregs. Blue peak represents negative 
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5.3.2 Adoptive transfer 
CD4+CD25+ Tregs were isolated from Nox2KO or C57Bl/6 mice, as described above, and 
re-suspended to a concentration of 5x106 cells/mL in sterile saline and kept on ice. WT 
mice were warmed in an incubator for 2 hours at 30˚C before injections, and were 
anaesthetised with 2% isoflurane. Tails were cleaned with 70% EtOH before 200μL of 
Nox2KO Tregs, WT Tregs or sterile saline were injected into the lateral tail vein to 
deliver 1x106 cells per injection. Mice were then implanted with a subcutaneous mini-
osmotic pump containing a pressor dose of AngII (1.1mg/kg/day) as described in 
section 2.3. Treatment continued for up to 14-days and both blood pressure and 
haemodynamic function were recorded at 0-, 3-, 7- and 14-days after treatment, as 
described in section 2.4.  
 
5.3.3 In vitro suppression assays 
Teff cells (CD4+CD25-), APCs and Tregs were isolated from C57Bl/6 or Nox2KO mice 
(Tregs) as described above and re-suspended in complete media. 50µL of each 
respective cell suspension was added to each well of a 96 well round-bottom plate 
with the conditions illustrated in Figure 5-7. Therefore each well contained a 
combination of 50,000 CD4+ T-cells, 100,000 APCs and 50,000 Tregs. With the ratio of 
Teff:Treg being altered in certain conditions by diluting Tregs with an equal volume of 
complete media. Purified anti-CD3 antibody (8µg/µL, final concentration, BD 
Pharmingen) was also added to certain wells. 
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Figure 5-7: Suppression assay plate setup. Different combinations of CD4 T-cells, APCs, 
Tregs and anti-CD3 antibody are plated in wells, each with three repeats. The same 
layout is used for WT and Nox2KO Tregs for the thymidine assay. 
 
5.3.3.1 Thymidine suppression assays 
After setting up the assay as described above, the 96-well plate was then incubated at 
37˚C, 5% CO2 for 48 hours. A mixture of 50μL complete media and 1μL 
3H-thymidine 
was then added to each well and the assay was incubated at 37˚C for a further 17 
hours. Cells were then transferred to a filter mat using a cell harvester. The filter mat 
was then dried by microwaving for at least 3 minutes before transferring it to a plastic 
pouch containing 17mL β-scintillation fluid and sealed. Levels of radioactivity were 
then detected for each well using a beta plate. 
 
5.3.4 Treg phenotype 
Tregs isolated from Nox2KO or WT littermates as described in section 5.3.1.3 were 
then treated for analysis by flow cytometry (section 2.6.2). These samples were 
incubated with antibodies shown in Table 11 and analysed on BD FACS CantoII™.  
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Table 11: Antibodies used for Treg phenotyping experiments using flow cytometry. 
 
5.3.5 Treatment of samples 
After 14-days of treatment, organs were harvested and treated as explained in section 
2.4 for histological analysis using WGA and PSR (section 2.8). RNA extraction and 
reverse transcription were performed as described in section 2.7 to enable analysis of 
fibrosis-related markers by qPCR. A second group of animals received the same 
treatment, but were harvested after 3-days of AngII infusion in order to analyse 
immune cell infiltration. Single cell suspensions were prepared from whole hearts, 
spleens, aortas and kidneys, and analysed by flow cytometry using the BD FACS 
CantoII™ as described in section 2.6. The level of leukocytes, T-cells and T-cell subsets 
were determined based on expression of CD45, TCRβ, CD4, CD8, CD25 and FoxP3. 
 
5.4 Results 
The experiments in chapter 4 showed a different response between Nox2KO and WT 
cardiac T-cell infiltration during AngII treatment, including altered cardiac infiltration of 
CD4+ T-cell and Treg populations. Therefore, it was important to investigate the effect 
of Nox2 in Treg function both in vivo and in vitro. 
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5.4.1 Adoptive transfer of Nox2KO Tregs blunts AngII-induced 
cardiovascular changes 
Tregs were isolated from global Nox2KO or WT littermate control mice using magnetic 
beads and the purity was verified using flow cytometry. Isolated Tregs, or sterile saline, 
were then injected via the tail vein into C57Bl/6 mice, before the implantation of a 
mini-osmotic pump containing a pressor dose (1.1mg/kg/day) of AngII. These three 
groups were treated with AngII for up to 14-days, during which time blood pressure 
and cardiac structure/function were recorded using tail cuff plethysmography and 
echocardiography respectively.  
Typical increases in systolic blood pressure were observed in saline-injected mice 
treated with AngII, as previously shown in chapter 3. This hypertensive response was 
attenuated in both WT- and, more efficiently, Nox2KO- Treg injected groups after 3-
days of treatment (Figure 5-8 A). AngII-treated animals that received a saline injection 
exhibited an expected increase in systolic blood pressure. Interestingly, all Treg 
injected animals showed a blunted hypertensive response to AngII after 3- and 7-days, 
with a more striking effect for KO Tregs. In the early phase of treatment (day 3), 
animals injected with WT-Tregs displayed systolic blood pressure lower than that 
observed in the control group (p=0.0340), however this difference was attenuated 
after 7-days.  In comparison, the Nox2KO-Treg treated group maintained a blunted 
systolic blood pressure response during 7-days of AngII infusion (day 3, p=0.0014) (day 
7, p=0.0008).  This attenuated response was observed from 3- to 7-days after AngII 
treatment was initiated, before blood pressure levels increased on par with saline 
injected animals at day 14. Cardiac function remained similar between all groups over 
the duration of AngII treatment (Figure 5-8 B-G). 
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Figure 5-8: Treg adoptive transfer blunts AngII-induced hypertension. Tail cuffing was 
used to record and analyse (A) systolic blood pressure. Haemodynamic function was 
observed using echocardiography looking at (B) LV end-diastolic and (C) LV end-systolic 
volume, and (D) ejection fraction. *p<0.05, **p<0.01, ***p<0.001.  N=6 per group.  
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After 14-days of treatment, mice were sacrificed and BW, HW and TL were recorded 
for all mice to generate HW/BW and HW/TL ratios. These were similar among the 
three groups (Figure 5-9). A gradual increase in IVS thickness was observed in saline 
injected animals treated with AngII, similar to the WT response to AngII seen in 
chapter 3. This prominent increase was significantly blunted in both WT- (p=0.001) and 
more efficiently, Nox2KO- (p<0.0001) Treg injected groups after 14-days of AngII 
treatment, where the Nox2KO-Treg IVS thickness was 26% lower than that of the 
control, saline injected AngII treated group.  
 
 
Figure 5-9: Treg adoptive transfer prevents AngII-induced hypertrophy. Organ-level 
hypertrophy was analysed by (A) heart weight-to-body weight (HW/BW) ratio, (B) 
heart weight-to-tibia length (HW/TL) ratio and (C) interventricular septum (IVS) 
thickness. *Saline AngII vs Nox2KO-Treg AngII. #Saline AngII vs WT-Treg AngII. 
**p<0.01, ****p<0.0001.  N=6 per group. 
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Paraffin sections prepared from heart samples were treated with WGA to stain cell 
membranes of cardiomyocytes. Analysis highlighted significantly smaller 
cardiomyocyte surface areas in groups treated with both WT- (p=0.003) and Nox2KO-
Tregs (p=0.002) compared to saline injected groups, (Figure 5-10). 
 
Figure 5-10: Blunted AngII-induced cardiomyocyte hypertrophy observed with Treg 
adoptive transfer. WGA staining highlighted smaller cardiomyocyte surface area in 
both Nox2KO-Treg and WT-Treg injected groups compared to saline, all treated with 
AngII for 14-days. **p<0.01, N=6 per group. 
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PSR staining was performed on cardiac paraffin sections to identify collagen, Figure 
5-11. The saline injected group, treated with AngII, resulted in interstitial fibrosis to a 
similar level to that observed in chapter 3. Comparable fibrosis was also observed in 
WT-Treg injected group treated with AngII after 14-days, however this was blunted in 




Figure 5-11: Nox2KO-Treg adoptive transfer prevents AngII-induced interstitial 
fibrosis. Paraffin sections stained with picrosirius red identify a lower percentage of 
collagen within Nox2KO-Treg injected hearts treated with AngII for 14-days.*Nox2KO-
Tregs vs saline. #Nox2KO-Tregs vs WT-Tregs. ****p<0.0001, N=6 per group. 
 
Furthermore, col1α1 (p=0.022) and col3α1 (p=0.014) mRNA levels were considerably 
lower in Nox2KO-Treg injected animals compared to WT and saline (Figure 5-12). 
However, fibronectin, TGFβ and CTGF were similar among groups.  
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Figure 5-12: Adoptive transfer of Nox2KO-Tregs decreases cardiac fibrotic-related 
markers. Analysis by qPCR of mRNA levels for (A) collagen1α1, (B) collagen3α1, (C) 
fibronectin, (D) TGFβ1, (E) TGFβ3 and (F) CTGF. *Nox2KO-Tregs vs Saline. #Nox2KO-
Tregs vs WT-Tregs.*p<0.05, N=5-6 per group. 
 
5.4.2 Cardiovascular inflammation is altered by Nox2KO-Treg adoptive 
transfer 
Quantification of immune cell infiltration was obtained by flow cytometry using BD 
FACS CantoII™. Adoptive transfer experiments were performed as described 
previously, but injected C57Bl/6 mice were treated for 3-days with AngII before 
analysis. Single cell suspensions were prepared from whole hearts, aortas, kidneys and 
spleens from all treated animals. 
In terms of cardiac infiltration, representative flow cytometry dot plots shown in Figure 
5-13 demonstrate a lower number of leukocytes, T-cells and T-cell subsets in the 
Nox2KO-Treg injected group compared to saline.  
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Figure 5-13: Representative flow cytometry dot plots illustrate lower cardiac 
inflammation with Treg adoptive transfer. Acquired on BD FACS CantoII™.  
 
Flow cytometric analysis, Figure 5-14, shows that total leukocytes (CD45+ cells) were 
significantly lower in WT- (p<0.001) and in Nox2KO- (p<0.0001) Treg injected groups 
compared to saline. Comparable results were observed with T-cell infiltration with 
hearts from both WT- (p=0.003) and Nox2KO- (p<0.001) Treg injected groups 
containing significantly less T-cells, 76% and 88% respectively, than saline injected 
animals. Each of the T-cell subpopulations showed a similar response, with DN T-cells 
(pWT=0.001; pNox2KO<0.001), DP T-cells (pWT<0.001; pNox2KO<0.001), CD8
+ T-cells 
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(pWT=0.006; pNox2KO=0.007) and CD4
+ T-cells (pWT=0.044; pNox2KO=0.009) each having a 
significantly lower infiltration with WT- and Nox2KO-Treg injections compared to 
saline, all treated with AngII. The Nox2KO-Treg injected group appeared to have a 
greater reduction in total T-cells and in CD4+ T-cells than the WT-Treg injected group, 
but this was not statistically significant.  
 
 
Figure 5-14: Treg adoptive transfer blunts AngII-induced cardiac inflammation. 
Analysis of (A) total leukocytes (CD45+), (B) T-cells (CD45+TCRβ+), (C) CD4-CD8- T-cells, 
(D) CD4+CD8+ T-cells, (E) CD8+ T-cells and (F) CD4+ T-cells. Represented as cells per mg 
of heart tissue, analysed on BD FACS CantoII™.*compared to Saline. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.  N=8-9 per group. 
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Spleen samples, analysed as a background control for the immune system, 
demonstrated equal proportions of total leukocytes, T-cells and T-cell subpopulations 
(Figure 5-15).  
 
 
Figure 5-15: Splenic immune cell levels remain unaltered with Treg adoptive transfer. 
Analysis of (A) total leukocytes (CD45+), (B) T-cells (CD45+TCRβ+), (C) CD4-CD8- T-cells, 
(D) CD4+CD8+ T-cells, (E) CD8+ T-cells and (F) CD4+ T-cells. Represented as a percentage 
of total cells, analysed on BD FACS CantoII™. N=8 per group. 
 
Within the CD4+ T-cell compartment, Tregs (CD4+CD25+ and CD25+FoxP3+) remained 
similar between all three groups (Figure 5-16). However, WT-Treg injected animals had 
a marked decrease in Tregs (CD25+FoxP3+) within the spleen compared to both 
Nox2KO-(p=0.019) and saline (p=0.001) injected mice. Highlighting a 34% lower level of 
Tregs in the spleen of WT-Treg injected animals compared to Nox2KO-Treg injected 
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animal, all treated with AngII. This may suggest a different Treg recruitment process 
between these two Treg injected groups. 
 
 
Figure 5-16: Splenic Treg levels are altered by WT-Treg adoptive transfer only. 
Cardiac samples analysed by (A) CD4+CD25+ Tregs and (B) CD25+FoxP3+ Tregs. Splenic 
levels of (C) CD4+CD25+ Tregs and (D) CD25+FoxP3+ Tregs were also analysed. 
**p<0.001, analysed by BD FACS CantoII™. N=8-9 per group. 
 
In order to fully understand immune cell compositions within this setting, the 
proportions of T-cells required further investigation. Therefore, analysis of cells as a 
percentage of their parent population was carried out (Figure 5-17). Within the heart 
of AngII-treated WT- (p<0.001) and Nox2KO-Treg (p<0.001) injected groups, T-cells as a 
percentage of CD45+ cells were significantly lower by 69% and 66% respectively. This 
suggests a reduction in T-cells but not necessarily other CD45+ leukocytes; hence T-
cells become a lower percentage of total CD45+ cells. In comparison to this, in Figure 
5-17C , CD4+ T-cells as a percentage of total T-cells show a marked increase in both 
WT- (p=0.023) and Nox2KO-Treg (p=0.026) injected groups by a factor of 
approximately two. This indicates that the reduction in overall T-cells is greater than 
the reduction in CD4+ T-cells, giving a larger ratio between the two. Interestingly, Tregs 
(CD4+CD25+) as a percentage of CD4+ T-cells (Figure 5-17E) are significantly higher in 
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the Nox2KO-Treg injected group compared to saline (p=0.017). This is also confirmed 
by FoxP3 staining (CD25+FoxP3+ Tregs, Figure 5-17G), which shows an increase from 
4.94±2.04% in saline hearts to 8.67±2.01% in Nox2KO-Treg injected hearts (p=0.013). 
Therefore, even though we do not see an increase in Tregs per mg of heart tissue, the 
proportion of Tregs to T-cells is significantly higher in the hearts of Treg-injected mice. 
In comparison WT-Treg injected animals tend to have a higher percentage of Tregs, 
within the CD4+ T-cell compartment, however this was not significant.  Spleen samples 
showed a similar level of T-cells as a percentage of CD45+ cells and CD4+ T-cells as a 
percentage of total T-cells (Figure 5-17B&D). However CD4+CD25+ Tregs as a 
percentage of CD4+ T-cells (Figure 5-17F) are greatly decreased in WT-Treg treated 
animals compared to both saline (p<0.001) and Nox2KO-Treg (p=0.034) injected mice, 
all treated with AngII for 3-days. This difference was also maintained with more 
specific FoxP3 staining for Tregs, shown in Figure 5-17H, indicating a reduction from 
7.46±0.28% in saline injected animals to 4.61±0.54% in WT-Treg injected mice 
(p<0.001).  This suggests a different immune-response mechanism between the WT-
Treg injected group and the Nox2KO-Treg injected group.  
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Figure 5-17: Adotive transfer of Tregs alters cardiac proportions of T-cells. Flow 
cytometric analysis of (A&B) T-cells as a percentage of CD45+ cells, (C&D) CD4+ T-cells 
as a percentage of total T-cells, (E&F) CD4+CD25+ Tregs as a percentage of CD4+ T-cells 
and (G&H) CD25+FoxP3+ Tregs as a percentage of CD4+ T-cells. *WT-Tregs vs Saline; 
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In order to examine the effect on the vasculature, aortas were also prepared for flow 
cytometry analysis. All investigated parameters paralleled the previous results 
observed in heart samples, as shown in Figure 5-18. Leukocytes were significantly 
lower in WT- (p=0.015) and Nox2KO- (p=0.007) Treg treated animals compared to 
saline. Aortic infiltration of T-cells was blunted in both WT- (p=0.001) and Nox2KO- 
(p=0.003) Treg injected groups compared to saline, Figure 5-18B. This effect was 
preserved within the T-cell subpopulations, where DN (pWT=0.014; Nox2KOp=0.012), 
DP, CD8+ (pWT=0.003; pNox2KO=0.008) and CD4
+ (pWT=0.002; pNox2KO=0.005) all showed a 
marked reduction compared to saline injected groups (Figure 5-18C-F). Aortic 
infiltration of Tregs was not different among the three groups, shown in Figure 5-18G-
H.  
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Figure 5-18: Adoptive transfer of Tregs blunted AngII-induced aortic inflammation. 
Analysis of (A) total leukocytes (CD45+)(WTp=0.015; Nox2KOp=0.007), (B) T-cells 
(CD45+TCRβ+) (WTp=0.001; Nox2KOp=0.003), (C) CD4-CD8- T-cells (WTp=0.014; 
Nox2KOp=0.012), (D) CD4+CD8+ T-cells, (E) CD8+ T-cells (WTp=0.003; Nox2KOp=0.008), 
(F) CD4+ T-cells (WTp= 0.002; Nox2KOp=0.005), (G) CD4+CD25+ Tregs and (H) 
CD25+FoxP3+ Tregs. All represented as cells per mg of aorta tissue. Analysed on BD 
FACS CantoII™. N=7-8 per group. 
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In addition to different immune cell compositions within WT- and Nox2KO-Treg 
injected groups compared to saline injected groups we also identified altered T-cell 
proportions. Figure 5-19A-B shows consistent levels of T-cells as a percentage of CD45+ 
cells, and CD4+ T-cells as a percentage of total T-cells. Meanwhile, Figure 5-19 C shows 
a significant increase in CD4+CD25+ Tregs as a percentage of CD4+ T-cells for both WT- 
(p=0.002) and Nox2KO-Treg (p<0.001) injected animals compared to saline. More 
specific Treg staining with FoxP3 confirms this trend but only shows significance in the 
Nox2KO-Treg (p=0.023) injected group (Figure 5-19 D).  
 
 
Figure 5-19: Aortic T-cell proportions are altered by adoptive transfer of Tregs with 
AngII treatment. Levels of (A) T-cells as a percentage of CD45+ cells, (B) CD4+ T-cells as 
a percentage of total T-cells, (C) CD4+CD25+ Tregs and (D) CD25+FoxP3+ Tregs. *p<0.05, 
**p<0.01, ***p<0.001, analysed BD FACS CantoII™. N=7-8 per group. 
 
Due to an impact on systolic blood pressure by the adoptive transfer of Tregs, kidney 
samples were also analysed for changes in immune cell composition (Figure 5-20). This 
was based on their vital role in blood pressure homeostasis245. Total leukocytes, T-cells 
and each of the T-cell subpopulations remained similar between all three groups, 
suggesting that the kidneys do not contribute to the differences in blood pressure. 
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Kidney T-cell proportions, analysed in Figure 5-21, also show no differences between 
the WT-Treg, Nox2KO-Treg and saline injected animals, all treated with AngII for 3-
days.  
 
Figure 5-20: Treg adoptive transfer does not alter kidney T-cell compositions. Analysis 
of (A) total leukocytes (CD45+), (B) T-cells (CD45+TCRβ+), (C) CD4-CD8- T-cells, (D) 
CD4+CD8+ T-cells, (E) CD8+ T-cells, (F) CD4+ T-cells, (G) CD4+CD25+ Tregs and (H) 
CD25+FoxP3+ Tregs. All represented as cells per mg kidney tissue. Analysed on BD FACS 
CantoII™. N=3 per group. 
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Figure 5-21: Kidney T-cell proportions remain consistent with Treg adoptive transfer 
and AngII treatment. Levels of (A) T-cells as a percentage of CD45+ cells, (B) CD4+ T-
cells as a percentage of total T-cells, (C) CD4+CD25+ Tregs and (D) CD25+FoxP3+ Tregs. 
Analysed BD FACS CantoII™, N=3 per group. 
 
5.4.3 Nox2 regulates Treg suppressive function in vitro 
Suppression assays were set up using CD4+ T-cells and APCs, isolated from C57Bl/6 
mice, in the presence of purified anti-CD3 antibody. Tregs obtained from either WT or 
Nox2KO mice were then incubated with the CD4:APC (1:2) pool at different Teff:Treg 
ratios (1:1, 1:2, 1:4, 1:8, 1:16) with WT CD4+ T-cells in the presence of WT APCs and 
purified anti-CD3 antibody. Thymidine incorporation was used as readout.  
CD4+ T-cell proliferation reached approximately 6x104 counts per minute (cpm) and in 
the presence of WT-Tregs this was suppressed by 63% with a 1:1 T-cell to Treg ratio 
(Figure 5-22). In comparison, Nox2KO-Tregs resulted in an 83% suppression of CD4+ T-
cell proliferation (2-way ANOVA Figure 5-22B, p=0.043). Therefore, Nox2KO-Tregs 
were significantly more suppressive than WT-Tregs at a 1:1 ratio (p=0.007). This 
difference in Treg suppressive ability between the two genotypes was maintained at a 
ratio of 1:2 (p=0.041) before reaching a plateau at a ratio of 1:4 and higher.  
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Figure 5-22: Nox2KO-Tregs have a greater suppressive function. Treg suppression 
assay was analysed using thymidine to show difference in (A) total cell counts (N=3 per 
group), (B) percentage of suppression (N=3 per group) and (C) percentage difference 
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In order to fully understand the differences in suppression, Treg phenotypes were 
compared between WT and Nox2KO animals. Specific markers associated with Treg 
function were analysed on isolated Tregs from both genotypes via BD FACS CantoII™. 
Nox2KO-Tregs had similar levels of CD25, FoxP3, GITR and CD62L, however they 
expressed a higher level of CD73 (p=0.001), CD39 (p=0.014), CTLA-4 (p=0.028) in 




Figure 5-23: Global Nox2KO Tregs express altered levels of phenotypic surface 
markers. Flow cytometry revealed similar expression levels of (A) CD25, (B) FoxP3, (C) 
GITR and (D) CD62L. Whereas expression of (E) CD73, (F) CD39, (G) CTLA-4 and (H) 
CD103 were altered in Nox2KO-Tregs compared to WT littermates. Analysed on BD 
FACS CantoII™, *p<0.05, **p<0.01. N=3-4 per group. 
 
Taken together, our results suggest that an increased baseline-level of Tregs in general, 
provides a protective response in terms of AngII-induced hypertension and cardiac 
hypertrophy. Furthermore, the inflammatory response in the heart and aorta of Treg 
injected mice changed, giving an anti-inflammatory response with greater Treg:T-cell 
ratios compared to saline. However, the adoptive transfer of Nox2KO-Tregs proved 
beneficial in the response to AngII-induced interstitial fibrosis and provided a more 
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efficient protection against AngII-induced inflammation. Hence, both in vitro and in 
vivo assays suggested that Nox2KO-Tregs have a greater suppressive function than WT-
Tregs.  
These findings may reflect a local protective cardiovascular phenotype with higher 
baseline concentrations of Tregs, which is greater in the setting of Nox2KO-Tregs. 
 
5.5 Discussion 
The experiments presented in this chapter show a clear distinction between Nox2KO- 
and WT-Treg function both in vivo and in vitro. Adoptive transfer of both Nox2KO- and 
WT-Tregs did not alter the level of CD4+CD25+FoxP3+ Tregs within the heart. One 
aspect to consider is that Tregs within the myocardium are difficult to obtain and 
analyse, due to their low numbers. In addition to this, the process of staining for FoxP3 
causes further loss of immune cells due to fixation, permeabilisation and extra washing 
steps involved. The protocol used here involved the injection of 1x106cells per mouse, 
however not all of these cells would migrate to the heart; therefore our flow 
cytometry method may not be accurate enough to identify this direct increase in Treg 
numbers per mg of cardiac tissue. On the other hand, Tregs as a percentage of total 
CD4+ T-cells tended to be higher in WT-Treg treated group and significantly higher in 
Nox2KO-Treg injected group. This confirms that after adoptive transfer, the CD4+ T-
cell:Treg ratio is altered to that favouring Tregs, and hence an anti-inflammatory 
processes is in action. Even though an increase in Tregs in the heart (per mg of tissue) 
cannot clearly be identified, their effect on T-cell numbers, specifically CD4+ T-cells has 
been observed here.  
The adoptive transfer of Nox2KO-Tregs compared to WT-Tregs was more effective at 
preventing AngII-induced hypertension and associated cardiac remodelling. 
Interestingly, AngII-induced systolic blood pressure was significantly lower after 3-days 
of treatment in mice injected with WT-Tregs. Compelling evidence supports these 
findings with WT-Tregs. For example a similar response was found by Barhoumi et al 
who performed adoptive transfer of Tregs into C57Bl/6 mice aged 10-12 weeks. This 
group observed a significantly lower blood pressure in WT-Treg injected mice 
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compared to PBS- and Teff-injected mice, all treated with a pressor dose of AngII for 
up to 14-days190. This experiment included multiple Treg injections, three times at two 
week intervals, prior to AngII-infusion, in addition to three Treg injections per week 
throughout treatment with AngII190. Therefore the gradual increase observed in blood 
pressure after 3-days of AngII treatment, which returns to similar levels as saline-
injected mice after 14-days, might be preventable by multiple Treg injections. This 
attenuated hypertensive response to AngII tended to be greater in mice injected with 
Nox2KO-Tregs. Until now, Nox2KO- Tregs have not previously been studied in this 
setting; results here indicate that Nox2KO-Tregs are more suppressive than WT-Tregs. 
The same research group also demonstrated similar results with aldosterone 
treatment192. 
The adoptive transfer of both types of Tregs prevented AngII-induced hypertrophy that 
was observed by IVS thickness and cardiomyocyte cross-sectional area. This confirmed 
the results of Kvakan et al who carried out a Treg adoptive transfer into Naval Medical 
Research Institure (NMRI) male mice, which are WT outbred albino mice, one day after 
initiation of AngII-treatment191. Blunted AngII-induced hypertrophy was observed after 
2 weeks of treatment as documented by LV wall thickness and LV weight-to-body 
weight ratio191. In this study, HW/BW and HW/TL ratios were analysed but with no 
differences between all groups. This may be because the hypertrophic response mainly 
occurs within the LV, so instead of weighing the whole heart, a more accurate method 
would be to weigh the LV only. Furthermore the IVS measurement is more accurate.  
Interestingly injection of Nox2KO-, but not WT-, Tregs inhibited AngII-induced fibrosis, 
observed by PSR staining. This was also confirmed by qPCR analysis of col1α1 and 
col3α1, which were both significantly lower in Nox2KO-Treg injected groups. Kvakan et 
al observed significantly lower cardiac fibrosis, analysed by PSR staining, with NMRI-
Treg adoptive transfers compared to AngII treatment alone191. This difference in WT 
results could be due to the specific genotype of mice used, NMRI instead of C57Bl/6, or 
due to a higher dose of AngII (1.44mg/kg/day instead of 1.1mg/kg/day). Furthermore, 
Kanellakis et al transferred Tregs, or control vehicle, into mice following TAC and 
observed that the adoptive transfer of Tregs attenuated cardiac fibrosis and 
hypertension189.  Even though these experiments have used a different model or 
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mouse genotype, both identify a role for Tregs within AngII-induced fibrosis and the 
results here highlight that Nox2KO-Tregs may be more efficient in this setting.  
Furthermore, Tregs have been implicated in cardiac remodelling resulting from MI. 
Tregs are observed in the peri-infarct zone (PIZ) of hearts from mice that have 
undergone MI193. An increase was observed 3-days after MI with a peak at 7-days and 
reduction 14-days after surgery, compared to sham animals. The author emphasises 
on the local recruitment of the cells as no alteration in Treg levels were observed in 
spleens or LNs193. Tang et al further increased the percentage of Tregs within the MI 
heart by an adoptive transfer, which led to attenuation of post-MI cardiac 
remodelling193.  
As Tregs have the ability to suppress inflammatory responses, the level of immune cell 
infiltration, specifically T-cells, within the myocardium was then analysed for saline-
injected, WT-Treg injected and Nox2KO-Treg injected mice all treated with AngII. In 
both Treg-injected groups, AngII-induced inflammation was significantly blunted 
compared to saline-injected controls. This prevented the accumulation of total 
leukocytes, T-cells and each of the T-cell subtypes within the myocardium, which was 
also confirmed in the literature within NMRI-Treg injected mice191. Similarly, previous 
studies have demonstrated a reduced level of cardiac inflammation during the 
adoptive transfer of Tregs. For instance, Kvakan et al and Barhoumi et al both 
highlighted that cardiac infiltration of T-cells in response to AngII was prevented by 
Treg adoptive transfer190-192.  Adoptive transfer performed by Kanellakis et al also 
prevented the accumulation of macrophages and T-cells within the LV after TAC189.  
Results here show that Nox2KO-Treg injected groups tended to be more efficient at 
preventing T-cell, specifically CD4+ T-cell, recruitment.  Furthermore, within the heart, 
T-cells as a percentage of total CD45+ cells were significantly lower in both Treg-
treated groups, suggesting that T-cells are specifically targeted and reduced by 
injected Tregs. In addition, CD4+ T-cells as a percentage of total T-cells were higher in 
both Treg injected groups, potentially suggesting that Tregs, which are included in the 
CD4+ T-cell subset, may be recruited to the heart.  
These published results and data presented in this chapter have harnessed the 
beneficial effects of Tregs within the setting of cardiovascular remodelling by 
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performing a Treg adoptive transfer. This process enables the basal level of Tregs in 
the animal to be systemically increased, allowing additional control of the 
inflammatory response.  
The increased efficiency of Nox2KO-Tregs observed in vivo was also confirmed in vitro. 
Under these experimental conditions, Nox2KO-Tregs are 20% more suppressive than 
WT-Tregs in vitro; however opposing results have been identified by Efimova et al. This 
research group performed a series of suppression assays by incubating Teff cells in the 
presence of anti-CD3/CD28 coated beads with varying concentrations of Tregs214. 
These cells were isolated from either P47phox-/- or WT mice214. The accuracy of the 
Treg:Teff ratios was also ensured by adjusting the concentration of Tregs based on the 
purity of isolated CD4+CD25+ Tregs214. They observed a lower level of suppressive 
ability in p47phox-/- Tregs compared to WT Tregs, when both incubated with either 
p47phox-/- or WT Teff cells214. However there are three aspects that vary between their 
protocol and that used in this study, which may account for the variation in results. 
Firstly, p47 phox-/- mice were used within this paper to analyse the KO-Treg suppressive 
function, whereas the study presented here used gp91-/- mice. Even though these two 
genetic models both result in dysfunctional Nox2, the first removes a Nox2 adaptor 
protein whereas the second model prevents transcription of the main Nox2 catalytic 
subunit. There have been a handful of studies that suggest differences between these 
two genotypes246,247. For instance, it has previously been reported that deletion of 
p47phox can worsen vascular endothelial dysfunction whereas the lack of Nox2 is 
beneficial in terms of cardiovascular remodelling108,175,246. Therefore differences in the 
genetic model used may influence variation in Treg responses. Furthermore, Tregs and 
Teff cells were isolated from mice aged 6-14 weeks, whereas this study used mice aged 
6-8 weeks. As discussed in section 4.5, the age of mice lacking Nox2 is important due 
to the onset of age-induced arthritis that may alter immune cell composition and 
function. For example Lee et al demonstrated that Nox2KO CD4+ T-cells isolated from 
mice aged 12-28 weeks were less able to differentiate into Tregs and hence may, at 
this age, possess a different Treg suppressive ability199. Finally, in the study by Efimova 
et al anti-CD3/CD28 beads were used to stimulate Teff cells, therefore the suppressive 
ability can only be analysed in terms of mechanisms directly affecting Teff cells. In this 
study, WT APCS were isolated that were used to stimulate Teff cells; thereby 
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suppression can also occur via macrophages or DCs. Furthermore, macrophage-derived 
ROS has also been implicated in Treg-mediated suppression and as isolated 
macrophages used here were from WT mice, which contain Nox2, this mechanism 
could occur in vitro. There may then be a potential benefit for Tregs lacking Nox2, in 
the environment of other Nox2-containing immune cells. This could further explain the 
increased efficacy of Nox2-Tregs in vivo.  
Moreover, results presented in this chapter indicate that Nox2KO Tregs express higher 
levels of CD73, CD39 and CTLA-4, whose suppressive activity may not necessarily be 
instigated in the presence of anti-CD3/CD28 beads. In addition, increased expression of 
these anti-inflammatory mediators in Nox2KO Tregs further corroborates in vitro 
findings presented in this chapter by demonstrating that Nox2KO-Tregs are more 
suppressive that WT-Tregs.  
Due to the initial impact of the Treg adoptive transfer on the blood pressure response 
to AngII, immune cells within the aorta and the kidney were also analysed. Within the 
aorta, a very similar immune cell infiltration was observed as found in the heart, with 
an overall blunted level of total leukocytes, T-cells and T-cell subtypes with both WT- 
and Nox2KO-Treg injected mice.   
In comparison, no significant differences were observed within the kidney. This 
suggests that Tregs are not taking effect on this tissue and hence the blood pressure 
alteration is primarily instigated by cardiovascular responses. Within the literature, 
Barhoumi et al investigated migration of Tregs within an adoptive transfer experiment 
during AngII-treatment and identified an increased level of Tregs within the renal 
cortex of the kidney190. From this they postulated that Treg action within this organ 
may elicit the beneficial responses observed on hypertension190. However, this 
research group performed multiple Treg adoptive transfers prior to, and during, AngII 
treatment, therefore potentially Tregs may accumulate in the kidney over time. In 
comparison, one Treg injection does not alter the level of immune cells within the 
kidney so the benefits observed within this study may not occur due to a kidney-
related mechanism.  
In comparison, within the spleen, Tregs were significantly lower in WT-Treg injected 
mice only, even though all other T-cell subtypes remained stable between the groups. 
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These findings were verified by looking at Tregs as a percentage of CD4+ T-cells, where 
in the spleens of WT-Treg injected mice only, there was a marked decrease. These 
results may suggest a different protective mechanism between WT- and Nox2KO-Tregs 
in this setting; however this would require further investigation to fully clarify.  
Further studies to help clarify the role of Tregs, and Treg-specific Nox2, could involve 
multiple-Treg injections that may provide a prolonged attenuated response to AngII in 
terms of hypertension and enable a clearer distinction between the benefits of WT- 
and Nox2KO-Tregs. Furthermore, sub-pressor doses of AngII have the ability to induce 
cardiac remodelling but without an increase in systolic blood pressure, therefore it 
would be interesting to observe the effects of adoptively transferred WT- and Nox2KO- 
Tregs within this setting. One could then distinguish the benefits related directly to 
cardiac remodelling and those arising as a consequence of reduced blood pressure. In 
addition, using an anti-CD25 antibody (such as PC61) to deplete Tregs in both Nox2KO 
and WT mice would allow to investigate whether the lack of Tregs holds any bearing 
on AngII-induced hypertension, cardiac remodelling and inflammation.  
Overall the results presented in this chapter have identified a clear role for Tregs 
during AngII induced hypertension and cardiac remodelling by reducing CD4+ T-cells 
within this setting. Furthermore, Nox2KO-Tregs have an increased suppressive function 
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6.1 Introduction 
T-cells, specifically CD4+ T-cells, have been identified by a number of research studies 
to be key mediators during the progression of cardiac remodelling. Separately, Nox2, 
and its product O2
•-, have been extensively shown to be involved in this setting. The 
global Nox2KO study in chapter 4 demonstrated that the lack of Nox2 prevents AngII-
induced hypertension, cardiac remodelling and inflammation. Furthermore, the 
adoptive transfer of Tregs, which suppress CD4+ T-cell functions, have proven 
beneficial within the setting of AngII-induced pathophysiology 190,191. Moreover, the 
studies with Nox2KO Tregs in chapter 5 demonstrated a different functional response 
and efficacy as compared to WT Tregs in this setting. Therefore further investigation of 
the specific role of CD4-Nox2 may provide an insight into the detrimental effects of 
these cells, in response to AngII treatment.  
 
6.1.1 Specific role of Nox2 in CD4+ T-cells 
Nox2-derived ROS has been implicated in a number of different cellular signalling 
pathways, such as proliferation, differentiation and apoptosis as described in section 
1.1.4. Activation of Nox2 has been identified following CD4+ T-cell stimulation by their 
TCR, and potentially modulates downstream signalling pathways133. Therefore, Nox2 
may be involved in a number of different responses that could alter CD4+ T-cell 
differentiation and functions133,248,249.  
As described previously, published research has revealed a role for Nox2 in T-cell 
differentiation and function. Furthermore, a specific response in Th differentiation was 
observed by Shatynski et al. T-cells that lack an active Nox2 enzyme demonstrate a 
decreased level of STAT5 phosphorylation and GATA-3 expression, which are 
important transcription factors during Th differentiation249. This encourages Th 
differentiation away from the Th2 lineage and towards Th1, resulting in increased 
secretion of IFN-γ and depletion of IL-4249. Similar findings have also been reported by 
other research groups248,250,251. In addition to this, IL-17 was also heavily upregulated in 
Nox2KO CD4+ T-cells, suggesting Th17 differentiation207,249. Further evidence 
corroborates this potential skewing towards Th17 cells. Lee et al also observed that 
  192  
activated Nox2KO CD4+ T-cells tend to produce a significantly higher level of IL-17 
compared to WT controls199. In addition to this, an upregulation of IL-17 in vivo during 
age-induced arthritis was also observed in global Nox2KO mice199.  
Research therefore suggests that endogenous CD4-Nox2 may be involved in pathways 
leading to Th2 differentiation; hence the lack of Nox2 could potentially enhance Th1 
and even Th17 differentiation. 
  
6.1.2 CD4 T-cell role in hypertension and cardiac remodelling 
Cardiac infiltration of CD8+ and CD4+ T-cells has been observed in response to a 
pressure overload model (TAC), where the associated cardiovascular remodelling was 
diminished in RAG-/- mice184. Lack of CD4+ T-cells (MHCIIKO), but not CD8+ T-cells 
(CD8KO) eliminated the expected cardiovascular response to TAC184. 
Further research showed that mice lacking CD4+ T-cells (CD4KO and MHCIIKO) 
responded more vigorously to MI with increased LV dilation, increased inflammation 
and augmented collagen deposition252. This highlights a role for CD4+ T-cells to 
facilitate wound healing of the myocardium.  One limitation of this study is that the 
CD4+ T-cell subpopulation encompasses Tregs, which have been proved beneficial in 
this setting (chapter 5)190,191. Therefore the responses to MI observed here may be due 
to depletion of Tregs rather than Teff cells.  
In comparison, Madhur et al further characterised the CD4+ T-cell response to the level 
of the Th17 subset and their IL-17 cytokine production185. AngII significantly increases 
IL-17 production from T-cells and IL-17-/- mice display a protective response to AngII 
treatment in terms of blood pressure, vascular function, O2
•- production and T-cell 
infiltration185.  
Th17 cells have also been implicated in the setting of atherosclerosis, but their role 
here is very controversial. As reviewed by Taleb et al, reducing IL-17 production may 
not prevent atherosclerotic lesion development, and increasing IL-17 levels may even 
be beneficial rather than detrimental, which was originally thought253. Research 
suggests that Th17 cells are implicated in CVD but in a context-dependent manner, 
which may vary according to the tissue microenvironment253. In addition, there is 
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accumulating data that suggests plasticity between Th17 and Treg subtypes of CD4+ T-
cells and the potential trans-differentiation between the two254-258.  
Taken together, these research studies highlight a specific role for CD4+ T-cells in the 
setting of cardiac remodelling and repair. However it is has also been highlighted that 
the presence of these cell types may also initially be beneficial. Therefore further 
understanding the endogenous mechanisms of CD4+ T-cells that drive their negative 
responses in this setting may prove beneficial. Hence, as Nox2 has also been 
demonstrated to modulate CD4+ T-cell activation and function this is an interesting and 
potentially beneficial route to investigate.  
 
6.2 Aims 
We previously investigated the role of Nox2 in AngII-induced cardiac pathophysiology 
and inflammation, and highlighted a potential role for CD4+ T-cell Nox2.  In addition to 
this, CD4+ T-cells have also been identified in the literature as an important component 
during the progression of cardiac remodelling. However the protective responses 
observed in our global Nox2KO model could be due to the lack of Nox2 in a range of 
different cell types within this setting. Therefore the aim for this chapter was to 
generate a CD4-specific Nox2KO model in order to study the endogenous role of Nox2 
within CD4+ T-cells in the setting of AngII-induced cardiac pathophysiology.  
 
6.3 Methods 
6.3.1 Generation of the novel CD4-specific Nox2KO mouse line 
In order to investigate the role of Nox2 in CD4+ T-cells, we generated a specific CD4-
Nox2KO mouse line. Novel in-house bred Nox2floxed females (Figure 6-1)259 were 
crossed with CD4-Cre mice (provided by R. Noelle, KCL Department of Immune 
Regulation and Intervention). Resulting hemizygous Nox2floxed, Cre+ males were then 
crossed with Nox2floxed Cre- females before the second generation, hemizygous 
Nox2floxed Cre+ males (CD4-Nox2KO) were used as experimental animals. Specifically 
within CD4+ cells, cre recombinase excises DNA between the two LoxP sites either side 
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of exon 1 and 2 of the gp91 gene (Nox2), and recombines remaining DNA, hence 
preventing transcription of Nox2 (Figure 6-2). This therefore generates a CD4-specific 
Nox2KO model. Male CD4-Nox2KO mice were used for experiments between 6-8 
weeks of age.  Nox2floxed Cre- mice were used as controls.  
 
 
Figure 6-1: Targeting strategy for Nox2floxed mice. The endogenous Nox2 locus is 
shown at the top and the targeting vector at the bottom. Blue triangles represent LoxP 
sites and double red triangles indicate FRT sites. After successful targeting, the Neo 
cassette was excised using the FRT sites.  
 
 
  195  
 
Figure 6-2: CD4-Nox2KO breeding schematic. CD4-Cre mice were bred with novel, in 
house bred, Nox2-floxed animals. Cre recombinase cleaves LoxP sites either side of 
Nox2 exons 1 and 2, preventing its transcription in CD4+ T-cells.  
 
6.3.2 CD4-Nox2KO genotyping 
Ear biopsies were treated with 300µL 50mM NaOH at 95°C for 30 minutes. Samples 
were vortexed to homogenise and 25µL 1M Tris-Hcl (pH 8.0) added and incubated at 
RT for 30 minutes. PCR cycles were then carried out to analyse Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)/Cre and Nox2-Flox (ASHL) genes (primers in Table 
12). For GAPDH/Cre analysis, 3µL of DNA added to 22µL of the PCR master mix, Figure 
6-3. All samples were run with a no-template sample and known Cre- and Cre+ samples 
on the PCR cycle shown in Figure 6-3. Cre+ animals (e.g. 37-38) were identified by the 
presence of a lower band (200bp), Figure 6-5, whereas Cre- animals only express the 
upper GAPDH band (300bp, e.g. 39-40). 
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Figure 6-3: GAPDH/Cre PCR cycle. 
 
For Nox2-Flox analysis, 3µL of DNA was added to 22µL of the PCR master mix shown in 
Figure 6-4. Control samples included a no-transcript sample, homozygous Nox2 Flox 
and WT samples, all run on the PCR cycle shown in Figure 6-4.   
 
Figure 6-4: Nox2-Flox genotyping PCR cycle. 
 
After the PCR cycles were completed, samples (20µL) were then run on a 2% Agarose 
gel (150mL 1 x TAE and 3g Agarose) infused with ethidium bromide (0.5µL/mL) at 180v 
for 30 minutes. The gel was then viewed under UV light using a transilluminator. Nox2 
floxed mice (e.g. 40-65) were verified by an upper floxed band (500bp), as shown on 
Figure 6-5. Whereas WT animals (+/+, e.g. 37-38) have a lower band (200bp) and 
heterozygotes (e.g. 39) display both bands.  
CD4-Nox2KO animals (e.g. 41-65) were then identified by containing the lower Cre+ 
band (200bp) on the first gel (Cre/GAPDH) and the upper Nox2 floxed band (300bp) on 
the second gel. 
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Table 12: Genotyping Primer sequences. 
 
6.3.3 Confirmation of the CD4-Nox2KO model 
CD4+ T-cells were isolated from whole spleens of CD4-Nox2KO mice and WT 
littermates. Harvested spleens were triturated and filtered separately through a 70μm 
nylon mesh. Cell suspensions were then washed in isolation buffer and centrifuged at 
1800rpm for 5 minutes at 4°C. Spleen samples were then treated for 3 minutes with 1x 
red cell lysis buffer (Biolegend) at room temperature followed by a final wash in 
isolation buffer. 
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Magnetic beads conjugated to streptavidin (50μL per sample, Dynabeads®M-280 
Streptavidin, Invitrogen) were prepared by washing in 1mL PBS and placed on a 
magnet for 2 minutes before removing the supernatant. Beads were then re-
suspended in in 50μL PBS and incubated with anti-CD4 antibody conjugated to biotin 
(1:200, ebioscience) and incubated for 30 minutes at RT under rotation. Beads were 
then washed using 1mL PBS as described previously using a magnet.  
Harvested splenocytes were then incubated with the dynabead-CD4 complex for 30 
minutes at RT under rotation. Cells bound by Dynabeads® were then isolated by 
placing samples on a magnet for 2 minutes and removing the supernatant, which 
contains all other immune cells. Beads bound to the magnet, which are CD4+ cells, 
were then washed in 1mL isolation buffer, incubated on the magnet for a further 2 
minutes and then the supernatant discarded. Remaining beads were then re-
suspended in 1mL isolation buffer, centrifuged at 13,000rpm, the supernatant 
discarded and the cell pellet stored at -80˚C. These samples were then treated for RNA 
extraction as described in section 2.7. 
Extracted RNA was reverse transcribed to generate cDNA (section 2.7.2) and used for 
qPCR analysis of Nox2, its related subunits, Nox4 and eNos (Table 13). 
 
 
Table 13: Fibrosis-related primer sequences used for qPCR. All sequences are shown as 
5’-3’. 
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6.3.4 Baseline characterisation and observation 
Initial experiments involved baseline observations and characterisation of CD4-Nox2KO 
mice and WT littermates. Blood pressure and haemodynamic function were analysed 
by tail cuff plethysmography and echocardiography respectively (section 2.5).   
Animals were then culled using increasing levels of CO2 prior to removal of peripheral 
LNs, spleen, thymus, liver, left kidney, lungs and tibia.  All organs were weighed and 
the tibia length measured and recorded to calculate organ weight-to-tibia length 
ratios. Representative photographs were taken comparing CD4Nox2KO and WT LNs, 
spleens, thymuses and hearts. Harvested hearts were treated as described in section 
2.8 for WGA and PSR staining.  
Baseline T-cell compositions were then analysed by isolating MLNS, PLNs and spleens 
as described in section 2.4.3 and treated for flow cytometry using the BD FACS 
Fortessa™ (section 2.6). 
 
6.3.5 Experimental model 
Subcutaneous mini-osmotic pumps containing a pressor dose of AngII (1.1mg/kg/day) 
were surgically implanted into CD4-Nox2KO mice and WT littermates for up to 14-days, 
as described in section 2.3. Blood pressure and haemodynamic function were analysed 
by tail cuff plethysmography and echocardiography respectively (section 2.5).  A 
second group of mice were also treated with a pressor dose of AngII for 3-days, before 
organs were harvested for flow cytometry (section 2.6).   
 
6.3.6 Treatment of samples 
Harvested hearts were treated as described in section 2.3. RNA was extracted and 
reverse transcribed to enable analysis by qPCR (section 2.7). Fibrosis-related markers 
were analysed as described in section 2.7. Histological analysis involved staining of 
harvested hearts for WGA and PSR (section 2.8). Flow cytometry was performed on 
whole hearts and spleens using the BD FACS CantoII™ as described in section 2.6. The 
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level of leukocytes, T-cells and T-cell subsets were determined based on expression of 
CD45, TCRβ, CD4, CD8, CD25 and FoxP3. 
 
6.4 Results 
6.4.1 Confirmation of CD4-specific Nox2KO model 
Initial confirmation of our novel CD4-specific Nox2KO animal model was verified by 
isolating CD4+ T-cells separately from CD4-Nox2KO animals and WT littermate controls. 
Extracted RNA was reverse transcribed to generate cDNA and used for qPCR analysis of 
Nox2 and its related subunits (Figure 6-6). Nox2 mRNA levels were significantly lower 
in CD4+ T-cells isolated from CD4-Nox2KO animals compared to WT littermates 
(p=0.0001). However, Nox2 mRNA levels in all other immune cells were not altered in 
either CD4-Nox2KO or WT. All Nox2 subunits (p67phox, p47phox and p22phox) were 
unaffected by the absence of CD4-Nox2, as assessed by mRNA expression level.  
 
Figure 6-6: CD4-Nox2KO T-cells have significantly lower Nox2 mRNA levels. 
Quantitative PCR analysis of (A) Nox2 mRNA in isolated CD4+ T-cells, (B) Nox2 mRNA 
levels in remaining immune cells and (C) p67phox, (D) p47phox and (E) p22phox mRNA 
levels in isolated CD4+ T-cells. ***p<0.001, N=5-6 per group.   
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6.4.2 Baseline characterisation of CD4-Nox2KO mouse model 
We initially assessed a number of simple morphometric parameters in the new specific 
CD4-Nox2KO line to determine whether there were any obvious gross baseline 
differences between the CD4-Nox2KO and WT littermate controls.  
Weights of vital organs were recorded and analysed between the two genotypes and 
standardised to tibia length.  In terms of lymphoid organs at baseline, Figure 6-7 shows 
that LNs and the spleen are similar sizes in CD4-Nox2KO animals compared to WT 
littermates whereas the thymus appears larger in the CD4-Nox2KO. Analysis of organ 
weights further corroborates these findings where Figure 6-8 shows similar spleen 
weights between the two genotypes, however the thymus is 1.5 fold larger (p<0.001) 
in the CD4-Nox2KO compared to WT littermates. Liver weight, lung weight and kidney 
weight were all similar between the two groups. 
 
 
Figure 6-7: CD4-Nox2KO lymphoid organ sizes. Representative images of CD4-Nox2KO 
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Figure 6-8: CD4-Nox2KO mice display thymus hyperplasia whereas other organs are 
similar to WT controls. (A) Lymph node weight (LN/TL) (B) Spleen weight (SW/TL), (C) 
Thymus weight (ThyW/TL), (D) Liver weight (LiW/TL), (E) Kidney weight (KW/TL) and (F) 
Lung weight (LuW/TL) all standardised to tibia length (TL). ***p<0.001. N=7-12 per 
group. 
 
Baseline cardiac parameters were also investigated in these mice. A smaller heart was 
observed in CD4-Nox2KO animals, as illustrated in Figure 6-9. Analysis of HW/BW 
(p=0.014) and HW/TL (p=0.033) also showed that these ratios were significantly lower 
in CD4-Nox2KO animals compared to WT littermates. HW/TL showed an average 
decrease in heart size by 7% in CD4-Nox2KO animals. 
 
 
Figure 6-9: Baseline cardiac characterisation of CD4 specific Nox2KO animals. (A) 
Representative photographs of excised hearts; (B) heart weight/body weight ratio 
(HW/BW) and (C) heart weight/tibia length ratio (HW/TL). *p<0.05, N=13-20 per 
group.  
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In addition, WGA staining revealed a significantly lower cardiomyocyte cross-sectional 
area (-19%; p=0.018) in the CD4-Nox2KO animals compared to WT littermates (Figure 
6-10). PSR staining showed no difference in the percentage of collagen between the 
two genotypes at baseline (Figure 6-11).  
 
 
Figure 6-10: Reduced baseline cardiomyocyte cross-sectional area in CD4-Nox2KO 
mice. Representative images of WGA staining, and cardiomyocyte cross-section 
measurement for CD4-Nox2KO and WT littermates, which is smaller in KO animals. 
Scale bar represents 25µm. *p<0.05. N=5 per group. 
 
 
Figure 6-11: CD4-Nox2KO picrosirius red staining at baseline. Amount of interstitial 
collagen was similar between the genotypes. Scale bar represents 25µm. N=6-7 per 
group 
 
Measurement of systolic blood pressure and cardiac function was carried out at 
baseline by tail cuff plethysmography and echocardiography, respectively (Figure 
6-12). Absence of Nox2 in the CD4 T-cells had no consequence on systolic blood 
pressure, heart rate, LVESV, LVEDV or ejection fraction. 
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Figure 6-12: Cardiovascular function conserved in CD4-Nox2KO animals. Baseline 
cardiovascular function analysed by (A) Systolic blood pressure, (B) heart rate (C) 
systolic volume, (D) diastolic volume and (E) ejection fractional. N=11-20 per group.  
 
These results indicate that CD4-Nox2KO animals have a similar baseline contractile 
function to WT littermates, even with the observed decrease in heart size. The 
increases in lymphoid organs may suggest an altered inflammatory response in these 
animals. 
 
6.4.3 Characterising CD4-Nox2KO immune system at baseline 
MLN, PLN and spleens were isolated from individual CD4-Nox2KO animals and WT 
littermate controls in order to verify immune cell composition. Single cell suspensions 
were prepared and both T- and B-cells were analysed using BD FACS Fortessa™. Total 
leukocytes were significantly higher in MLNs (p=0.025) and PLNs (p<0.001) compared 
to WT littermates, but unchanged within the spleen (Figure 6-13). A similar pattern 
was observed with T-cells (CD45+TCRβ+) with an increase in MLNs (p=0.061) and a 
marked increase in PLNs by 47% (p=0.006). Analysis of T-cell subpopulations revealed 
no changes between DN, DP or CD8+ T-cells in the lymphoid organs, however a 
significant increase in CD4+ (p=0.014) T-cells was observed within the PLNs of CD4-
Nox2KO animals. Interestingly, CD4+ T-cells increased by 59% in the CD4-Nox2KO mice 
compared to WT littermates. CD4+CD25+ Tregs were significantly higher in MLNs and 
  205  
PLNs of CD4-Nox2KO mice, and this was confirmed with FoxP3 staining. CD25+FoxP3+ 
Tregs were 40% higher in MLN’s (p=0.010) and 57% higher in PLN’s (p=0.0001) of CD4-
Nox2KO mice compared to WT littermates. Within the spleen, Treg levels tended to be 
lower in CD4-Nox2KO mice, however this was not significant. No changes were 
observed in B-cell numbers within the lymphoid organs (Figure 6-14).   
 
Figure 6-13: Altered T-cell composition in CD4-Nox2KO lymphoid organs at baseline. 
Analysis of mesenteric lymph nodes (MLNs), peripheral lymph nodes (PLNs) and spleen 
of CD4-Nox2KO compared to WT littermate controls. Analysing composition of (A) total 
leukocytes (CD45+), (B) T-cells (CD45+TCRβ+), (C) CD4-CD8- T-cells, (D) CD4+CD8+ T-cells, 
(E) CD8+ T-cells, (F) CD4+ T-cells, (G) CD4+CD25+ Tregs and (H) CD25+FoxP3+ Tregs. 
*P<0.05, **P<0.01, ***P<0.001, N=5-7 per group, analysed on BD FACS Fortessa™.  
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Figure 6-14: Composition of B-cells within CD4-Nox2KO animals. (A) Total B-cells and 
(B) follicular B-cells analysed from mesenteric lymph nodes (MLNs), peripheral lymph 
nodes (PLNs) and spleens of CD4-Nox2KO mice compared to WT littermate controls. 
Analysed on BD FACS Fortessa™, N=3 per group. 
 
As the composition of immune cells was different within the lymphoid organs of CD4-
Nox2KO animals it was also important to identify whether there was impairment in 
proportions of immune cells. Therefore we analysed cells as a percentage of their 
parent population (Figure 6-15). T-cells as a percentage of CD45+ cells, CD4+ T-cells as a 
percentage of total T-cells and Tregs as a percentage of CD4+ T-cells were all similar 
between the two genotypes in all three tissue samples.  
 
Figure 6-15: Lymphoid T-cell proportions remain unaltered between CD4-Nox2KO and 
WT littermates. (A) T-cells as a percentage of CD45+ cells, (B) CD4+ T-cells as a 
percentage of total T-cells, (C) CD4+CD25+ Tregs as a percentage of CD4+ T-cells and (D) 
CD25+FoxP3+ Tregs as a percentage of CD4+ T-cells. Analysed on BD FACS Fortessa™, 
N=5-7 per group. 
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Flow cytometry dot plots (Figure 6-16) suggest an increased basal level of total 
leukocytes in CD4-Nox2KO heart tissue, including T-cells and T-cell subpopulations. 
Upon analysis (Figure 6-17) it becomes apparent that total leukocytes (CD45+ cells) 
tend to be amplified in CD4-Nox2KO hearts at baseline compared to WT littermate 
controls, with a similar response in terms of T-cells. Significantly higher basal level of 
CD4+ T-cells (p=0.014) was observed in CD4-Nox2KO animals compared to WT 
littermate controls. Whereas DP (CD4+CD8+) T-cells remain similar between the two 
genotypes and DN (CD4-CD8-) and CD8+ T-cells tend to be higher, however this is not 
significant. This amplification was also maintained down to the level of Tregs, where 
there are 4 times more within CD4-Nox2KO heart compared to WT (CD4+CD25+FoxP+) 
(p=0.041). 
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Figure 6-16: Representative dot plots showing baseline cardiac T-cell levels.  
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Figure 6-17: Lack of CD4 Nox2 altered baseline level of cardiac T-cell subpopulations. 
(A) Total leukocytes (CD45+), (B) T-cells (CD45+TCRβ+) and T-cell subpopulations 
including (C) CD4-CD8-, (D) CD4+CD8+, (E) CD8+ and (F) CD4+ T-cells. Tregs are also 
significantly higher in CD4-Nox2KO show by analysis of (G) CD4+CD25+ and (H) 
CD25+FoxP3+ Tregs. All represented as cells per mg of heart tissue. *p<0.05, analysed 
on BD FACS CantoII™. N=4 per group. 
 
Baseline analysis of the spleen showed that total leukocytes (CD45+ cells), T-cells 
(CD45+TCRβ+) and each of the T-cell subpopulations, remain at a similar level in the 
two genotypes (Figure 6-18). However Tregs are significantly lower in CD4-Nox2KO 
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spleen compared to WT (p=0.014), following a similar pattern to that observed 
previously in Figure 6-13. 
 
Figure 6-18: Tregs significantly lower in spleens of CD4-Nox2KO animals at baseline. 
Comparable levels of (A) total leukocytes (CD45+), (B) T-cells and each of the T-cell 
subpopulations: (C) CD4-CD8-, (D) CD4+CD8+, (E) CD8+ and (F) CD4+ T-cells. In addition 
to alterations in (G) CD4+CD25+ Tregs and confirmed by (H) CD25+FoxP3+ Tregs. 
*p<0.05, analysed on BD FACS CantoII™. N = 3-4 per group. 
 
  211  
As baseline levels of immune cells were altered in the CD4-Nox2KO animal, the 
proportions of immune cells, as a percentage of their parent population, was analysed 
for both heart and spleen samples, shown in Figure 6-19. Within the heart, T-cells as a 
percentage of CD45+ cells are the same between WT littermates and CD4-Nox2KO 
mice. CD4+ T-cells as a percentage of total T-cells tended to be higher in CD4-Nox2KO 
mice, however this was not significant. CD4+CD25+ Tregs as a percentage of CD4+ T-
cells were significantly higher, by 40%, within the CD4-Nox2KO animals (p=0.012), 
however the significance was lost when staining for FoxP3. Within the spleen, T-cell 
sub-population ratios did not alter between the two genotypes analysed. A higher 
proportion of Tregs within the CD4+ compartment may alter the CD4-Nox2KO immune 
response to AngII infusion.  
 
 
Figure 6-19: Increased cardiac Treg:CD4 T-cell ratio in CD4-Nox2KO at baseline. (A&E) 
T-cells as a percentage of CD45+ cells, (B&F) CD4+ T-cells as a percentage of total T-
cells, (C&G) CD4+CD25+ Tregs as a percentage of CD4+ T-cells and (D&H) CD25+FoxP3+ 
Tregs as a percentage of CD4+ T-cells.*p<0.05, N=4 per group. 
 
These results suggest an altered basal organisation of immune cells, both in the 
lymphoid organs and cardiac tissue, which may reflect an altered inflammatory 
response, comparable to that seen in the global Nox2KO model.  
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6.4.4 CD4-Nox2KO physiological response to AngII treatment 
CD4-Nox2KO mice and WT littermates were treated with AngII (1.1kg/mg/day) for up 
to 14-days, and empty mini-osmotic pumps were used for both genotypes as a sham 
control. Systolic blood pressure and cardiac function and morphology were analysed 
using tail cuff plethysmography and echocardiography, respectively at time points 
highlighted in Figure 6-20.  
WT littermate controls displayed a rapid increase in systolic blood pressure after 3-
days of AngII treatment (p=0.002), which was maintained after 7 and 14-days of 
treatment. This increase in systolic blood pressure with AngII was significantly blunted 
in CD4-Nox2KO animals, reaching only 103±7mmHg, after 3-days (p<0.001) and 
remaining at this low level up until day 14 (p=0.003). Analysis of LVESV and LVEDV 
revealed no changes in terms of cardiac function over the 14-day treatment period. 
This was also true for ejection fraction and fractional shortening. 
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Figure 6-20: Blunted AngII-induced hypertension in CD4-Nox2KO animals. (A) Systolic 
blood pressure, accompanied by stable (B) LV end-diastolic and (C) LV end-systolic 
volume and hence similar (D) ejection fraction. *WT AngII vs CD4-Nox2KO AngII. 
**p<0.01, ***p<0.001, N=6-8 per group. 
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After the 14-day treatment period BW, HW and TL of all animals were recorded, Figure 
6-21. HW/BW was significantly lower in sham CD4-Nox2KO animals (p=0.004) 
compared to WT littermates as observed in the baseline characterisation. This HW/BW 
ratio significantly increased after AngII treatment in CD4-Nox2KO animals (p=0.001) 
reaching 5.38±0.20mg/g, i.e. a similar level to WT littermates treated with AngII. No 
difference was identified between WT sham and WT AngII animals after 14-days. 
HW/TL ratios, a more accurate measure, showed a similar pattern but were statistically 
similar between all groups observed. In comparison the IVS thickness in WT littermates 
slowly increased over the 14-day treatment period with AngII, reaching significance at 
day 14 (p<0.001). However, CD4-Nox2KO animals did not develop an increase in IVS 
thickness throughout treatment, and had a 24% lower value than WT littermates after 
14-days of AngII infusion (p<0.0001), as shown in Figure 6-21.  
 
Figure 6-21: Attenuated AngII-induced cardiac hypertrophy in CD4-Nox2KO model. 
Analysis of (A) Heart weight/body weight ratio (HW/BW), (B) Heart weight/tibia length 
ratio (HW/TL) and (C) interventricular septum thickness (IVS). *CD4-Nox2KO sham vs 
WT sham. # CD4-Nox2KO AngII vs CD4-Nox2KO sham. **p<0.01, ****p<0.0001, N=5-
10 per group. 
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Representative WGA staining images show an increase in cardiomyocyte size in AngII-
treated WT animals as compared to WT sham (p<0.001), visualised in Figure 6-22. In 
comparison, CD4-Nox2KO animals showed a minimal increase in cardiomyocyte size 
with AngII. The cardiomyocyte cross-sectional area after AngII was 489±42μm2 in WT 
littermate versus 311±16μm2 in AngII-treated CD4-Nox2KO (p=0.005). 2-way ANOVA 
analysis confirmed a significant difference between CD4-Nox2KO and WT littermate 
groups (p=0.0002) and between sham and AngII treated groups (p<0.0001). This 
included a significant difference in interaction (p=0.023), showing the two genotypes 
respond differently to AngII.   
 
 
Figure 6-22: Attenuated AngII-induced cardiomyocyte hypertrophy in CD4-Nox2KO 
model. Representative WGA images and analysis confirmed tissue-level hypertrophy, 
which was blunted in CD4-Nox2KO mice. *WT AngII vs WT sham. +CD4-Nox2KO AngII 
vs WT AngII. Scale bar=25µm; ***p<0.001; N=6 per group 
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Paraffin sections were also stained with PSR to identify collagen within heart tissues, as 
illustrated in Figure 6-23. The characteristic increase in the percentage of collagen was 
observed in AngII treated WT littermate animals (p<0.0001) as previously shown. 
However, the CD4-Nox2KO group showed no increase in fibrosis after AngII 
treatments. After 14-days of AngII treatment CD4-Nox2KO animals had significantly 
lower levels of collagen compared to the WT littermates treated with AngII (p<0.0001). 
 
Figure 6-23: AngII-induced interstitial fibrosis is attenuated in CD4-Nox2KO animals. 
Representative images of picrosirius red staining and analysis. *WT AngII vs WT sham. 
+CD4-Nox2KO AngII vs WT AngII. ****p<0.0001, Scale bar=25µm; N=6 per group.  
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Supporting these findings, mRNA levels of col1α1 (p=0.048) and col3α1 (p=0.076) were 
lower in CD4-Nox2KO animals compared to WT littermates after AngII treatment 
(Figure 6-24). However, pro-fibrotic markers fibronectin, cTGF and TGFβ remained 
mRNA levels remained similar after 14-days of AngII treatment between both 
genotypes.  
 
Figure 6-24: qPCR pro-fibrotic markers diminished in CD4-Nox2KO treated with AngII. 
Fibrosis confirmed by quantification of (A) collagen1α1, (B) collagen3α1, (C) 
fibronectin, (D) CTGF and (E) TGFβ mRNA levels.*p<0.05, N=5-6 per group.  
 
The above results show that AngII induced hypertension, cardiomyocyte hypertrophy 
and interstitial fibrosis in WT littermate controls, similar to that observed in chapter 3. 
These responses to AngII were significantly attenuated in CD4-Nox2KO animals. This 
model gives us further insight into the development of AngII-induced cardiovascular 
responses and pinpoints CD4+ T-cells as an important mediator of AngII-induced 
hypertension and cardiac remodelling.  
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6.4.5 Blunted cardiac infiltration of immune cells in CD4-Nox2KO mice  
In order to quantify immune cell infiltration in the heart, aorta and spleen, single cell 
suspensions were prepared from animals treated with AngII for 3-days, or sham 
controls, and analysed using the CantoII™. 
Flow cytometry dot plots, Figure 6-25, looking at total leukocytes (CD45+ cells) and T-
cells (TCRβ+ cells) showed a blunted infiltration of these immune cells in the CD4-
Nox2KO heart compared to WT littermates when treated with AngII (Figure 6-25).  
 
Figure 6-25: Representative flow cytometry dot plots showing reduced AngII-induced 
inflammation in hearts of CD4-Nox2KO animals. Analysed on the BD FACS CantoII™. 
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As observed previously, a significant cardiac infiltration of leukocytes occurs in WT 
littermate animals when treated with AngII (p=0.034), as shown in Figure 6-26. 
However, this increase is lost in CD4-Nox2KO mice (p=0.008) treated with AngII. 
Infiltration of T-cells behaves in an analogous manner, with a pronounced increase in 
WT littermates treated with AngII (p=0.007), which is blunted in AngII-treated CD4-
Nox2KO animals (p=0.010). Each of the T-cell subpopulations follows a similar trend, 
with most prominent attenuation of CD4+ T-cells (p=0.010) in CD4-Nox2KO compared 
to WT littermate controls. In comparison splenic immune cell levels, shown in Figure 
6-27, are not influenced by the genotype or the treatment with AngII. 
 
 
Figure 6-26: Reduced AngII-induced inflammation in CD4-Nox2KO animals. The lack 
of CD4-Nox2 affects AngII-induced infiltration of (A) CD45+ cells and (B) T-cells 
infiltration. Individual T-cell subpopulations, (C) CD4-CD8-, (D) CD4+CD8+, (E) CD8+ and 
(F) CD4+ T-cells. All data are represented as cells per mg of cardiac tissue acquired on 
the CantoII. *WT AngII vs WT sham. +CD4-Nox2KO AngII vs WT AngII.*p<0.05, 
**p<0.01, ***p<0.001, N=4 per group.  
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Figure 6-27: Lack of CD4-Nox2 does not alter splenic immune cell levels. Spleen levels 
of (A) total leukocytes (CD45+), (B) T-cells (CD45+TCRβ+) and T-cell subpopulations (C) 
CD4-CD8-, (D) CD4+CD8+, (E) CD8+ and (F) CD4+ T-cells were analysed as a background 
control.  All data are represented as a percentage of total cells, acquired on the 
CantoII™. N=4 per group.  
 
Of the CD4+ T-cell population, Treg cardiac infiltration was also affected by the lack of 
CD4-Nox2, as shown in Figure 6-28. A significant increase in Tregs with AngII treatment 
was observed (pCD4+CD25+<0.001; pFoxP3+=0.023), as previously identified in chapter 3. 
CD4+CD25+ Tregs were 43% lower in AngII-treated CD4-Nox2KO mice compared to 
AngII-treated WT littermates however this was not significant. This pattern of response 
was also confirmed with FoxP3 staining, also showing a 43% difference between AngII-
treated WT and CD4-Nox2KO, however this remained not statistically significant. The 
Treg composition within the spleen of the CD4-Nox2KO animals tended to be lower in 
sham animals compare to WT littermates but no significant differences were observed, 
especially after AngII treatment. 
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Figure 6-28: Cardiac Treg levels altered in CD4-Nox2KO treated with AngII compared 
to WT littermate controls. Blunted AngII-induced cardiac Tregs observed by levels of 
(A) CD4+CD25+ Tregs and (B) CD4+CD25+FoxP3+ Tregs. (C&D) Splenic levels of Tregs 
remain consistent in response to AngII. *WT AngII vs WT sham. *p<0.05, ***p<0.001. 
N=4 per group. 
 
The proportions of T-cells within the heart and spleen were also investigated to see if 
any T-cell ratios change between groups (Figure 6-29). T-cells as a percentage of CD45+ 
cells, CD4+ T-cells as a percentage of total T-cells and Tregs as a percentage of CD4+ T-
cells all remain consistent within the heart and spleen. However the sham-level of 
Tregs as a percentage of CD4+ T-cells tends to be higher in CD4-Nox2KO compared to 
WT littermates, as previously identified in baseline measurements, however this was 
not significant using a 2-way ANOVA.  
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Figure 6-29: Impact of CD4-Nox2 deficiency on T-cell proportions during AngII 
treatment. (A&B) T-cells as a percentage of CD45+ cells, (C&D) CD4+ T-cells as a 
percentage of total T-cells, (E&F) CD4+CD25+ Tregs as a percentage of CD4+ T-cells and 
(G&H) CD25+FoxP3+ Tregs as a percentage of CD4+ T-cells. N=4 per group, analysed on 
BD FACS CantoII™. 
 
Infiltration of immune cells into the aorta of these animals was also investigated in 
order to decipher the impact of CD4-Nox2KO on the vasculature, especially as there is 
an altered response to AngII in terms of systolic blood pressure. Within the aorta, 
equivalent immune cells were analysed and followed a similar trend to that within the 
heart, as shown in Figure 6-30, however these responses were not statistically 
significant probably due to low numbers of immune cells within the aorta. The aorta 
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reflected a similar immune cell response to the heart with AngII treatment, suggesting 
the response is cardiovascular-wide and not just restricted to the heart tissue.  
Taken together, these results show that the CD4-specific Nox2KO has a protective 
phenotype against AngII-induced hypertension, cardiac remodelling and immune 
response. Within the CD4-Nox2KO at baseline, certain aspects may explain the 
protective responses observed with AngII. These include an altered immune 
composition and proportions, especially with Tregs in the heart, LNs and spleen. 
Overall this highlights the importance of CD4-specific Nox2 to the progression of AngII-
induced inflammation and associated remodelling. 
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Figure 6-30: T-cell infiltration into the Aorta of CD4-Nox2KO and WT littermate 
animals after AngII treatment. (A) Total leukocytes (CD45+ cells), (B) T-Cells 
(CD45+TCRβ+ cells) and each of the T-cell subpopulations: (C) CD4-CD8-, (D) CD4+CD8+, 
(E) CD8+ and (F) CD4+ T-cells all reflect that observed in the heart. This is also shown 
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6.5 Discussion 
Until now, there has been a lack of clear understanding of the effects of T-cell Nox2 in 
the cardiovascular response to AngII due to the presence of Nox2 in multiple cell types, 
where it may affect different functions. Generation of a CD4-Nox2KO model has 
enabled the investigation of the specific role of endogenous Nox2 within CD4+ T-cells in 
vivo, and the impact this has in the setting of AngII-induced cardiovascular 
remodelling.  
Firstly, the fidelity of the new murine model was confirmed by observing a significantly 
lower level of Nox2 specifically within CD4+ T-cells isolated from CD4-Nox2KO mice 
compared to WT littermates. The CD4-Cre mice used to generate the CD4-Nox2KO 
used in this study, have previously been used by Pino-Lagos et al, to generate a mouse-
line where CD4+ T-cells express a double-negative retinoic acid (RA) receptor (dnRAR), 
thereby inhibiting downstream signalling260. However, as this was not a typical KO 
model, no results were shown to determine how effective this was under the CD4-Cre 
promoter. Other research groups utilised a similar CD4-Cre mouse model and 
demonstrated an 80-95% decrease with their floxed target genes261-264.  
Results presented here showed a smaller decrease in the target gene by qPCR; 
however there are a few aspects to bear in mind. During T-cell development (section 
1.3.2.2) CD4-Cre is activated during later stages of DN cell development and is only 
fully expressed during the DP stage265. In addition, residual Nox2 mRNA may still 
remain after the initial DN stages of development, where CD4 is not yet expressed265. 
Therefore, in theory peripheral CD4+ T-cells should be deficient in Nox2; however some 
may still express Nox2 mRNA, which could skew the results. Lack of Nox2 within CD4+ 
T-cells may cause other cell types to compensate for this deficiency by increasing their 
expression of Nox2. Nox2 expression within all remaining immune cells was also 
examined, which was similar between the two genotypes, suggesting that the results 
were not confounded by compensatory changes in other cell types.  
Interestingly, at baseline a number of differences between the CD4-Nox2KO and WT 
littermates were observed. The new mouse model displays thymus hyperplasia, 
whereas the LNs and spleen are a similar size to that of WT littermate controls. This 
may suggest an impact of the target gene on T-cell development, causing an 
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accumulation of cells or increased differentiation265. As observed previously, global 
Nox2KO mice also displayed enlarged lymphoid organs199. Therefore the lack of Nox2 
specifically within CD4+ T-cells, gives a similar response but directed towards the 
thymus, where T-cells develop.  
Furthermore, the immune cell composition of MLNs and, more significantly, PLNs in 
the CD4-Nox2KO model was different compared to the WT littermate control. This 
included an increased level of T-cells, with an emphasis on CD4+ T-cells in addition to 
Tregs. Interestingly, the Treg:T-cell ratio did not alter within the LNs, therefore both 
total T-cells and Tregs increased by the same amount. Lee et al, examined the LNs of 
global Nox2KO mice aged 15-18 weeks, in this setting they noticed increased levels of 
B-cells, macrophages and monocytes but a lower level of T-cells199. As this study was 
carried out in older animals, with a high incidence of arthritis, the T-cell composition of 
the LNs may be different. In addition, this study allows the novel investigation of Nox2 
specifically in the CD4+ T-cell subset, whereas previous experiments lack Nox2 within 
all cell types. 
In comparison to this finding, immune cell levels in the spleen remained the same 
between both genotypes, except for a reduction in Tregs. Similar findings were 
observed with the global Nox2KO study. Here, this would suggest a potential change in 
the distribution of immune cells, potentially being recruited to the periphery in the 
CD4-Nox2KO mice.  
An important and fascinating finding from this study was the observation of a smaller 
heart within the CD4-Nox2KO mice compared to WT littermates at baseline. This was 
confirmed by a smaller cardiomyocyte cross-section. It is interesting to postulate that 
the lack of Nox2 within cardiac-resident CD4+ T-cells may influence cardiomyocyte 
development. One important aspect is that both cells of the cardiovascular system and 
immune cells are derived from the mesodermal layer during embryogenesis266,267; 
therefore early cellular signalling may affect cardiac development in CD4-Nox2KO 
mice. For instance, cardiac-resident CD4+ T-cells that lack Nox2 may secrete 
modulators during development that affect cardiomyocyte growth. One such 
modulator may be RA, which has been implicated in CD4+ T-cell differentiation and is 
also involved in cardiomyocyte development260,268. More RA may be utilised by CD4-
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Nox2KO cells, reducing cytoplasmic levels, and hence slowing down cardiac 
development. However this would require further investigation. This difference 
observed in cardiomyocyte size, and overall heart size, was not substantial enough to 
affect heart rate, blood pressure or haemodynamic function. Moreover, collagen 
deposition, which is tightly linked to inflammation, remained the same between both 
genotypes.  
Immune cell infiltration was highly affected by the lack of CD4-Nox2. AngII treatment 
of CD4-Nox2KO mice did not elicit the cardiac-infiltration of immune cells, previously 
observed with WT mice. Hence, compared to WT littermates, AngII-treated CD4-
Nox2KO mice displayed significantly lower levels of total leukocytes and T-cells with an 
emphasis on CD4+ T-cells and Tregs.  
Within the CD4-Nox2KO mice at baseline, there is a higher ratio of cardiac-resident 
Tregs:T-cells, which may provide a protective response preventing further infiltration 
of immune cells with AngII treatment. Previous research where an adoptive transfer of 
Tregs has been used to increase basal levels of Tregs (as in the studies in chapter 5), 
has provided a beneficial response to AngII190,191. This was associated with lower 
immune cell infiltration and prevention of subsequent cardiac remodelling190,191.  
Analysis of AngII-induced immune cell infiltration within the aorta of CD4-Nox2KO mice 
followed a similar trend to that observed in the heart. However due to low numbers of 
immune-cells in the aorta, these data were not significant.  
Intriguingly, in the heart at baseline there is an altered composition of T-cells with an 
enhanced level of CD4+ T-cells and Tregs, in addition to an increased Treg:T-cell ratio. 
This increase in cardiac-resident Tregs, in combination with reduced splenic Treg 
levels, may suggest Treg recruitment to the heart. In-line with this, the global Nox2KO 
study also showed increases in CD4+ T-cells and Tregs, however this was accompanied 
by increases in other T-cell subtypes. Therefore the CD4-Nox2KO model seems to 
possess similar basal characteristics to the global Nox2KO model, but with a specific 
effect on the CD4+ T-cell compartment. This also falls in line with previous research 
suggesting increased inflammatory cells in the LNs of Nox2KO mice199.  
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Furthermore, the lack of endogenous Nox2 in cardiac-resident CD4+ T-cells may have a 
key role here in proliferation, maintenance or even migration of CD4+ T-cells and/or 
Tregs, which would be interesting to investigate further. Nox2 has already been 
implicated in the setting of Th differentiation, where the absence of Nox2 leads to 
enhanced Th1 and Th17 differentiation199,248-251. This shows the capacity of Nox2 to 
augment CD4+ T-cell responses. However, the direct ability of Nox2 to modulate T-cell 
apoptosis, cell maintenance and proliferation is not yet understood. One paper 
touching on this topic suggests that ROS are implicated in T-cell apoptosis via the 
costimulatory receptor programmed death-1 (PD-1)269. Nevertheless, this research 
mainly concentrated on mitochondrial-derived ROS instead of Nox-derived ROS; 
therefore conclusions cannot be drawn from this evidence. Hence, further 
investigation is required in this area.  
As Nox2 has previously been shown to be involved in hypertension and cardiovascular 
remodelling, experiments were carried out using AngII to analyse the effect of CD4-
Nox2 on cardiac hypertrophy and fibrosis. CD4-Nox2KO animals displayed a blunted 
hypertensive response to AngII, in addition to attenuated hypertrophy and fibrosis. 
Within this model, cardiomyocyte size is initially smaller but even taking this into 
account there was a minimal increase in size after AngII infusion. The differences 
between genotypes could be explained by the difference in blood pressure response 
although one cannot exclude a difference in the direct effects of AngII on the heart.  
In terms of cardiac fibrosis, there is an important link between inflammation and 
fibroblasts, whereby inflammatory cells release pro-fibrotic stimuli and in turn 
fibroblasts can release pro-inflammatory mediators. CD4+ T-cells have previously been 
identified to play a direct role in fibrosis by secretion of IFN-γ, TGFβ, IL-1 and IL-6, 
which all potentiate the development of fibrosis115,122,123. Cardiac fibroblasts also have 
been demonstrated to recruit CD4+ Th17 cells to the myocardium during acute viral 
myocarditis270. Furthermore, direct molecular interactions between fibroblast-like cells 
and CD4+ T-cells have been identified in other settings such as rheumatoid arthritis and 
chronic pulmonary disease271-273. Thereby, the CD4-Nox2KO model may display 
blunted fibrosis due to altered interactions between fibroblasts and CD4+ T-cells in this 
setting. In addition, Tregs have the ability to modulate the phenotype and function of 
cardiac fibroblasts. Saxena et al identified that Treg depletion, using an anti-CD25 
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antibody (PC61), causes increased collagen deposition in an infarcted myocardium241. 
Furthermore, this group identified that, in vitro, Tregs displayed the ability to reduce α-
SMA and MMP-3 mRNA expression by cardiac fibroblasts in addition to reducing their 
contractile ability, a process key to infarct healing241. Hence, it may be the Treg 
component of CD4+ T-cells in the CD4-Nox2KO model that are important within this 
setting. 
Previous research identified that the lack of CD4+ T-cells provides a beneficial response 
to a pressure-overload model184. This research group clearly demonstrated that the 
lack of CD4+ T-cells prevents fibrosis, collagen accumulation and cross-linking within 
the cardiac tissue after TAC184. In comparison, experiments in this chapter essentially 
pinpoint this response to a specific component of CD4+ T-cells, Nox2, which is 
instigated in the response to pressure-overload, for example by AngII-treatment.  In 
contrast to this, research by Hofmann et al identifies that the lack of CD4+ T-cells 
provides an enhanced response to MI and hence implicates CD4+ T-cells in the setting 
of cardiac wound healing252. By completely diminishing animals of CD4+ T-cells, Tregs 
are also removed that have been shown to be beneficial during the cardiac response to 
stress193,240. Therefore a potential suggestion is that, it is the Tregs that have the ability 
to reduce CD4+ T-cell levels, which are advantageous within this setting.  
At baseline the CD4-Nox2KO mice displayed an increased cardiac-specific Treg:T-cell 
ratio, suggesting a regulatory phenotype that may provide a local protective 
mechanism.  Hence, this balance between Tregs and Teff cells may determine the 
outcome to cardiac stressors such as AngII. Moreover, results show that Nox2 has the 
ability to impact Treg function214. In line with this, results presented here showed that 
Nox2KO-Tregs are more effective than their WT counterparts (chapter 5). This 
therefore suggests that the CD4-Nox2KO model may possess enhanced Treg abilities, 
which in turn could protect the heart from AngII-induced remodelling. 
Furthermore, the lack of IL-17, a cytokine produced by the Th17 subset of CD4+ T-cells, 
protects mice from AngII-induced cardiac remodelling185. This further confirms the 
involvement of Teff subsets of CD4+ T-cells in this setting; hence an increased level of 
Tregs here may control Teff levels and could prove beneficial in the response to AngII. 
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Therefore one may suggest that the cardiac Teff:Treg ratio is pertinent to the cardiac 
outcome in response to stress. 
Taken together, the results presented in this chapter show that CD4-Nox2KO mice 
have an increased level of cardiac-resident CD4+ T-cells and Tregs at baseline with an 
augmented Treg:T-cell ratio. This in turn may provide a cardiac-specific protective 
mechanism due to the observed attenuated AngII response in terms of cardiac 
inflammation, hypertension and fibrosis. Therefore this study has identified a crucial 
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7.1 General overview of findings  
Nox2 is expressed in a variety of cell types including cardiomyocytes, fibroblasts, 
endothelial cells and immune cells. Nox2-derived ROS within T-cells may have the 
ability to mediate signalling pathways that can influence their differentiation, 
proliferation, migration and even maintenance. A handful of studies have identified a 
role for T-cells in cardiovascular remodelling. For instance a key paper by Guzik et al 
demonstrated that RAG-/- mice, lacking T- and B-cells, displayed a blunted response to 
AngII-induced hypertension. Furthermore, the adoptive transfer of T-, but not B-cells, 
back into these RAG-/- mice restored the expected pathophysiological response134. In 
addition to this, Nox2 is a major mediator of cardiovascular remodelling and has been 
implicated in the setting of cardiac hypertrophy, fibrosis and apoptosis. Such a role 
includes the potentiation of interstitial fibrosis in response to AngII, where in the 
absence of Nox2, this response fails to develop108. Convincing evidence has also placed 
T-cell Nox2 in the limelight. In the vasculature, Guzik et al also reconstituted RAG-/- 
mice with T-cells isolated from p47phox-/-, lacking Nox2, and showed that this partially 
restored the expected hypertensive response to AngII134.  
Nox2 and inflammation have separately been identified in the potentiation of AngII-
induced hypertension and fibrosis; however the specific, endogenous role of T-cell 
Nox2 within the cardiovascular setting requires further investigation. Therefore the 
aim of this thesis was to identify the function of T-cell Nox2 and its capacity to regulate 
cardiovascular remodelling in the setting of increased RAAS activation.  
AngII is extensively used in mouse models to induced hypertension and cardiac 
fibrosis, both of these processes have previously been identified to be potentiated by 
inflammation and Nox2. Thereby AngII infusion was an ideal model for this 
investigation. Firstly, efficiency of AngII to induced hypertension and associated 
cardiac hypertrophy and fibrosis was confirmed, verifying the efficacy of the model, 
and characterised the precise pattern of inflammatory infiltration of the myocardium. 
Interestingly, cardiac inflammation with AngII occurred in a time-dependant manner, 
with a peak after 3-days of AngII. In addition a distinct spatial orientation of infiltrated 
immune cells was observed. AngII treatment also augmented the level of cardiac T-
cells, specifically CD4+ T-cells and Tregs. Furthermore, these results highlighted that 
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AngII treatment increased the level of cardiac-specific chemokines, which may suggest 
a direct impact of AngII on T-cells to encourage cardio-tropism. Therefore CD4+ T-cells 
and Tregs potentially play a key role in the development of AngII-induced 
pathophysiology in a time-dependent manner.  
To address how Nox2 within infiltrating immune cells may affect the cardiac-response 
to AngII, a global Nox2KO model was used. Initially, we confirmed that these mice 
show an attenuated response to AngII-treatment in terms of hypertension and cardiac 
hypertrophy. Until now, the effect of Nox2 on cardiac immune-cell infiltration in this 
setting was unknown. Global Nox2KO mice at baseline display larger lymphoid organs 
that suggest a potential altered inflammatory response. We identified that the lack of 
Nox2 augmented cardiac-resident T-cell compositions at baseline. Moreover, the ratio 
of Tregs:T-cells was markedly increased in global Nox2KO hearts prior to treatment. In 
line with the cardiac-response to AngII, global Nox2KO mice presented an attenuated 
infiltration of immune cells into the myocardium compared to WT littermate controls. 
These results suggested a potential protective, anti-inflammatory mechanism related 
to the altered Treg:T-cell ratio at baseline that may be important in the setting of 
AngII-induced cardiac remodelling.  
Tregs have the ability to suppress inflammatory responses and have been identified 
previously to provide a protective response to cardiovascular stressors189-192. Here we 
highlighted that by increasing basal Treg-levels in mice via adoptive transfer, a 
protective phenotype can be achieved in response to AngII. Furthermore, this 
protective response was accompanied by an increased Treg:T-cell ratio, therefore the 
Treg ability to suppress CD4+ Teff cells may prove beneficial. Moreover, Nox2KO-Tregs 
are more efficient at protecting the heart and along with in vitro data this shows that 
the lack of Nox2 in Tregs generates a greater suppressive function.  
To fully appreciate the function of Nox2 in T-cells in vivo, it is vital to create a T-cell 
specific Nox2KO model. The previous global Nox2KO model gave us an essential insight 
into how Nox2 altered the cardiac inflammatory response, with a specific influence on 
T-cells. However, as all cell types were deficient in Nox2 it was difficult to ascertain 
which components are truly important during this setting. Furthermore, robust data 
from Laroumanie et al demonstrated that CD4KO, but not CD8KO, mice display 
protective responses to pressure overload, highlighting the importance of CD4+ T-cells 
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here184. Therefore a novel in-house CD4-Nox2KO mouse was generated. This enabled 
further clarification of the involvement of endogenous Nox2 within CD4+ T-cells. At 
baseline, these mice displayed an enlarged lymphoid organ, similar to global Nox2KO 
mice but with a specific impact on the thymus, where T-cells develop. CD4-Nox2KO 
mice also have an increased cardiac-specific ratio of Treg:T-cells, similar to that found 
in the global Nox2KO experiments, but without increases in other T-cell subsets. 
Additionally, these mice displayed a blunted response to AngII in terms of cardiac 
inflammation, hypertension and fibrosis. Overall the lack of Nox2 in CD4+ T-cells is 
sufficient to protect mice from AngII-induced hypertension and remodelling. Therefore 
endogenous T-cell Nox2 may be essential to the progression of cardiovascular 
remodelling.  
 
7.2 Implications of T-cell Nox2 
During AngII-infusion, infiltration of T-cells into the WT mouse myocardium occurs with 
a peak after 3-days of treatment. However in both the global Nox2KO and CD4-
Nox2KO mice this infiltration at 3-days is blunted. A potential explanation is that Nox2 
in T-cells may modulate their migration to the heart and prevent upregulation of 
chemokines involved in cardio-tropism.  
Fascinating results from Komarowska et al revealed that myocardial-produced 
hepatocyte growth factor (HGF) enters the heart-draining LN, where this cytokine can 
prime T-cells to express a unique and specific molecular signature, c-
Met+CCR4+CXCR3+, that allows cardio-tropism183,274. LNs allow drainage of fluid from 
circulating blood and local tissues, which enables the interaction of components from 
innate and adaptive immunity. Furthermore, the pharmacological blockade of c-Met 
during T-cell priming encouraged cardiac allograft survival, with an impaired ability of 
T-cells to localise to cardiac allografts183.  
In addition to this, AngII has been implicated in regulating cardiac-HGF levels. In SHR 
rats, that have naturally higher AngII levels, circulating HGF concentrations were higher 
whereas tissue-HGF within the heart, aorta and kidney were lower than controls275. 
Moreover, HGF within the heart has been linked to a reduction in myocardial injury in 
response to AngII, due to its anti-fibrotic mechanisms276. To my knowledge, no studies 
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have yet investigated the impact of AngII on HGF levels specifically within the LNs 
draining the heart. Hence, as AngII is associated with lower HGF levels in the 
myocardium, but increased levels within the heart-draining LNs, AngII may potentially 
encourage transportation of HGF to the LNs, or even upregulation of HGF within the 
LNs. Here, HGF primes T-cells to acquire vital cues that enable cardio-tropism 
potentially in response to AngII183,275. Primed T-cells can then elicit a cardiac-targeted 
immune response to resolve cardiac tissue homeostasis.   
Data presented here have demonstrated that in the hearts of WT mice treated for 3-
days of AngII, levels of cardiac-specific T-cell chemokines were upregulated, these 
included cMet, CCR4 and CXCR3. We were unable to study these levels in the KO 
models due to the lower level of T-cells infiltrating the heart after AngII treatment. 
Therefore, one interesting hypothesis is that Nox2 in T-cells may modulate 
upregulation of chemokines or adhesion molecules that are essential to T-cell 
recruitment to non-lymphoid tissues, such as the heart.  
This hypothesis (Figure 7-1) is supported by the known implication of Nox2 in the HGF-
c-Met signalling pathways within other cell types277,278. For instance Schroder et al 
showed that within endothelial progenitor cells (EPCs), HGF-induced mobilization of 
EPCs and the proangiogenic effects of HGF require Nox2, as in its absence these 
processes were inhibited277. The same research group also pinpointed Nox2-derived 
ROS signalling to the activation of JAK2 and JNK, which in turn activates the signal 
transducer and activator of transcription 3 (STAT3) transcription factors277. STAT3 has 
also been identified as a key component of HGF-induced chemokinesis within T-
cells183. Therefore a similar process may occur in T-cell HGF priming, whereby the lack 
of Nox2 prevents STAT3 activation of cardiac-specific chemokine receptors. 
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Figure 7-1: Proposed mechanism of AngII induced cardiac T-cell infiltration mediated 
by HGF. 
 
A lower level of ROS within the local-environment has been found to influence the 
redox status of lymphocyte cell surface molecules, by an increased reduction of thiol 
groups (cysteine-SH)279,280. This in turn has been linked to a more reactive and 
proliferative cell type279,280. Further investigation by Gelderman et al identified that the 
endogenous capacity of T-cells to produce ROS, is also linked to an increased level of 
reduced thiol groups on the T-cell membrane surface281. Thereby, in the Nox2KO 
models, the lack of endogenous Nox2 in CD4+ T-cells could cause an increased level of 
reduced thiols upon T-cell surface proteins, enhancing or reducing their function. This 
may then increase proliferation and function of all subsets of CD4+ T-cells and hence 
may explain an increased basal level of CD4+ T-cells observed in the Nox2KO hearts.  
Further to this, downstream signalling from both TCR activation and AngII has the 
ability to activate Nox2 and subsequent ROS production212. In T-cells, Nox2-derived 
ROS could signal to activate certain transcription factors, such as NF-κB and STAT3. NF-
κB activation is involved in chemotaxis of a variety of immune cells, potentially 
including T-cells. In macrophages, NF-κB is known to upregulate chemokines, such as 
MCP-1 and CCR2, which are vital in macrophage recruitment2. Moreover, the lack of 
  237  
Nox2 prevents NF-κB mediated upregulation of these chemokines, inhibiting 
macrophage recruitment201. Hence a similar control mechanism may exist in T-cells.  
Similarly STAT3, as described above, may trigger transcription of chemokine receptors 
such as CCR4 and CXCR3, involved in T-cell migration during an inflammatory 
setting282. Hence, Nox2-derived ROS signalling downstream from AT2R and TCR may 
regulate NF-κB-driven synthesis of cardiac-specific chemokine receptors. Therefore in 
the absence of Nox2, the lack of ROS may reduce the activation of NF-κB and impede 
chemokine upregulation. Furthermore NF-κB can activate synthesis of AngII within T-
cells, which in turn would amplify the response. Lack of Nox2 would prevent this 
activation and further amplification, hence dampening down the AngII-response to a 
greater extent.  
Overall, the lack of Nox2 in CD4+ T-cells may inhibit signalling pathways required for 
the upregulation of molecules essential to their recruitment during AngII-induced 
cardiac stress. Consequently, the altered recruitment of CD4+ T-cells observed here in 
the global and CD4-specific Nox2KO models, when treated with AngII, may provide the 
basis for their lack of response to the molecule. Published papers have identified the 
detrimental role of CD4+ T-cells during the progression of cardiovascular 
remodelling184. Further to data already presented from Laroumanie et al, Koller et al 
also showed a similar link between CD4+ T-cells and heart failure in a clinical setting283. 
A subset of circulating CD4+ T-cells, CD4+CD28null, were associated with severity of 
chronic heart failure (CHF) in patients and may provide an indicator for mortality283. 
This subset of CD4+ T-cells lacks the co-stimulatory CD28 molecule, and therefore is 
associated with repeated antigenic stimulation that may lead to CHF283. Further studies 
investigating this particular CD4+ T-cell subset have also linked their adverse responses 
to autoimmune disease and coronary artery disease284,285. No reference has yet been 
made to this CD4+CD28null subset in relation to the AngII-response; however this may 
comprise a detrimental component in the related cardiovascular remodelling process. 
Moreover, if the lack of Nox2 prevents infiltration of these cells into the heart, this 
may, in part, support the advantageous phenotype observed in the Nox2KO models. It 
is also possible that in the periphery these cells may accumulate in certain tissues and 
lead to autoimmune diseases such as arthritis, to which Nox2KO mice are 
susceptible199. Whereas, in the heart these cells are unable to accumulate or cause 
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damage in response to AngII, hence there is a local cardiac-specific protective 
mechanism in both the global Nox2KO and CD4-Nox2KO mice. 
When studying CD4+ T-cell effects one must take into account the various CD4+ T-cell 
subtypes, which present different roles depending on the type of immune response 
required. A specific T-cell subset, Th17, has been implicated in AngII-induced cardiac 
inflammation. During AngII treatment, the level of a Th17-specific cytokine, IL-17, was 
found to significantly increase both in vivo within aorta and from T-cells isolated from 
treated mice and stimulated ex vivo185. Moreover, mice deficient in IL-17 displayed 
unstable hypertension, preserved vascular function and reduced vascular T-cell 
infiltration in response to AngII185. Therefore the Th17 subset of CD4+ T-cells appears 
to be critical for the maintenance of AngII-induced hypertension in addition to 
subsequent cardiovascular remodelling. Furthermore, Nox2 has been implicated in Th 
differentiation pathways promoting Th2 responses, therefore in Nox2KO models the 
Th1 and Th17 responses may be enhanced.  
 In contrast, a few papers suggest a beneficial role of CD4+ T-cells during cardiovascular 
remodelling, however these usually link to regulatory functions. For instance, a 
population of CD4+AT2R
+ T-cells identified by Skorska et al were found to be favourable 
during post-infarct remodelling286. This group also identified the ability of this CD4+ 
subset to express FoxP3 and secrete IL-10, thereby taking on a regulatory function 
within this context286. The CD4+ T-cell population includes subtypes that can 
orchestrate a variety of immune responses. Therefore, it is important to take this into 
account when trying to decipher the function of Nox2 within this population, as it may 
differ between subtypes.  
The difficulty that arises with the model presented in this thesis is the lack of Nox2 
within both Teff cells, such as Th17, and Tregs, which have opposing roles. The cardiac-
inflammatory response to AngII treatment observed in the WT animals was 
accompanied by a transitory infiltration of Tregs, however the Treg:T-cell ratio 
remained consistent before and after treatment. Therefore this transitory Treg 
infiltration in the WT mice was insufficient to prevent further cardiac-inflammation 
and subsequent damage. In contrast, global Nox2KO and CD4-Nox2KO mice at baseline 
possess a higher cardiac-specific Treg:T-cell ratio. Tregs have the ability to suppress the 
immune response; hence they play an opposing role to other T-cell subsets. Therefore 
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one can postulate that it is this Treg:T-cell component that protects both global and 
CD4-sepcific Nox2 deficient mice from AngII-induced cardiac inflammation and 
subsequent remodelling. Data regarding the adoptive transfer of Tregs into WT mice 
treated with AngII, also shows that increasing the Treg:T-cell ratio in this manner can 
provide protection against cardiovascular remodelling. This has also been explored by 
a handful of studies, described previously, which demonstrates that an increase in 
basal Treg levels is beneficial during cardiovascular remodelling190-192.  
Results presented in this thesis also identified an increased suppressive function by 
Nox2KO-Tregs both in vitro and in vivo. This may involve a redox mechanism described 
by Yan et al, whereby DCs have the ability to increase extracellular cysteine levels that 
in turn provide a reduced environment for T-cell proliferation287. Tregs were shown to 
significantly lower extracellular cysteine levels, mediated by direct CTLA-4 interaction 
with DCs288. A fascinating concept is that the lack of Nox2 within Tregs may enhance 
this mechanism. Nox2 deficiency in T-cells has been linked to enhanced function, 
which may still be true in the Treg subset279,280. In addition, Tregs may also reduce 
cysteine levels by competitive uptake, which could in turn further enhance their 
function288. Data presented here support these ideas as a higher expression of CTLA-4, 
CD39 and CD73 was observed in the Nox2KO Tregs, thereby the lack of Nox2 may 
increase expression of these molecules and enhance their function. CTLA-4 expression 
upon Treg membranes enables interaction with APCs such as DCs, which express 
CD80/CD86, thereby preventing further inflammatory responses229. CD39 and CD73 
degrade ATP, ADP and AMP to adenosine creating an adenosine-rich anti-inflammatory 
environment176. However, CD39 and CD73 can also regulate the function of APCs and 
encourage an anti-inflammatory phenotype176. Another possibility is that Nox2-derived 
ROS may signal within Tregs and regulate cytokine release, such as IL-10 or TGFβ. 
However, these indirect-mechanisms may not be involved here as previous papers 
identified a lower suppressive capacity of Nox2KO-Tregs, when analysed in the 
presence of anti-CD3/CD28 beads214. Tregs elicit a regulatory response by either 
secreting anti-inflammatory cytokines, directly interacting with Teff cells or by 
interacting with APCs to indirectly suppress Teff cells. The use of CD3/CD28 beads 
allows analysis of the first two suppressive mechanisms but not by interactions with 
APCs, suggesting that the enhanced suppressive capacity observed here is due to 
direct Treg interactions with APCs.  
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Numerous inflammatory diseases have been associated with an impaired Treg:Th17 
ratio in a diverse range of tissues. These include human graft-versus-host disease in 
transplant patients289, chronic hepatitis B driven liver disease progression290,  acute 
respiratory distress syndrome291, chronic obstructive pulmonary disease292 and 
rheumatoid arthritis293. Interestingly, an imbalance in the Treg:Th17 ratio has also 
been associated with cardiovascular pathophysiologies294-296. Chen et al observed a 
significant increase in Th17 cells, and a lower Treg:Th17 ratio, in uremic patients with 
cardiovascular complications compared to uremic patients without cardiovascular 
complications, both undergoing hemodialysis294. A similar imbalance was also 
identified in patients with acute coronary syndrome, with an increase in Th17 cells and 
its related cytokines (IL-17, IL-6 and IL-23)295. Furthermore, analysis of peripheral Th17 
and Tregs from patients with chronic heart failure revealed a significant increase in the 
Th17 response and a blatant reduction in Tregs296. Thereby in the setting of chronic 
heart failure the peripheral Treg/Th17 balance is impaired296.  
These studies identify the importance of peripheral Treg:Th17 balance within a 
cardiovascular-related disease setting; however the specific cardiac-resident ratio has 
not yet been investigated. This Treg:Th17 balance controls inflammation and may 
therefore be crucial to the pathogenesis of AngII-induced cardiac remodelling. 
Furthermore, this may explain the protective response observed in the global Nox2KO 
and CD4-Nox2KO mice. 
Due to these reports, an interesting concept to consider is the plasticity between CD4+ 
T-cell subsets, specifically between Th17 cells and Tregs62-64,70,254. This plasticity is 
determined by the promiscuity of cytokine expression, phenotype and even the 
expression of master regulators between different subtypes63. There are a number of 
factors that link Tregs and Th17 cells. Firstly, both cell types require TGFβ for their 
differentiation and mice deficient in this cytokine lack both Tregs and Th17 cells63,255. 
Treatment of naïve CD4+ T-cells with TGFβ in vitro can cause differentiation of both 
Tregs and Th17 cells in a concentration-dependent manner, leading to upregulation of 
either RORγt (at low concentrations) or FoxP3 (at high concentrations)68. Furthermore, 
FoxP3+RORγt+ cells, which express both master regulators indicative of Treg and Th17 
lineages, have been identified in both mice and humans64,68. These transcription 
factors can interact with each other to alter T-cell phenotype and cytokine 
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production63. For instance a study from Voo et al demonstrated that these 
FoxP3+RORγt+ cells could produce IL-17 but still maintain a suppressive function297. 
Hence, these cells may reside as a transitory population that can give rise to either 
Treg or Th17 cells, and additional cytokines may determine the outcome63,68,297.  
In addition to this, Tregs can lose their FoxP3 expression and acquire the capacity to 
produce pro-inflammatory cytokines, such as IL-17. This could stipulate the trans-
differentiation from Tregs to Th17 cells. For example a study by Komatsu et al, in the 
context of autoimmune arthritis, observed the conversion of Tregs into Th17 cells 
driven by synovial fibroblast-derived IL-6298. This involved the loss of Foxp3 expression 
and acquired capacity of Tregs to produce IL17. On the contrary, more recent literature 
has described the trans-differentiation of Th17 cells into Tregs. Gagliani et al carried 
out a series of in vivo and ex vivo experiments, using a sophisticated reporter mouse to 
study Th17 conversion257. This group discovered that Th17 cells could acquire an anti-
inflammatory phenotype, expressing both IL-10 and FoxP3. Further in vitro 
experiments attributed this conversion to TGFβ signalling, which occurred in a dose-
dependent manner. The downstream activation of Smad3 enables the reduction of 
RORγt activity, which in turn deters the Th17 phenotype257. A similar mechanism was 
also described in the setting of mesenchymal stem cell (MSC)-mediated allograft 
survival, where Tregs were derived from Th17 cells256. This group also indicated that 
the RA receptor gamma (RARγ) might play a role in Th17-Treg conversion in this 
setting. Further studies identify a role for RA in promoting Treg differentiation and 
expansion in addition to having the ability to prevent transition of T-cell into Th17 
lineage299,300.  
An increased Treg:T-cell ratio was observed within both of the Nox2KO models, that 
demonstrate a better response to AngII, may suggest a role for Nox2 in the Treg/Th17 
balance (Figure 7-2). There are two approaches that may explain how Nox2 could be 
involved here. Nox2-derived ROS signalling could either be involved in promoting the 
Th17 differentiation pathway or, ROS could signal to prevent the Treg differentiation. 
Ergo, in the Nox2KO models, the lack of CD4+ T-cell Nox2 would promote an enhanced 
Treg:T-cell ratio. Furthermore, this could be specific to the heart due to a unique 
molecular component in the microenvironment, which is absent in peripheral 
lymphoid organs. For instance TGFβ or RA could be involved in this setting, as they are 
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both implicated in cardiac and Treg processes. ROS signalling mechanisms involved 
here could include the activation or inhibition of downstream signalling molecules or 
transcription factors, as described in the introduction. For instance, Nox2-derived ROS 
has been shown to activate the JAK2-STAT3 signalling cascade301. In turn, STAT3 is an 
important modulator of RORγt expression and may modulate Th17/Treg balance302. 
Furthermore, increased levels of STAT3 prevents STAT5 binding to FoxP3 promoter, 
hence reduce Treg levels302. Likewise, Nox2-derived ROS regulation of cell-surface 
receptors for cytokines that drive Th17-Treg trans-differentiation is also conceivable. 
This redox regulation of cell-surface molecules, as discussed earlier, suggests an 
increased function with the lack of Nox2 due to reduced cell surface thiols. Hence 
Nox2 may negatively regulate TGFβ receptors or RARs, which are involved in 
promoting Treg differentiation. Overall, the extent of plasticity between Tregs and 
Th17 cells is becoming more apparent and resultant effects may be context 
dependent, due to specific-tissue microenvironments. This could in part explain the 
differences observed between the Nox2KO models and WT littermates; however this 
would require further analysis of the Th17 population in this setting.  
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Figure 7-2: Proposed involvement of Nox2 in CD4+ T-cell signalling. Nox2-derived ROS 
activation of JAK2/STAT3 signalling pathway encourages RORγt expression and Th17 
differentiation in turn preventing Treg development. 
 
Furthermore, TGFβ involved in Treg differentiation and suppression within the heart is 
also a pro-fibrotic modulator, which is related to AngII-induced fibrosis. In the Nox2KO 
models, a higher level of cardiac-resident Tregs was observed, hence when treated 
with AngII, extracellular TGFβ produced may be quenched by Nox2KO-Tregs and the 
resultant fibrotic response inhibited. Supporting this, the adoptive transfer of Nox2KO-
Tregs, but not WT-Tregs, prevented AngII-induced cardiac fibrosis. One may 
hypothesise that Nox2KO-Tregs use a direct cell-cell mechanism for their enhanced 
suppression and hence may not secrete TGFβ as an anti-inflammatory cytokine. This 
could in turn reduce the level of fibrosis within this setting.  
Taken together, both the detrimental role of CD4+ Teff cells and the beneficial role of 
Tregs have been observed, and potentially determine the outcome of the cardiac-
inflammatory response to AngII. Nox2 in CD4+ Teff cells may be implicated in migratory 
mechanisms to the heart and regulate their function. Whereas, Nox2 in Tregs may 
  244  
regulate redox-sensitive suppression mechanisms and control a location-specific 
Treg/Th17 balance. Hence, the lack of Nox2 in the global and CD4-specific models 
prevents CD4+ T-cell infiltration with AngII treatment. In addition, the Nox2 alteration 
of the cardiac-resident Treg:T-cell ratio empowers Tregs to prevent incoming 
inflammatory cells and therefore protect the heart from subsequent damage. Data 
presented in this thesis suggests a double-mechanism allowing cardiac-specific 
protection in the absence of Nox2. However, difficulty arises in deciphering the relative 
contributions of both in this setting.   
 
7.3 Clinical implications  
In the UK more than a quarter of deaths (155,000 each year) result from CVD and an 
estimated 7 million people suffer from CVD (British Heart Foundation statistics, 2015). 
Therefore it is essential to fully understand the mechanisms that underline CVD in 
order to identify potential therapeutic targets. The inflammatory response observed in 
CVD can propagate disease development and ultimately lead to heart failure. Nox 
enzymes also are implicated in a wide variety of cardiovascular remodelling process, 
and also potentiate disease progression towards heart failure.  
Targeting Nox enzymes to improve CVD outcomes has been suggested as a potential 
therapeutic approach22,303.  However, this blanket approach does not take into account 
the specific actions of individual Nox isoforms. For instance, contrasting roles of Nox2 
and Nox4 have been identified304,305. Pharmacologically, many Nox inhibitors do not 
allow specificity for a single Nox isoform306. The first technological advance towards 
the development of Nox2-specific inhibitors by Smith et al identified ebselen as a 
potential inhibitor307. By interrupting p47phox binding and interacting with p22phox, 
ebselen prevents Nox2 assembly and subsequent activity. A recent study by Bosco et al 
have utilised an in silico screen to identify Phox-I1, an inhibitor of the interaction 
between Rac and p67phox 308. Here, Phox-I1 binds to p67phox, preventing Rac1 binding 
and therefore effectively inhibits Nox2-derived superoxide production in a dose-
dependent manner308. Further Nox2-specific inhibitors are coming to light, such as 
bridged tetrahydroisoquinolines, which may serve as a platform for developing new 
therapeutic agents against Nox2309. 
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Furthermore, Nox2 function can differ depending on its role in specific cell types, 
therefore in some cells Nox2 may be beneficial to CVD, whereas in other cells its role 
may propagate disease progression. Data in this thesis demonstrate that T-cell specific 
Nox2 is a major mediator of the inflammatory component observed prior to 
cardiovascular remodelling. In addition, eliminating Nox2 within CD4+ T-cells is 
beneficial for disease outcome in mice. In light of this, a more specific therapeutic 
approach is necessary to target the main factors orchestrating a detrimental 
phenotype observed in CVD. This could include a direct cardiovascular target of CD4+ T-
cells. One method may involve delivering Nox2-specific therapeutic agents directly to 
cardiac tissue or to specific cell types, such as CD4+ T-cells. This could involve using 
delivery materials such as lipid nanoparticles with targeting-ligands, enabling direct 
delivery of therapeutic agents310. Another technique may involve identifying 
downstream targets that are specific to Nox2 function within CD4+ T-cells, or Tregs, a 
specific inhibitor could be generated. For instance, the proposed mechanism suggests 
JAK2/STAT3 pathway as an important modulator of Treg:Th17 balance downstream 
from Nox2. Therefore a specific JAK2 inhibitor, such as TG101348, or even siRNA 
mediated depletion of STAT3, could be delivered to cardiac CD4+ T-cells to skew the 
Treg:Th17 towards an anti-inflammatory response302.  
Results presented in this thesis also highlight a beneficial role for Tregs within the 
setting of cardiovascular remodelling, specifically Nox2KO-Tregs. Additionally, 
published papers have suggested that the Treg/Th17 balance may dictate a patient’s 
cardiovascular-outcome. Therefore a potential therapeutic approach may be Treg-
therapy to provide CVD patients with an enhanced anti-inflammatory component 
promoting resolution of cardiovascular tissue homeostasis. Clinical trials are already in 
place using Treg therapy to aid allograft survival in transplant patients. For example a 
clinical trial called ‘The ONE study’ that Guy’s and St Thomas’ hospitals are part of, 
uses Tregs to aid kidney graft survival in end-stage renal failure patients311-315. 
Naturally occurring Tregs are isolated and purified from living-donor transplant 
recipients, amplified by sterile cell culture methods and re-infused into the transplant 
patient five days post-transplantation. A similar therapeutic method could be 
employed to enhance a patient’s outcome to CVD. Isolated Tregs could also be 
depleted of Nox2 or important downstream signalling targets using siRNA310, or other 
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silencing mechanisms, and these treated Tregs can be injected back into the patient to 
provide an enhanced cardiac-specific protective mechanism.  
Further therapeutic approaches could involve exploiting the plasticity of Th17 cells to 
enhance a Treg:T-cell ratio within CVD patients. Therefore a more in depth 
understanding of the role Nox2 plays within this setting could provide a means to 
promote Treg differentiation and function specifically within cardiovascular tissues.  
Therapeutic approaches to target cardiac fibrosis would also be beneficial to prevent 
subsequent cardiac arrhythmias and cardiac dysfunction. Currently there are no 
specific treatments for fibrosis; however ACE inhibitors, which prevent the conversion 
of AngI to AngII, may also have a beneficial effect on collagen deposition316. In 
addition, dual treatment with ARBs and ACE inhibitors could be an advantageous 
approach to fibrosis treatment84,317. However, the effects of these inhibitors are very 
general and more specific fibrosis-targeting therapeutics are required. Therefore 
results within this thesis may be relevant for identifying new therapeutic targets to 
prevent progression of fibrosis due to the close interaction between fibrosis and 
inflammation.  
Findings within this thesis highlight a number of interesting therapeutic ideas; however 
one caveat is the difference between mice and humans, which must be taken into 
account when translating these data into potential clinical therapies.  
 
7.4 Study limitations and future work  
In this study a cardiac-infiltration of T-cells during AngII treatment was observed; 
however the mechanism that underlies T-cell migration to the heart and within the 
myocardium in this setting requires further clarification. To fully investigate this, a 
more detailed approach is required by analysing more time points during AngII 
treatment, to fully appreciate the individual stages in immune cell recruitment. In 
addition to this, identifying AngII-dependent upregulation of endothelial markers, such 
as VCAM-1, would provide insight into how immune cells are encouraged into the 
myocardium in the first place. Finally, investigations into which vessels are associated 
with the inflammatory recruitment, arterioles or venules, could help determine how 
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immune cells infiltrate the tissue. There are limited techniques available to analyse 
immune cell migration within the heart specifically. In recent years a research group 
were able to study neutrophil trafficking to the heart using two-photon intravital 
microscopy318,319. Optimisation of this method could allow detection of different 
immune cells, or even specific T-cell subtypes, using fluorescently labelled dyes to fully 
elucidate their response to AngII in real-time.  Furthermore, one could directly inject 
AngII and analyse the immediate responses using this technique. This would help to 
clarify how the lack of Nox2 within these immune cells affects T-cell migration.  
Flow cytometry data presented in this thesis are represented as cells per mg of cardiac 
tissue, or for lymphoid organs, as a percentage of total cells acquired. Another method 
for analysis would be to use counting beads (e.g. Invitrogen™Countbright™), which 
enables an accurate calculation of cell concentration. Counting beads are a calibrated 
suspension of fluorescent microspheres with a known concentration. Therefore a 
specific volume of counting beads can be added to a specific volume of sample so that 
a ratio of sample volume to microsphere volume is known. From this the volume of 
sample analysed can be calculated based on the number of microsphere events 
acquired. This would enable data to be accurately represented as cells per ml of 
sample. It could be interesting in another set of experiments to implement this 
method to further refine this quantification. 
The lack of Nox2 in the CD4-Nox2KO line could be further verified by stimulating 
isolated CD4+ T-cells with phorbol 12-myristate 13-acetate (PMA) to prompt ROS 
production. ROS can then be detected using dihydroethidium (DHE) by flow cytometry. 
This would be a good way of demonstrating lower ROS levels in the Nox2KO-CD4+ T-
cells. In addition to this, further confirmation could be achieved by western blot for 
Nox2 protein expression within a variety of tissues in addition to isolated CD4+ T-cells. 
This would verify that Nox2 in other tissues is unaffected and demonstrate specificity 
for CD4+ T-cells.  
Further in vitro studies to analyse the role of Nox2 in naïve CD4+ T-cell differentiation 
would also help to unravel the role that Nox2 plays in directing T-cell responses. 
Additionally, an important concept to study further is the mechanism that underlines 
the role of endogenous Nox2 in CD4+ T-cells.  
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Herein, WT- and Nox2KO- Tregs isolated from LNs and spleens were characterised, 
which may portray a different phenotype to cardiac-resident T-cells. Currently, as 
baseline levels of CD4+ T-cell subtypes, especially Tregs, are so low it is impossible to 
accurately analyse these cells. Accumulating data is identifying distinct phenotypes and 
roles for Tregs within non-lymphoid tissues. Therefore, as more sensitive methods for 
studying T-cells within the heart emerges, phenotyping cardiac-resident CD4+ T-cell 
subsets fully would provide further understanding of their role, and the role of 
endogenous Nox2, within this setting.  
In the adoptive transfer experiments, an increased Treg:T-cell ratio was identified, 
however flow cytometry was not sensitive enough to ascertain a change in cardiac 
Treg numbers. Further analysis here could involve an adoptive transfer using 
fluorescently labelled WT- or Nox2KO-Tregs, either from YFP animals or by staining 
isolated cells with CFSE.  This would eliminate steps in the isolation protocol so that 
more cells survive for flow cytometry analysis. Additionally, cells would be easily 
identified in a range of tissues using fluorescence microscopy. Hence, organs that 
enable regulation of blood pressure could also be analysed, such as the kidney, aorta 
and brain. Alternatively, the intravital two-photon microscopy may also be useful for 
identifying Treg migration within this experiment. Pre-clinical in vivo imaging systems 
(IVIS) could also be used to identify Treg migration using a technology such as IVIS® 
Lumina (Perkin Elmer) using fluorescence markers.  Furthermore, if operated in a 
clinical setting, MRI can be used as a non-invasive method to detect delivery and 
function of Tregs using a tracer molecule320.   
To further add to the understanding of Tregs within AngII-induced cardiac remodelling, 
a Treg depletion experiment could be undertaken using an anti-CD25 antibody (PC61) 
within both WT and the two Nox2KO models.  The effect of this on blood pressure and 
cardiac remodelling in response to AngII could then be analysed to discern the impact 
of Tregs in this setting. Additionally, adoptive transfer of WT- or Nox2KO- CD4+ Teff 
cells in similar settings could be beneficial to show their impact here.  
The data showed, both in vitro and in vivo, that Nox2KO-Tregs display an increased 
suppressive phenotype. In addition to the suppression assays presented in this thesis, 
using thymidine uptake as a read out, a carboxyfluorescein succinimidyl ester (CFSE) 
suppression assay was also performed.  This involves fluorescently labelling CD4+ Teff 
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cells with CFSE, and co-culturing them with APCs, anti-CD3 antibody and either WT- or 
Nox2KO-Tregs for 3-days. The numbers of Teff cells can then be analysed by flow 
cytometry to indicate the level of proliferation. Data from this assay also suggest that 
Nox2KO-Tregs have a greater suppressive function; however this method needs 
further optimisation. Therefore repeating this protocol, which is more accurate, would 
be beneficial to confirm the thymidine suppression assay findings presented in this 
thesis. Furthermore, published papers have suggested opposing results when co-
culturing Nox2KO-Tregs with Teff cells in the presence of anti-CD3/CD28 beads instead 
of isolated APC. This method allows analysis of Treg suppression by direct interaction 
with Teff cells or secretion of anti-inflammatory cytokines but not the indirect 
suppression via APC. Therefore, repeating these experiments using these conditions 
and evaluating the level of cytokines within the supernatant using an enzyme-linked 
immunosorbent assay (ELISA) may decipher the mechanisms used by Nox2KO-Tregs to 
suppress Teff cells. Further analysis of supernatants from these co-cultures could also 
determine whether secretion of anti-inflammatory cytokines differs between WT- and 
Nox2KO-Tregs.  
Within this thesis, experiments concentrated on CD4+ T-cells; however this population 
of cells encompasses a variety of subtypes. Further experiments would be required to 
understand the role of Nox2 specifically within these different subtypes, such as Th17 
and Tregs. This could involve the generation of further specific-Nox2KO models such as 
Th17- or Treg-Nox2KOs. Initially, I planned to generate a Treg-specific Nox2KO model 
by crossing a FoxP3-Cre line with the novel Nox2 floxed line. However, both FoxP3 and 
Nox2 are X-linked therefore the generation of a FoxP3-Nox2KO mouse was near 
impossible. However, CD25 (IL2-R) is located on chromosome 15 and hence may be a 
better promoter to use for Nox2 deletion in Tregs321,322.  Revisiting this idea and 
potentially generating a CD25-Nox2KO model may be beneficial for further 
understanding the depth of Treg involvement within the AngII-model.  
Finally, limitations in the studies also arise when translating these findings to a clinical 
setting due to the use of mouse models. Differences in species, such as additional Nox 
enzymes within humans, the young age of mice studied, potential differences in 
immune and inflammatory responses between mice and humans, must be taken into 
account.  
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7.5 Conclusions  
In conclusion, the work presented in this thesis demonstrates a clear role of 
endogenous Nox2 in CD4+ T-cells within the setting of AngII-induced cardiovascular 
remodelling. Herein, the T-cell subtypes that are critical during the development of 
AngII-induced inflammation and cardiovascular remodelling have been deciphered. I 
have demonstrated two components in Nox2KO models that enable cardiac-specific 
protection: preventing migration of CD4+ T-cells and a protective Treg response. The 
cardiac-infiltration of CD4+ T-cells drives cardiovascular remodelling and Nox2 within 
these cells is an important orchestrator of the resultant pathophysiological responses. 
Although the detrimental effect of CD4+ T-cells observed here plays the main role in 
disease progression, it is the Tregs that maintain the power to resolve cardiac-
inflammation and tissue homeostasis. Moreover, I observed the intrinsic regulatory 
effect of Nox2-derived ROS within Tregs, controlling their suppressive function. 
Therefore by further understanding the Treg:Th17 balance, and the function of 
endogenous Nox2 within this setting, a potential therapeutic strategy could be 
developed.  
Taken together, the results presented in this thesis provide further clarity to the role of 
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